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In the United States in 2009, 192,370 women are expected to be diagnosed with invasive breast 
cancer, and 62,280 with in situ disease. About 70% of these cases are estrogen receptor positive 
(ER+). There are two isoforms of the ER, α and β, that differ somewhat in structure and action.  
ERβ expression plays a protective role in breast cancer, and selective targeting of this isoform 
would have many beneficial effects.  Tamoxifen has long been the standard of care for patients 
with ER+ breast cancer.  A major problem with tamoxifen is the development of drug resistance.  
One of the mechanisms proposed for the development of tamoxifen resistance involves the loss 
of ERβ expression.  
The first objective of this study was to screen a library of biphenyl C-
cyclopropylalkylamides for their ability to function as ERβ-selective ligands.  Two compounds 
were identified with modest selectivity for ERβ and anti-proliferative effects in breast cancer 
cells where they inhibited expression of c-Myc. 
The nuclear matrix (NM), the structural scaffolding of the nucleus, plays a major role in 
many fundamental processes of the cell.  Using the ER+ breast cancer cell line MCF-7 and an 
antiestrogen resistant derivative, along with subtype selective ER ligands, alterations in the 
abundance of specific proteins present in the NM were identified using a mass spectrometry 
(MS)-based relative quantitative methodology.  Some of the most interesting proteins with 
altered abundance are NuMA, serpin H1, hnRNP R, and dynein heavy chain 5. These proteins 
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may represent putative biomarkers to customize treatment.  The alterations also provide a 
mechanistic understanding of tamoxifen resistance.   
The NM was also investigated by MS in the earliest stage of breast cancer, ductal 
carcinoma in situ (DCIS), utilizing novel cell lines derived from normal (breast reduction), 
DCIS, and non-diseased contralateral breast surgical specimens.  Two of the interesting proteins 
found to be altered in DCIS were HSP90 and EEF1D.  These studies may provide biomarkers to 
aid in the diagnosis and treatment of breast cancer.  In addition by understanding the mechanism 
behind the development of breast cancer, prevention becomes a possibility. 
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1.0  INTRODUCTION 
1.1 THE ESTROGEN RECEPTORS 
1.1.1 Overview 
The steroid hormone 17β-estradiol (E2) (Figure 1) plays a major role in the growth, 
differentiation and function of many different target tissues, including the mammary gland, 
uterus, ovary, testis and prostate.  Additionally, E2 functions in bone maintenance and the 
cardiovascular system (Clark, 1992).  Estrogens are produced mainly by the testes and ovaries 
and then diffuse in and out of all cells (Murdoch, 1991). In a target cell, E2 exerts its effect 
primarily through the ER.  ERα was discovered in the 1960s as a protein that specifically bound 
tritium-labeled E2 in the uterus (Jensen, 1962).  The cDNA for ERα was cloned in 1986 (Green, 
1986A; Greene, 1986).  For ten years ERα was believed to be the only ER, but in 1996 a second 
ER was cloned from rat prostate, ERβ (Kuiper, 1996). 
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Figure 1:  The structure of E2 (1).  
The structure of steroid hormone E2, which binds the ERs and plays a major role in the growth, 
proliferation, and/or function of many target tissues, including the male and female reproductive, cardiovascular, 
and skeletal systems. 
 
   The ERs belong to a superfamily of nuclear hormone receptors.  ERα and ERβ are 
produced by distinct genes located on chromosomes 6 and 14, respectively (Green, 1986B; 
Kuiper, 1996).  ERα is a 595 amino acid protein with a molecular weight of 66 kDa (Green, 
1986A).  ERβ is a 530 amino acid protein with a molecular weight of 54.2 kDa (Kuiper, 1996).   
In the human body, both receptors display both overlapping and tissue-specific distribution.  ERα 
is the predominant receptor in the pituitary gland, thecal and interstitial cells in the ovaries, 
uterus, liver, kidneys and adrenals, while ERβ is the predominant receptor in the prostate, bone, 
granulosa cells of the ovaries, lung, and in the central and peripheral nervous system  (Kuiper, 
1997; Emmen, 2005; Harris, 2007).  
  3 
1.1.2 Structure 
The ER has a well-defined organization with five domains designated A/B, C, D, E, and F 
(Kumar, 1987).  Figure 2 illustrates the domain organization of the two ERs.  The A/B domain is 
located at the N-terminus of the protein and contains the activation function 1 (AF1).  AF1 is the 
ligand-independent, constitutively-active activation function (Tora, 1989).  The C domain 
contains the DNA-binding and receptor dimerization regions (Mader, 1993).  The DNA-binding 
domain (DBD) contains two zinc-fingers responsible for specific binding to DNA (Enmark, 
1997).  In DNA, the ERs bind an estrogen-response element (ERE) located in the promoter of 
estrogen-regulated genes.  An ERE has the sequence GGTCAnnnTGACC (O’Lone, 2004; 
Carroll, 2006).  The D domain is the flexible hinge between the C and E domains and bears a 
nuclear localization sequence (NLS) (Picard, 1990).  The E domain contains the ligand-binding 
domain (LBD) and a second NLS.  The ligand-binding region contains twelve helices and is 
involved in both ligand binding and receptor dimerization. Activation function 2 (AF2) is also 
located in the E domain and is responsible for the ligand-dependent activation of the ER (Tora, 
1989).  The F domain,\ is located at the extreme C terminus of the receptor.  This small domain 
is unnecessary for transcriptional activation but does modulate both AF1 and AF2 activity 
(Weatherman, 2001; Koide, 2007; Skafar 2008). 
The two isoforms of the ER differ somewhat in their structures. The highest level of 
homology, 96%, is present in their DBDs (domain C).  Their ligand binding domains (domain E) 
share 55% homology (Kuiper, 1996).  There are only two amino acid differences in the residues 
within the ligand binding pockets.  Met421 in ERα corresponds to Ile373 in ERβ, and Leu384 in 
ERα corresponds to Met336 in ERβ.  These amino acid differences have an effect on the overall 
volume of the ligand binding pocket. ERα’s binding pocket has a volume of 490 Å3 and ERβ’s 
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binding pocket has a volume of 390Å3 (Veeneman, 2005).  E2 binds to the two isoforms with 
similar affinity due to the similarity in their binding pockets.  The Kd for E2 binding to ERα is 
0.05 nM, while the Kd for E2 binding to ERβ is 0.9 nM (Kuiper, 1998).  The most variable 
regions of the receptors are the N-terminal A/B domain and the C-terminal F domain, where the 
receptors share less than 20% homology.  These regions likely account for some of the subtype-
specific actions on target genes (McInerney, 1998). 
 
Figure 2:  The domains of ERα and ERβ. 
The least homology, less than 20%, is seen in domains A/B, which contains AF1, and F.  Domain C 
contains the DNA binding domain and is the most homologous between the two isoforms, with 96% homology.  
Domain D is the hinge and has 30% homology between the two isoforms, while domain E is the ligand binding 
domain with 55% homology.   
1.1.3 Mechanism of Action 
The ER functions as a ligand-inducible transcription factor. When estrogen is absent from a cell, 
the ER exists as an inactive, monomeric protein bound to heat shock proteins (Cheung, 2000).  
When bound to estrogen, the ER regulates the transcription of specific target genes (Osborne, 
2001; Osborne, 2005A). Estrogen binds to the LBD of the ER and induces a conformational 
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change, promotes phosphorylation of the receptor, leads to dissociation from heat shock 
chaperone proteins, and induces receptor dimerization (Osborne, 2001).  The ER then functions 
through two different mechanisms: genomic and non-genomic. 
1.1.3.1 Genomic Signaling 
In the genomic signaling pathway, ligand-bound ER dimer binds to the ERE located in the 
promoter of estrogen-regulated genes (O’Lone, 2004; Carroll, 2006).  The ER dimer then 
regulates expression of ERE-containing genes, which are primarily involved in cell proliferation 
and survival (Dobrzycka, 2003; Frasor, 2003).  The perfect palindrome ERE, 
GGTCAnnnTGACC, is derived from highly E2-responsive genes of Xenopus laevis (Klein-
Hitpass, 1988; Peale, 1988). Most human E2-target genes contain an imperfect palindrome 
sequence in their promoter.  Variations in ERE sequence slightly change the confirmation of the 
ER and modulate gene transcription (Wood, 2001).  Complement 3 and pS-2 are two example 
genes that contain EREs in their promoters and are regulated via this pathway, the classical 
pathway of ER action (Berry, 1989). 
Several non-classical genomic pathways involve an interaction of the ER with another 
transcription factor.  This interaction stabilizes the direct binding of the ER to DNA to influence 
the transcription of genes lacking an ERE.  The first of these pathways involves the Jun/Fos 
transcription factors and their binding with the ER to regulate Ap-1 sites in DNA (Kushner, 
2000).  Another pathway involves c-Jun/ATF-2, which binds with the ER to cyclic AMP-
response elements in DNA (Sabbah, 1999).  One other pathway involves the Sp-1 transcription 
factor, which binds with the ER to Sp1 sites in DNA (Saville, 2000).  Cyclin D1 and insulin-like 
growth factor-I receptor (IGF-IR) are two example genes that are regulated by E2 in this non-
classical manner (Eeckhoute, 2006; Maor, 2006).   
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Once recruited to the promoter of estrogen-responsive genes through either the classical 
or non-classical mechanism, gene transcription is induced only if AF1 and/or AF2 are activated 
(Tora, 1989).  AF1 activation is ligand independent and is regulated by phosphorylation at 
specific serine residues.  These residues are phosphorylated following activation of the p42/p44 
mitogen-activated protein kinase (MAPK), phosphatidylinositol-3-kinase (PI3K)/protein kinase 
B (AKT) and p38 MAPK pathways (Kato, 1995; Bunone, 1996; Campbell, 2001; Thomas, 
2008).  Phosphorylation of AF1 then stimulates ER-mediated transcription by recruiting 
coactivators (Webb, 1998).  AF1 can also be activated in response to estrogen and interacts 
synergistically with AF2 to recruit coactivators that interact with both AFs to influence 
transcription (Hall, 2001; McInerney, 1996; Kobayashi, 2000). The activation of AF2 depends 
on the presence of the ligand.  When estrogen binds to the ER it induces a rearrangement of 
several helices in the LBD.  This creates a hydrophobic cleft with helix 12 enclosing the 
hormone in the pocket and exposing the AF2 region to the outside of the receptor.  The AF2 
region is where coregulatory proteins, both coactivators and corepressors containing LXXLL 
motifs, or NR boxes, bind and influence gene expression (Brzozowski, 1997; Shiau, 1998; 
McKenna, 1999).  The roles of coregulatory proteins recruited to the ER are determined by both 
the specific ERE sequence present in the target gene and the specific ligand bound to the ER 
(Gruber, 2004; Yi, 2002). 
1.1.3.2 Non-genomic Signaling 
The ERs also influence cellular behavior through a non-genomic signaling mechanism.  The non-
genomic signaling pathway is also known as the membrane-initiated steroid-signaling (MISS) 
pathway (Razandi, 2003).  A response occurs within minutes of the addition of estrogen, much 
faster than the genomic signaling pathway, and is mediated through membrane-bound ER, 
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independent of gene transcription (Evinger, 2005).  This membrane bound ER is the same ER as 
nuclear ER (Pedram, 2006).  In bone and endothelial cells, estrogen signaling occurs primarily 
through this pathway (Kousteni, 2002).  At the membrane, the ER is associated with caveolin 
rafts (Marino, 2008).  There are specific motifs within the E domain of the ER that are required 
for membrane-localization of the receptor (Pedram, 2007).  When estrogen binds, the ERs 
dimerize and interact with adaptor proteins, such as Src, the p85 subunit of PI3K and G-proteins, 
and activate a variety of growth factor signaling pathways including EGFR, IGFR1, HER2, 
MAPKs, PI3K, AKT, and mammalian target of rapamycin (mTOR) (Marino, 2008; Evinger, 
2005; Kahlert, 2000; Wong, 2002; Schiff, 2004).  The cytoplasmic kinases in these growth factor 
signaling pathways phosphorylate the ER and its coactivators and activate nuclear ER-driven 
transcription as described in the genomic signaling pathway (Shou, 2004).  The genomic and 
non-genomic activities of the ER complement each other and can even act in a synergistic 
manner (Zilli, 2009). 
1.1.4 Ligands 
One class of ligands for the ER is the selective estrogen receptor modulators (SERMs). SERMs 
elicit estrogenic or anti-estrogenic activity depending upon the tissue where they are located 
(McDonnell, 1999).  SERMs act by competitively inhibiting estrogen from binding to the ERs 
and affect both the genomic and non-genomic signaling mechanisms of the ERs (Brzozowski, 
1997). The most common SERMs are tamoxifen and raloxifene.  Tamoxifen (Figure 3) is a 
triphenylethylene that displays a variety of estrogenic and anti-estrogenic activities.  Metabolism 
of tamoxifen produces a highly active metabolite, 4-hydroxytamoxifen (Figure 3), that has a 
higher affinity for the ERs than tamoxifen.  Raloxifene is a dihydroxylated nonsteroidal 
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compound that contains a benzothiophene core.  It has high affinity for both isoforms of the ER 
(Kuiper, 1997).  Other ER ligands are pure anti-estrogens.  The most common pure antiestrogen 
is fulvestrant (Figure 3).  This compound is a 7α-alkylamide derivative of E2 that binds both 
isoforms of the ER (Van Den Bemd, 1999).  It binds the ER and prevents it from activating 
transcription.  Fulvestrant is considered a selective estrogen receptor downregulator (SERD). 
A variety of ligands are currently being developed in order to selectively target one 
isoform or the other of the ER.  The first of these is propylpyrazole triol (PPT) (Figure 3), which 
is a 410-fold selective agonist for ERα with no ability to stimulate transcription through ERβ 
(Stauffer, 2000).  A second pyrazole, methyl-piperidinopyrazole (MPP) (Figure 3), is an ERα-
selective antagonist that binds the α isoform of the ER with about 200-fold greater affinity than it 
has for the β isoform of the ER, and suppresses E2-stimulation through ERα but not through ERβ 
(Sun, 2002).  Another ligand is diarylpropionitrile (DPN) (Figure 3), a selective ERβ agonist that 
binds to ERβ with 70-fold selectivity compared to ERα.  DPN activates transcription through 
ERβ with 170-fold more potency than it does through ERα (Meyers, 2001). 
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Figure 3:  The structures of several ER ligands.  
ER ligands include the SERM tamoxifen (2); its metabolite 4-hydroxy tamoxifen (3); the SERM, raloxifene 
(4); the SERD, fulvestrant (5); PPT (6), an ERα-selective agonist; MPP (7), an ERα-selective antagonist; and DPN 
(8), an ERβ-selective agonist. 
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1.2 BREAST CANCER 
1.2.1 Overview 
Breast cancer occurs when the cells in the breast grow uncontrollably because of genetic and 
epigenetic alterations.  The breast is composed of lobules, the glands that produce milk; ducts 
that connect the lobules to the nipple; fatty, connective tissue; and lymphatic tissue.  Breast 
cancer is classified as in situ when it remains confined within the duct (DCIS) or within the 
lobule (lobular carcinoma in situ (LCIS)).  The majority of breast cancer diagnosed is classified 
as invasive and originated in the duct or lobule then broke through the epithelial architecture and 
invaded the surrounding tissue of the breast (American Cancer Society, 2007).  In the United 
States in 2009, 192,370 women are expected to be diagnosed with invasive breast cancer, while 
62,280 women are expected to be diagnosed with in situ disease.  Of these in situ cases, 85% will 
be DCIS.  Additionally in 2009, 40,170 women are expected to die from breast cancer, making it 
the second leading amongst cancer deaths to lung cancer.  Mammography detects breast cancer 
at an early stage and on average detects 80-90% of breast cancers in women without symptoms 
(American Cancer Society, 2009).  When a breast tumor is discovered, it is assigned a stage in 
order to aid in prognosis and treatment decisions.  The stage is assigned based upon the size of 
the tumor, invasiveness, the involvement of lymph nodes and if the cancer has spread beyond the 
breast and metastasized to other organs (National Cancer Institute, 2009).  The characteristics of 
each stage can be seen in Table 1. 
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Table 1:  The staging of breast cancer. 
Stage Tumor Size Lymph Node Status Metastasis Status 
0 (in situ) Any Negative Negative 
1 < 2 cm Negative Negative 
2A < 2 cm 
2-5 cm 
Positive 
Negative 
Negative 
Negative 
2B 2-5 cm 
> 5 cm 
Axillary Positive 
Axillary Negative 
Negative 
Negative 
3A < 5 cm Ipsilateral Axillary Positive Negative 
3B Any Internal Mammary Positive Negative 
4 Any Any Positive Positive 
 
1.2.2 The Estrogen Receptors in Breast Cancer 
In breast cancer, ER status is determined as a binary factor of (+) or (−).  The ER is expressed in 
about 70% of invasive breast cancers.  ER status provides prognostic information and is a 
predictor of response to endocrine therapy.  The current assays used to determine ER status in a 
patient usually detect only the α isoform (Murphy, 2006). ERβ is expressed in both normal and 
neoplastic breast tissue (Leygue, 1998; Jarvinen, 2000).  The typical levels of the two ERs in the 
breast are similar. Sucrose gradient profiling demonstrates the range of ERα protein in breast 
tissue as 13 – 3,700 fmol/mg and 20 – 475 fmol/mg for ERβ protein (Pearce, 2004).  
Immunohistochemical analysis of 512 breast tumors showed 78% were ERα positive while 50% 
were ERβ positive and ERβ expression was positively correlated with ERα expression (Borquist, 
2008).  Within the breast ERβ is more broadly expressed in both epithelial and stromal cells, 
while ERα is primarily observed in epithelial cells (Park, 2003). Studies investigating the levels 
of the two ER isoforms in different stages of breast abnormalities demonstrate that the receptors 
function differently in the development of breast cancer.  A larger ratio of ERα:ERβ is present in 
many breast cancer tumors compared to benign lesions and normal tissues (Roger, 2001; Shaw, 
  12 
2002; Park, 2003).  ERβ expression is strong in the normal mammary gland and expression is 
reduced during carcinogenesis (Shaaban, 2003; Skiliris, 2003).  In an immunohistochemical 
analysis of 283 breast tissue samples ERβ expression was present in the following percentages in 
each class examined: 94% of normal breast lobules, 77% of ductal hyperplasia, 70% of DCIS, 
and 60% of invasive cancer (Shaaban, 2003).  Additionally, ERβ expression is associated with a 
better prognosis in breast cancer patients (Sugiura, 2007). Immunohistochemical analysis of 
breast cancer patients receiving hormone therapy demonstrated patients with ERα positive 
tumors demonstrated increased disease free survival when also expressing ERβ compared to 
those only expressing ERα (Borgquist, 2008).  Therefore the loss of ERβ expression may be 
involved in tumor progression (Bardin, 2004).  Subtype selective ER knockout mice also 
demonstrate how the receptors function differently in the breast. ERα-knockout mice 
demonstrate very little growth of their mammary ducts, while ERβ-knockout mice develop 
mammary glands with normal ductal branching  (Labahn, 1993; Förster, 2002). 
Altering the expression of the ER isoforms in breast cancer cell lines has also added to 
the understanding of their roles.  Overexpression of ERβ inhibits the E2-induced proliferation of 
ERα expressing breast cancer cells (Omoto, 2003; Ström, 2004; Paruthiyil, 2004; Williams, 
2008).  This ERβ overexpression represses c-myc, cyclin D1, and cyclin A1 expression; 
increases the expression of p21 and p27; and leads to a cell cycle arrest in the G2 phase 
(Paruthiyil, 2004).  ERβ expression additionally decreases the expression of positive 
proliferation regulators such as cyclin E, Cdc25A, and p45skp2 (Ström, 2004).  ERα positive 
T47D breast cancer cells altered to express ERβ show a reduced tumor size, less intratumoral 
blood vessels, and lower expression of proangiogenic vascular endothelial growth factor (VEGF) 
and platelet-derived growth factor β (PDGFβ) than the parental ERα positive T47D cells in mice 
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(Hartman, 2006).  ERβ completely inhibits cyclin D1 gene expression while ERα induces 
expression (Liu, 2002).  In MCF-7 breast cancer cells expressing both ERα and ERβ, shRNA 
knockdown of ERβ causes a significant growth increase in the cells and diminished responses to 
estrogen and tamoxifen with decreased protein levels of p21 (Treeck, 2009).   All of these studies 
support the idea of ERβ as a tumor suppressor (Lazennec, 2006). 
ERα and ERβ exhibit similar gene regulatory activities through the classical pathway 
involving ERE-containing target genes (Petterson, 2000).  In the non-classical pathway involving 
AP-1 sites, however, ERα activates while ERβ inhibits transcription (Paech, 1997; Webb, 1993; 
Webb, 2003).  Messenger RNA microarray studies have identified some of the genes differently 
regulated by the two ER isoforms. Using U20S osteosarcoma cells expressing either ERα or 
ERβ, 52 genes have been identified as commonly regulated by the receptors, 24 are enhanced 
only by ERα, and nine are induced only by ERβ  (Stossi, 2004).  
1.2.3 Therapy Strategies 
There are currently three categories of treatment used for patients diagnosed with breast cancer.  
These three categories are: surgery, radiation therapy and systemic therapy.  Within systemic 
therapy there are the three sub-categories of biological therapy, chemotherapy and hormone 
therapy.  These different therapies are often used in combination with one another (American 
Cancer Society, 2007). 
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1.2.3.1 Surgery 
 
Once diagnosed with breast cancer, most women undergo surgery to remove the cancer from the 
breast.  This surgery may be a breast conserving procedure, either a lumpectomy or a partial 
mastectomy.  A lumpectomy removes the tumor and a small amount of tissue surrounding it.  A 
partial mastectomy removes a larger portion of the breast including the tumor and a portion of 
the normal tissue surrounding it.  In addition to the breast conserving surgeries, another surgical 
procedure is a total mastectomy.  This is the removal of the entire breast that contains the cancer. 
A modified radical mastectomy is another surgical option.  This involves removal of the entire 
breast that contains the cancer, many of the lymph nodes under the arm, the lining over the chest 
muscles, and in some cases part of the chest wall muscles.  The last surgery option is a radical 
mastectomy, which involves removal of the entire breast with the cancer, the chest wall muscles 
under the breast, and all of the lymph nodes under the arm.  Many patients also receive radiation, 
chemotherapy, or hormone therapy after surgery (National Cancer Institute, 2009).   
1.2.3.2 Radiation Therapy 
 
Radiation therapy involves the use of high energy-x-rays in either an external or internal manner.  
External radiation involves using a machine outside of the body.  Internal radiation involves the 
introduction of radioactive substance in a needle, seed, wire, or catheter inserted into or near the 
tumor.  The stage of the cancer determines the specifics of the radiation therapy (National Cancer 
Institute, 2009).  Typically with breast cancer, external radiation therapy is used.  It is focused on 
the breast and possibly the chest wall and underarm area.  The therapy is usually given for five to 
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seven weeks.  Radiation therapy is almost always used after lumpectomy and sometimes 
following a mastectomy (American Cancer Society, 2007).   
1.2.3.3 Systemic Therapy 
There are three types of systemic therapies used to treat breast cancer:  biological therapy, 
chemotherapy and hormone therapy. 
Biological Therapy 
Biological therapy works with the immune system to fight cancer.  About 15-30% of breast 
cancers overexpress human epidermal growth factor receptor 2 (HER2/neu; a.k.a. ERBB2, 
CD340, and p185), a growth-promoting, membrane-bound tyrosine kinase.  Tumors 
overexpressing HER2/neu tend to grow faster and are more likely to recur (American Cancer 
Society, 2007).  Trastuzumab is a monoclonal antibody that directly targets HER2 and was 
initially used in the treatment of women with HER2 positive metastatic tumors (Cobleigh, 1999; 
Vogel, 2002; Slamon, 2001).  Clinical trials then demonstrated adding trastuzumab to standard 
chemotherapy for early stage breast cancer reduces the risk of death by 33% compared to 
chemotherapy alone (Romond, 2005).  In 2006, the FDA approved trastuzumab for the treatment 
of all HER2 positive breast tumors (Wolff, 2007). 
Chemotherapy 
Chemotherapy involves the use of drugs to stop the growth of cancer cells by either cytotoxic 
(killing the cells) or cytostatic (preventing the cells from dividing) mechanisms.  There are two 
types of chemotherapy, systemic and regional.  Systemic chemotherapy reaches the cancer cells 
through the blood stream.  Regional chemotherapy involves placing the chemotherapy directly 
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into the organ containing the tumor.  As in radiation therapy, the stage of the cancer determines 
the specifics of chemotherapy (National Cancer Institute, 2009).  The most common 
chemotherapeutic agents used for the treatment of breast cancer include:  cyclophosphamide, 
methotrexate, fluorouracil, doxorubicin, epirubicin, paclitaxel and docetaxel (American Cancer 
Society, 2007). 
Hormone Therapy 
For breast cancer, hormone therapy involves blocking the action of estrogen to stop cancer cells 
from growing.  Hormone therapy is used when the breast cancer is ERα positive.  About 70% of 
breast cancers diagnosed are ERα positive  (Murphy, 2006).  There are three different classes of 
agents used for hormone therapy of breast cancer.  These are SERMs, aromatase inhibitors (AIs) 
and SERDs. 
Selective Estrogen Receptor Modulators 
SERMs display both estrogen agonistic and antagonistic effects, depending upon their location 
(McDonnell, 1999).  Tamoxifen was the first SERM approved for the treatment of advanced 
breast cancer in the United States in 1977.  In 1998, this approval was extended to reducing 
breast cancer development or recurrence in women who are at a high risk for the disease (Jordan, 
2003).  Tamoxifen functions largely through its phenolic metabolite 4-hydroxytamoxifen  which 
competes with estrogen for binding to the ER. Tamoxifen then induces dimerization of the ERs 
and localization to EREs.  The receptor-bound drug causes a modified positioning of helix 12 in 
the ER, which alters the cofactor-binding domain and inhibits AF2-dependent interactions 
(Brzozowski, 1997; Shiau, 1998; Privalsky, 2004; Nettles, 2005).  Due to its classification as a 
SERM tamoxifen acts as an estrogen receptor agonist in some tissues.  One of the side effects of 
tamoxifen is an increased risk of endometrial cancer because it acts as an agonist in this tissue.  
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The ability of a SERM to act as an agonist depends on the AF1 region of the ER and the cellular 
availability of cofactors (Lees, 1989; McDonnell, 1999; Privalsky, 2004; Smith, 2004; Jordan, 
2007).  Tamoxifen exhibits strong agonistic activity in endometrial cell lines where the steroid 
receptor coactivator-1 (SRC-1) is present in high levels.  In comparison, tamoxifen exhibits 
antagonistic activity in mammary cells, which have low levels of SRC-1 in comparison to 
endometrial cells (Shang, 2002). 
The second approved SERM for the treatment of breast cancer is raloxifene.  Raloxifene 
was first investigated for its use in osteoporosis and was clinically approved for the prevention of 
this condition in 1998 (Jordan, 2003).  Clinical trials then demonstrated in postmenopausal 
women tamoxifen and raloxifene are equal in their ability to reduce the risk of invasive disease, 
while only tamoxifen is effective for in situ cancer.  Raloxifene, however, has a lower risk of 
side effects, which include uterine cancer and blood clots (Vogel, 2006).  Raloxifene was 
approved in 2007 for the reduction of breast cancer in postmenopausal women who are at high 
risk for the development of invasive breast cancer (American Cancer Society, 2008). 
Aromatase Inhibitors 
Aromatase is a cytochrome P-450 family member and is the enzyme responsible for the 
production of estrogens from androgenic substances (Evans, 1986).  It is highly expressed in the 
placenta and in the granulosa cells of the ovaries where its expression depends on cyclical 
gonadotropin stimulation.  Aromatase is also produced in smaller amounts in the subcutaneous 
fat, liver, muscle, brain, normal breast and breast cancer tissue (Miller, 1982; Nelson, 2001).  
After menopause, the subcutaneous fat is the source of most residual estrogen production 
(Longcope, 1986).  Plasma levels of E2 fall from 400 pM to 25 pM at menopause, yet the 
concentration of E2 in breast carcinoma tissue in post-menopausal women is about ten times the 
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level seen in plasma (Thiijssen, 1989).  These levels are partly due to the aromatase enzyme 
located in the tumor (Smith, 2003). Therefore, AIs are of most use in postmenopausal women 
whose estrogen production occurs by the peripheral aromatization of androgens.  The steroidal 
AI exemestane, which binds aromatase irreversibly, and the non-steroidal AIs, anastrozole and 
letrozole, are currently in clinical use (Smith, 2003).  Studies have demonstrated the AIs are at 
least as effective as tamoxifen in the treatment of advanced breast cancer.  AIs are approved for 
the treatment of advanced breast cancer in post-menopausal women and for the prevention of 
recurrence after surgery (American Cancer Society, 2008).     
Selective Estrogen Receptor Downregulators 
There is one clinically approved SERD, fulvestrant.  Fulvestrant competes with E2 for binding to 
the ER LBD and its long bulky side chain alters the conformation of the binding pocket and 
inhibits receptor dimerization and DNA binding (Fawell, 1990; Pike, 2001).  Fulvestrant is 
approved for the treatment of post-menopausal women whose cancer no longer responds to 
tamoxifen (American Cancer Society, 2008). 
1.2.4 Tamoxifen Resistance 
Tamoxifen has been the cornerstone of breast cancer treatment for the last thirty years; however, 
a major problem with tamoxifen therapy is the development of drug resistance.  While there are 
new hormone therapies that are approved for clinical use as described above, resistance to all 
forms of hormone therapy remains a problem.  ER transcriptional activity is a complex process 
and the actual binding of E2 to the ER is only a small part of this process.  The growth factor 
signaling pathways present in a cell and the ER cofactors available make up the cellular context 
that determines ER-transcriptional activity.  Hormone therapies are therefore influenced by a 
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multitude of factors.  A better understanding of the mechanisms behind antiestrogen resistance 
will allow for the design of more effective hormonal therapies  (Zilli, 2009).  Many different 
mechanisms have been attributed to the development of tamoxifen resistance, yet the 
phenomenon is not fully understood. 
One of the areas that has received much attention is ER status.  The main predictor for a 
positive response to endocrine therapy is the presence of the ER, therefore a lack of ER 
expression is the main mechanism of de novo resistance.  A lack of ER expression in breast 
cancer has been explained by several different mechanisms.  The first is the aberrant methylation 
of CpG islands in the 5’ regulatory region of the ERα gene (Ottaviano, 1994).  The second is an 
increased deacetylation of histones, which leads to a more compact nucleosome structure and 
limits transcription of the ER (Yang, 2001; Parl, 2003).  Finally, ER-negative breast cancers 
display a higher level of expression of several growth factor receptors compared to ER-positive 
breast cancers, suggesting that growth factor signaling may reduce ER expression (Normanno, 
1994; Creighton, 2006).  The loss of ER expression has also been hypothesized to be responsible 
for acquired resistance to tamoxifen.  It has been shown, however, that only 17-28% of tumors 
with acquired resistance to tamoxifen have lost ER expression (Johnston, 1995; Gutierrez, 2005).  
Additionally, 20% of tumors that develop tamoxifen resistant still respond to another hormone 
therapy (Osborne, 2002; Howell, 2005).  Therefore in the case of tamoxifen, loss of the ER alone 
does not account for drug resistance. Another explanation suggested to contribute to resistance is 
mutation of the ERα.  Mutation of the ER occurs in less than 1% of human breast cancers, 
however (Herynk, 2004). 
The levels of ERβ expression have also been investigated in tamoxifen resistance because 
of ERβ’s negative influence on ERα-promoted transcription (Pettersson, 2000).  High levels of 
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ERβ were demonstrated in tamoxifen-resistant cell lines via analysis of mRNA levels (Speirs, 
1999). Overexpression of ERβ protein in MCF7 breast cancer cells confirmed by Western blot 
does not lead to antiestrogen resistance but is associated with an increased sensitivity to 
tamoxifen (Murphy, 2005).  Low levels of ERβ at the protein level are predictive of tamoxifen 
resistance  (Hopp, 2004; Esslimani-Sahla, 2004). 
The intracellular environment has been investigated in relationship to acquired 
antiestrogen resistance.  Coregulatory proteins play a major role in the impact the ER has on 
transcription (McKenna, 1999). Overexpression of coactivators and/or down-regulation of 
corepressors alter the effects of SERMs (Smith, 1997).  Nuclear receptor corepressor 1 (NCOR1) 
is a corepressor that binds the ER and inhibits the partial agonistic activity of tamoxifen 
(Cottone, 2001).  Low levels of NCOR1 are associated with a shorter relapse-free survival in 
women treated with tamoxifen (Girault, 2003).  Increased growth factor signaling may also 
contribute to antiestrogen resistance.  Estrogen is involved in cell cycle regulation as a member 
of a negative feedback loop that downregulates genes involved in proliferation, such as 
epidermal growth factor receptor (EGFR) (Yarden, 2001).  When antihormonal agents bind and 
inhibit ER activation, the negative feedback caused by the activated ER signaling is removed.  
Thus, the downstream MAPK pathways from EGFR are activated.  These pathways add 
activating phosphorylations to the ER and therefore the ER maintains nuclear activity and can 
influence ER-sensitive genes involved in cell proliferation (Gee, 2003; Knowlden, 2003).  MCF-
7 cells made resistant to tamoxifen through long-term exposure to the drug exhibit ERα 
redistribution with a greater number of receptors in the cytoplasm and at the plasma membrane 
compared to the parent MCF-7 cell line.  At the plasma membrane, ERα associates with EGFR.  
These resistant cells present increased sensitivity to EGF and E2-stimulated activation of MAPK, 
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supporting the idea that enhanced non-genomic functions of the ER and its interaction with 
EGFR play a role in acquired tamoxifen resistance (Fan, 2007).  Plasma membrane ER can 
activate HER2 signaling, and tamoxifen has been demonstrated to act as an agonist on the 
membrane ER and stimulate the ER-HER2 crosstalk.  The kinase cascade downstream of HER2 
adds the activating phosphorylations to the ER and its coregulators, which can then influence cell 
proliferation (Schiff, 2004; Shou, 2004). 
Another proposed mechanism of antiestrogen resistance is the ability of breast cancer 
cells to become hypersensitive to estrogen.  ER positive MCF-7 cells cultured in estrogen-free 
media for a long period of time provide one model to study this phenomenon.  The MISS 
pathway and the rapid increase of growth factor signaling is the mechanism by which these 
MCF-7 cells are able to grow in very low concentrations of E2.  IGF-IR and ER cross-talk is 
increased, leading to activation of MAPK and PI3K/AKT (Santen, 2003; Santen, 2005). 
1.2.5 Biomarkers 
1.2.5.1 Overview 
Early detection of breast cancer not only lessens human suffering, but also reduces the burden 
placed on society in terms of socioeconomic resources (Levenson, 2007).  Early detection allows 
patients to live longer, receive less treatment, and, in general, fare much better than those 
patients who receive a much more advanced diagnosis (Etzioni, 2003).  Additionally, prognostic 
indicators and predictors of response to therapy during the clinical management of breast cancer 
have an important role in treatment decisions and may improve clinical outcome (Ravaioli, 
1998). The characteristics of tumor cells are different from normal cells, biomarkers can use this 
difference and be developed to aid in the diagnosis and treatment of breast cancer.  Different 
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biomarkers will be able to define risks and identify early stages of tumor development, assist in 
tumor detection, stratify patients for treatment, predict disease outcome, and help in monitoring 
for recurrence (Levenson, 2007). 
The current major technique used in the diagnosis of breast cancer is mammography.  
While this technique is highly sensitive, 67.8%, and specific, 75%, in the diagnosis of DCIS, it 
does have drawbacks.  The sensitivity of mammography drops to 45.8%-55% in women with 
dense breast tissue (Berg, 2006). Mammography depends on the presence of a certain volume of 
tumor cells in a specific location and may miss smaller or diffuse tumors (Levenson, 2007).    
The reading and assessment of mammography is also highly subjective due to the different 
experience levels of radiologists (Burnside, 2005). A diagnostic test for a biomarker removes the 
influence of the observer.  Nipple aspirate fluid (NAF) has been suggested to be the source for 
biomarker screening in breast cancer.  Screening based on NAF is, however, unlikely to be very 
successful, as many women do not produce NAF (Levenson, 2007).  Ductal lavage is another 
suggested route for the detection of breast cancer biomarkers.  This procedure requires the time-
consuming procedure of the cannulation of each individual and only a few ducts can be 
successfully cannulated (Badve, 2003).  The indirect analysis of diagnostic biomarkers from the 
blood offers the highest potential for use in population-wide screening of breast cancer.  Blood 
interacts with every cell in the body and tumor cells, tumor-specific antigens, autoantigens and 
tumor RNA and DNA can be recovered from the blood (Levenson, 2007). 
1.2.5.2 Breast Cancer Biomarkers in Clinical Use 
The American Society of Clinical Oncology (ASCO) first published evidence-based clinical 
practice guidelines for the use of tumor markers in breast cancer in 1996 and last updated these 
guidelines in 2007.  There are several breast tumor markers that demonstrate evidence of clinical 
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utility and are recommended for use.  ASCO guidelines state ER and progesterone receptor (PR) 
should be measured on every primary invasive breast cancer; in DCIS, the data is, however, 
insufficient to recommend routine measurement of these receptors.  The next biomarker 
recommended for clinical use by ASCO is HER2.  HER2 expression and/or amplification should 
be evaluated in every primary invasive breast cancer at the time of diagnosis or at the time of 
recurrence.  CA 15-3 and CA 27.29 assays detect circulating MUC-1 antigen in peripheral blood.  
These assays are recommended for monitoring patients with metastatic disease in conjunction 
with diagnostic imaging, history, and physical examination during active therapy.  The 
guidelines do not recommend these assays to be used independently, nor for the screening, 
diagnosis or staging of breast cancer.  The detection of carcinoembryonic antigen (CEA) is 
recommended along the same guidelines as CA 15-3 and CA 27.29 by ASCO.  The guidelines 
also recommend the performance of enzyme-linked immunosorbent assays (ELISAs) on 300 mg 
of fresh or frozen breast cancer tissue for the detection of urokinase plasminogen activator 
(uPA)/plasminogen activator inhibitor (PAI-1) for the determination of prognosis in patients with 
newly diagnosed, lymph node-negative breast cancer.  Low levels of both of these markers are 
associated with a sufficiently low level of recurrence, therefore chemotherapy will only 
contribute minimal additional benefits (Harris, 2007).  OncotypeDX is an RT-PCR assay 
measuring the expression of 21 genes in RNA extracted from formalin-fixed, paraffin embedded 
(FFPE) samples of tissue from primary breast cancer.  An algorithm manipulates the levels of 
expression of these 21 genes and assigns a patient to a group referring to the risk of distant 
recurrence:  low, intermediate or high (Cronin, 2004).  The guidelines recommend this assay to 
be used in prediction of the risk of recurrence in newly diagnosed patients with lymph node-
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negative, estrogen receptor-positive breast cancer who are undergoing tamoxifen treatment 
(Harris, 2007). 
The majority of the recommended biomarkers in breast cancer involve later stage or 
specific treatment decisions. ER status has proven very effective for use in guiding endocrine 
therapy decisions (Clark, 1983).  Antiestrogen resistance is, however, a problem that occurs in 
many patients receiving endocrine therapy (Zilli, 2009).  The development of biomarkers of 
antiestrogen resistance will help to optimize the use of endocrine therapy. Additionally, there is 
no current biomarker recommended for the early detection of breast cancer. 
1.2.5.3 Isobaric Tags for Relative and Absolute Quantitation 
Isobaric tags for relative and absolute quantitation (iTRAQ) is a technique that can be used in the 
search for new biomarkers for breast cancer.  iTRAQ is a proteomic technique that allows for the 
identification and quantification of hundreds of proteins in up to eight different biological 
samples in a single MS experiment.  iTRAQ involves a multiplexed set of reagents, which place 
isobaric mass labels via amide linkage to the N terminus and lysine side chains of peptides in a 
protein digestion mixture.   The same peptides, despite being labeled with a different reagent, are 
chromatographically indistinguishable. Since they are isobaric, they are also indistinguishable in 
a single MS experiment.  The isotopically-enriched label does, however, yield unique reporter 
ions following collision-induced dissociation (CID), which allows for identification of the 
peptide from the multiplex set (Ross, 2004).   
The label consists of a reporter group (based upon an N-methylpiperazine), a mass 
balance group (carbonyl), and a peptide-reactive group (N-hydroxysuccinimide (NHS) ester).  
The overall mass of the reporter and balance components are kept constant using isotopic 
enrichment with 13C, 15N, and 18O.  The amide linkage of the tag to the peptide fragments similar 
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to the peptide backbone when subjected to CID and the reporter group retains a charge and 
appears in the m/z 113 – 121 range of the mass spectrum.  This region does not usually contain y 
and b peptide ions (Ross, 2004).  The peptide backbone generates y and b ions in an MS/MS 
spectrum. B ions are those where the N terminus retains the charge, while y ions are those where 
the C terminus retains the charge (Johnson, 1987).  Along with the sequence information 
provided by the y and b ions, the unique iTRAQ reporter ion present in the spectrum identifies 
the sample from which the peptide arose and provides the relative abundance of that peptide 
from that particular sample to be calculated amongst the other samples (Ross, 2004).  Confidence 
in the protein identification and quantification is gained because more than one peptide from the 
same protein provides quantitative information (Glen, 2008). 
The iTRAQ methodology has been used in many studies to identify differentially 
abundant proteins in cancer.  One example study involved investigation of proteins associated 
with the progression of human prostate cancer using a poorly metastatic line along with its 
highly metastatic variant.  Whole cell lysates made from the lines were labeled with the iTRAQ 
reagents followed by two-dimensional-liquid-chromatography-mass spectrometry/mass 
spectrometry (2D-LC-MS/MS).  A large number, 280, of unique proteins were identified, and 
relative expression data was obtained on 176 proteins.  Of the 176 proteins, ten were 
significantly increased (>1.5 fold) and four were significantly decreased (<1.5 fold).  Tumor 
rejection antigen, gp96, was one of these altered proteins.  Western blotting was used to confirm 
the levels of gp96 in the cell lines and immunohistochemistry was performed on patient samples 
to demonstrate its clinical relevance (Glen, 2008). 
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1.3 THE NUCLEAR MATRIX 
1.3.1 Overview 
An area that holds promise for the development of biomarkers in breast cancer is the NM.  The 
NM, discovered in 1974, is the structural scaffolding of the nucleus.  It is comprised of 98% 
protein, 0.1% DNA, 0.5% phospholipid and 1.2% RNA and accounts for 5-10% of the total 
nuclear protein (Berezney, 1974).  The NM consists of the peripheral lamins and pore 
complexes, an internal ribonucleoprotein network, and residual nucleoli (Sjakste, 2004).  A two-
dimensional gel of proteins isolated from the NM demonstrates about 200 spots (Zink, 2000).  
Proteins found in the NM are known as nuclear matrix proteins (NMPs). 
  The NM is the three-dimensional support scaffold of the nucleus and, as a consequence, it 
is involved in many of the fundamental functions of a cell, including determining nuclear 
morphology, organizing DNA throughout the cell cycle, stabilizing and orienting DNA during 
replication, organizing gene regulatory complexes and RNA synthesis (Davido, 2000).  There are 
many studies to support these roles for the NM.  Newly replicated DNA is tightly associated with 
the NM (Berezney, 1975).  Proteins found in the NM reach their maximum level of 
phosphorylation just before the onset of DNA replication in the regenerating liver, indicating the 
phosphorylation of NMPs regulates DNA synthesis (Allen, 1977).  DNA loop domains are the 
sites of DNA replication, and incorporate DNA replicases and topoisomerase II into complexes 
that are bound to the NM (Earnshaw, 1985).  These sites of attachment to the NM in the DNA 
are known as matrix attachment regions (MARs) (Ludérus, 1992).  DNA loops on the NM can be 
directly visualized with fluorescent and electron microscopy (McCready, 1979; Vogelstein, 
1980; Lebkowski, 1982).  The NM is also the site of RNA transcription, as newly synthesized 
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hnRNA and its processing intermediates are associated with the NM (Jackson,1981; Ciejek, 
1982). 
The NM’s role is its regulation of gene expression is linked to breast cancer.  E2 binds 
the NM in an estrogen responsive tissue, chicken liver, with a Kd of 1 x 10-9 M (Barrack, 1980).  
These NM E2 binding sites have been confirmed to be the ER (Alexander, 1987). Several studies 
have suggested that anywhere from 46-62% of the total ER content of a nucleus is associated 
with the NM upon estrogen stimulation (Barrack, 1977; Barrack, 1980; Barrack, 1982). Several 
studies of estrogen-regulated genes demonstrate the NM plays a role in gene expression 
regulation.  The gene for ovalbumin, a major egg white protein, associates with the NM in hen 
oviduct cells where it is actively transcribed, but it does not associate with the NM in hen brain 
cells where it is inactive.  The ovalbumin gene disassociates from the NM when the hen 
undergoes estrogen withdrawal and reassociates when restimulated with estrogen (Robinson, 
1983).  DNA dot blot assays demonstrate the gene for vitellogenin II, a major egg yolk protein, 
associates with the NM upon E2 stimulation before its mRNA synthesis begins. When the 
vitellogenin gene is no longer being transcribed, it is released from the NM.  Stimulation with E2 
again leads to a reassociation of the gene with the NM (Jost, 1984).  
The NM is a component of the tissue matrix system, which also includes the cytoskeleton 
and the extracellular matrix (ECM).  The tissue matrix system connects the cell periphery to 
DNA in the nucleus in a structural and functional manner (Pienta, 1992).  The cytoskeleton is 
composed of actin-containing microfilaments, tubulin-containing microtubules, and intermediate 
filaments (IFs).  These IFs are made up of cytokeratins and vimentin (Ingber, 1993). These IFs  
maintain physical association between the NM and the cytoskeleton (Nickerson, 1990; Hendrix, 
1996).  The IF protein vimentin is anchored to the nuclear lamina via lamin B (Georgatos, 1987; 
  28 
Djabali, 1991).  Lamins are present at the nuclear periphery and in the internal NM (Hozak, 
1995).  This supports the notion of a molecular network that connects the plasma membrane of 
the cell and cytoskeleton with the nucleoskeleton.  The linkage of the NM to the cytoskeleton 
and ECM suggests the NM may be altered by what occurs in and affects the extracellular 
framework (Getzenberg, 1991A). 
1.3.2 Alterations to the Nuclear Matrix in Cancer 
One of the hallmark events that occurs in cancer progression is that cellular structure becomes 
increasingly abnormal, particularly with regard to alterations of the nucleus (Zink, 2000).  
Nuclear alterations are commonly used as pathological indicators of malignancy.  In transformed 
cells, the nucleus is often enlarged, has an abnormal chromatin pattern, and is irregular in shape.  
As the NM partly maintains the spatial arrangements of the nucleus, this suggests it has a 
fundamental link to the development of cancer (Replogle, 1996).  Additionally, because of its 
role in many of the fundamental processes of a cell described earlier, disruption to the NM is a 
likely determinant in carcinogenesis (Davido, 2000).  The NM’s link to the ECM also suggests 
that the NM is altered in cancer, because tumor-induced changes in the surrounding ECM may 
alter the NM composition (Getzenberg, 1991A). 
In 1979 the NM of hepatoma cells was shown to differ qualitatively from the NM of 
normal liver cells by microscopy.  This provided the initial support for investigation into how the 
NM composition can provide insight into the origin of cells and how disease alters these cells 
(Berezney, 1979).  Since the initial study, numerous investigations of the NM in cancer have 
been performed.  Because of the potential role of the NM in cell transformation, there is much 
interest in finding markers for cancer screening in the NM  (Davido, 2000).  Further promise for 
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the use of NMPs for the diagnosis of cancer is supported by the detection of NMPs in the serum 
of cancer patients (Miller, 1992).  This detection may allow for the development of a non-
invasive screening procedure that could be used in the clinic. 
  The NM’s role in cancer is supported by its binding sites for various tumor-associated 
proteins. The apoptotic proteins, bax and bcl-2, localize to the NM in glioblastoma (Wang, 
1999). The tumor suppressor p53 binds to the NM and this binding increases in response to DNA 
damage (Ming, 2001). The tumor suppressor retinoblastoma (Rb) protein has also been 
demonstrated to be a NMP that interacts with lamin A (Mancini, 1994; Ozaki, 1994).  Several 
inherited cancer disorders also suggests a role for the NM in cancer.  For example, multiple 
endocrine neoplasia type I (MEN1), characterized by tumors in multiple endocrine organs, 
involves a defective NMP, menin (Jin, 2003). 
The NM has shown some promise in terms of affording predictive biomarkers for bladder 
cancer.  BLCA-4, a protein found only in the NM of bladder cancer samples, is being developed 
for use in an urine immunoassay.  This protein is detectable in both tumor and normal cells from 
bladder cancer patients, but not in cells in bladder tissue from healthy individuals (Konety, 
2000A).  A clinical trial demonstrated very positive results, showing that BLCA-4 levels may be 
able to accurately identify individuals with bladder cancer and distinguish them from normal 
individuals (Konety, 2000B).  Matritech, Inc. has developed an assay that measures urine levels 
of another NMP, NMP22.  This assay is approved by the FDA for the detection of occult or rapid 
recurring disease after transurethral resection of bladder cancer (Sjakste, 2004).  Matritech Inc. 
also produces an antibody to NMP 179, which has been demonstrated to be an effective marker 
of cervical cancer (Keesee, 1999).  Further information on the NM’s link to cervical cancer is 
revealed by the origin of the disease.  Human papillomavirus (HPV) underlies 90% of all 
  30 
cervical cancer cases and HPV-16 DNA binds to different NMPs in normal and cervical 
carcinoma cells.  HPV-16 DNA has a higher affinity for the more recently expressed acidic 
proteins present in the transformed cells (Yang,1997).  Additionally, drug treatment of cervical 
cancer alters the composition of the NM.  Dexamethasone, which inhibits the growth of cervical 
cancer cells, decreases the expression of the NMP NuMa (Yam, 1998).   
Dunning rat prostate tumor cell lines have significant NMP alterations compared to a 
normal prostate tissue line.  Additionally, the NM composition is different for each of the lobes 
of the normal rat prostate (Getzenberg, 1991B).  Matritech Inc. discovered an NMP unique to the 
blood of prostate cancer patients, NMP48, and developed a kit for the determination of this 
protein in the clinic (Sjakste, 2004).  High mobility group nonhistone protein HMG1(Y), is 
localized to the NM in prostate cancer cells of a late stage prostate cancer mouse model (Leman, 
2003).  Nucleophosmin, a protein related to proliferation, is localized to the NM in prostate 
cancer cell lines  (Subong, 1999). 
NMPs in colon cancer demonstrate that throughout disease progression, the proteins 
localized to the NM change.  In ulcerative colitis dysplasia tissue, three unique NMPs are found, 
while two NMPs are unique to colon cancer tissue and three NMPs are common to both 
ulcerative colitis dysplasia and colon cancer (Izzo, 1998).  A more recent study identified four 
NMPs that are present in tumor samples and not in the matched normal adjacent tissue or normal 
colon tissue.  Additionally two NMPs are found in the cancer and normal tissue, but not in the 
normal adjacent tissue (Brunagel, 2002A).  NMPs have also been identified that are specific to 
colon cancer metastases to the liver (Brunagel, 2002B).  In another study of the NM in colon 
cancer, creatine kinase B (CKB) and heterogeneous nuclear ribonucleoprotein F (hnRNP F) were 
demonstrated as potential biomarkers.  CKB is present at higher levels in 78% of colon tumors 
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compared to normal colon tissues.  hnRNP F is expressed in 89% of colon tumors and 100% of 
liver metastases and also at higher frequencies in colon polyps compared to normal donor colon 
(Balasubramani, 2006). 
1.3.3 Alterations to the Nuclear Matrix in Breast Cancer 
NMPs have also been investigated in breast cancer.  An initial study investigating the NM in 
breast cancer involved analysis of human tumors.  The NM of normal breast tissue is similar in 
terms of protein composition to that of breast tumor tissue.  Specific differences exist though, as 
four NMPs are expressed in the tumor tissue but not the normal tissue.  Also, two other NMPs 
are present in the normal breast tissue, but absent from the breast tumor sample  (Khanuja, 
1993).  In another study, the ER+, hormone-dependent lines  T47D, MCF-7 and ZR-75; the ER−, 
hormone-independent lines  MDA-MB-231 and BT-20; the ER+, hormone-dependent line T5-
PRF; and the nontumorigenic, spontaneously immortalized human breast epithelial line MCF-
10A1 were examined.  Five spots in a 2D gel are unique to the NM in ER+ cell lines, while one 
spot is associated exclusively with the NM of the ER− cell lines. The expression of these six 
NMPs has been examined in tumor samples from patients.  The first five NMPs are found in the 
ER+ breast tumors, while the sixth is found in some but not all of the tissue samples.  
Additionally the sixth NMP is present in the ER− breast tumors, while the first five are not 
(Samuel, 1997). 
Studies of the NM in breast cancer have also focused on the IFs and their interactions 
with the NM.  Using the T-47D5 human breast cancer cell line, an ER+ and E2-responsive line, 
an estrogen-independent line, T5-PRF, was developed by chronically depleting the levels of 
estrogen used in the culture over a long period of time.  The NM-IF isolated from the cell lines 
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showed three proteins as the major components; cytokeratin 8, cytokeratin 18, and cytokeratin 
19.  These proteins are expressed at much higher levels in the T5-PRF cell line, suggesting they 
are estrogen regulated (Coutts, 1996). In another study, cis-diamminedichloroplatinum (II) 
(cisplatin) was used to cross-link the nuclear proteins to nuclear DNA and determine if these IFs 
are bound to the nuclear DNA.  Cytokeratins 8, 18, and 19 are attached to the nuclear DNA of 
T47D5 and T5-PRF cells, and this interaction is influenced by estrogens in the hormone 
dependent T-47D5 cell line, but not the hormone-independent T5-PRF line (Spencer, 1998).  
Differences in the nuclear proteins associated with nuclear DNA in hormone-dependent and 
hormone-independent breast cancer cell lines have been determined.  Using two-dimensional gel 
electrophoresis, several proteins were found crosslinked to DNA in all cell lines investigated.  
These include the transcription factor hnRNP K, Lamins A and C, and cytokeratins 8, 18 and 19.  
Some variations was found in the levels of proteins identified amongst the lines used.  Three 
proteins are detected only in the pseudo-normal MCF10A1 cell line, while three proteins are at 
significantly higher levels in the hormone-dependent, ER+ lines.  Two proteins are found only in 
the hormone-independent, ER− lines.  These proteins may serve to distinguish breast cancer 
epithelial cell types in breast tumors, because breast cancer cells are often very similar to their 
corresponding tumor.  In order to verify that these cross-linked proteins are NMPs, two-
dimensional gels of NM preparations from each of the cell lines was examined for the presence 
of the cross-linked proteins.  All but two of the proteins detected only in the MCF10A1 line were 
present in the NMP preparations. The IF protein vimentin was also demonstrated to associate 
with DNA in MDA-MB231 breast cancer cells but not the other lines examined (Spencer, 2000). 
NMPs also associate with DNA differently during progression of breast cancer.  The 
parental cell line MCF-7 and the MIII, LCC1 and LCC2 derivatives of this line demonstrate this 
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concept (Spencer, 2001).  MIII and LCC1 are ER+, invasive, metastatic, estrogen-independent, 
estrogen-responsive and antiestrogen-sensitive lines.  LCC2 is an ER+, invasive, metastatic, 
estrogen-independent, estrogen-unresponsive, and tamoxifen-resistant line (Brunner, 1993).  
Fifteen NMPs are altered in their expression in a variety of ways over the cell lines.  One 
particular NMP demonstrates decreased levels as the cell lines progress from MCF-7 to MIII, 
LCC1 and LCC2.  Additionally, a general loss of the cross-linking of NMPs to nuclear DNA can 
be observed as samples progress to estrogen independence and antiestrogen insensitivity.  This 
study also showed cytokeratins 8, 18 and 19 are the most abundant proteins that cross-linked to 
DNA.  The levels of lamins A and C also progressively increase in the level of cross-linking to 
DNA as the cells progress from MCF-7 to LCC2.  This study supports the idea that as ER 
positive breast cancer cells progress, there is a loss of contacts between the chromatin and NMPs 
(Spencer, 2001). 
Matritech has evaluated an NMP, NM-200.4™, as a clinical screening assay for breast 
cancer.  This NMP was first identified in T-47D breast cancer cells, where it is present at a high 
concentration.  An antibody to NM-200.4 shows high reactivity to the nuclei of breast cancer 
cells. The NM-200.4 antibody also reacts to nuclei from lung carcinoma, papillary thyroid 
carcinoma, ovarian fibroma, a lymphoma and also other normal tissues, demonstrating it is not 
very specific.  Though only one in ten benign breast biopsies show reactivity, the antibody is 
reactive with other normal tissues (Weidner, 1991).  This antibody has therefore not been 
recommended for clinical use (Sjakste, 2004).  This exercise does, however, provide support to 
continue to investigate the NM for other, more specific markers (Weidner, 1991).  Matritech has 
also discovered a specific NMP, NMP66, in the blood of breast cancer patients that is not present 
in the blood of women without detectable breast cancer (Sjakste, 2004). 
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Heat shock protein 27 (HSP27) is known to have a role in growth and drug resistance in 
breast cancer cells (Oesterreich, 1993).  Elevated levels of HSP27 correlate with increased 
invasion (Lemieux, 1996).  A large study of 425 samples by immunohistochemistry and 788 
samples by Western blotting revealed, however, that HSP27 is not an independent prognostic 
marker (Oesterreich, 1996).  There is still support for HSP27’s role in breast cancer development 
though because of its correlation with ER expression and its response to estrogen (Moretti-Rojas, 
1988; Seymor, 1990).  In order to try to understand more about HSP27’s function in breast 
cancer, the promoter of HSP27 and the promoter-associated proteins have been investigated.  
One protein, HET (HSP27-ERE-TATA-binding protein), binds to the imperfect ERE in the 
promoter of HSP27 and is a NMP. Overexpression of HET decreases the activity of the HSP27 
promoter (Oesterreich, 1997).  HET binds the ER in its DNA-binding domain and hinge region.  
This interaction occurs both in the presence and absence of estrogen, and is increased when the 
ER is bound to tamoxifen.  The protein enhances the action of tamoxifen.  When HET is 
overexpressed, however, it represses the activity of both estrogen and tamoxifen on the ER 
(Oesterreich, 2000).   
The levels of HET in many commonly used breast cancer cell lines have been 
investigated.  The protein is expressed at various levels in MDA-MB468, ZR-75, MDA-MB330, 
T47D, MCF-7/MG and MDA-MB231 cell lines, with MDA-MB231 expressing the highest 
amount. HET expression appears to be inversely correlated with cell proliferation (Townson, 
2000).  In DNA isolated from laser capture microdissected samples of paired primary breast 
tumor and normal tissue, 78% of the patient tumor samples demonstrate a loss of heterozygosity 
in the gene locus for HET, with a microsatellite marker that colocalizes with the HET locus, 
19p13.2-3.  This suggests that there is a tumor suppressor gene in the area of HET (Osterreich, 
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2001).  Results of a large study examining patient samples with long-term clinical follow-up to 
determine HET’s potential to serve as a prognostic factor (natural progression) or a predictive 
factor (tamoxifen responsiveness), show that HET levels are correlated with ERα, Her-2, and 
bcl-2.  No correlation exists, however, between HET protein levels and disease free survival.  
Low levels of expression in women who did not receive adjuvant therapy are, however, 
significantly associated with worse overall survival.  Therefore HET does have some prognostic 
value, and women with breast cancer and low levels of HET have poorer prognoses 
(Hammerich-Hille, 2009). 
A novel role in oxidative stress responses has been suggested for the NM in breast 
cancer.  NF-E2-related factor 2 (Nrf2) is a basic leucine zipper transcription factor that  
translocates to the nucleus in response to oxidative stress and binds to genes containing the 
antioxidant response element (ARE) promoter sequence and up-regulates ARE-driven 
detoxifying and antioxidant genes  (Itoh, 1999; Venugopal, 1996).  These detoxifying and 
antioxidant genes are necessary because of the toxic by-products generated by cellular 
metabolism, and perhaps more so in cancer cells whose metabolic processes have become 
unchecked.  When the detoxifying pathways are impaired, toxic free radicals and abnormal 
proteins accumulate and cause oxidative stress-induced damage to cells, disrupting the functions 
of lipids, DNA and proteins, and eventually leading to cancer progression.  Analysis of the Nrf2 
pathway in MDA-MB231 breast cancer cells shows that Nrf2 colocalizes with the NMP NRP/B 
(Seng, 2007).  The NMP NRP/B is a member of the kelch-related family of actin-binding 
proteins (Kim, 1998).  Nrf2 and NRP/B associate both in vitro and in vivo, and this association is 
increased in response to the oxidative stress agent, hydrogen peroxide (H2O2).  This result was 
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the first demonstration of the involvement of the NM in an oxidative stress response in breast 
cancer cells (Seng, 2007). 
As demonstrated by the examples provided, alterations to the protein composition of the 
NM occur in a unique and detectable fashion.  These alterations demonstrate the potential for the 
use of NMPs as biomarkers in breast cancer.  These biomarkers may provide helpful information 
for the diagnosis, treatment, prognosis and monitoring of disease recurrence.  
1.4 HYPOTHESIS AND SPECIFIC AIMS 
1.4.1 Hypothesis 
The hypothesis addressed in my studies was as follows.  The composition of the NM, and the 
influences ERα and ERβ have upon this composition, change during the progression of breast 
cancer and the development of antiestrogen resistance.  Understanding these differences will 
help to unravel the underlying mechanisms of breast cancer.  The differences may additionally 
provide biomarkers to assist in the diagnosis and prognosis of breast cancer. 
1.4.2 Specific Aims 
In order to address the hypothesis, three specific aims were pursued.  These were: 
Aim 1.  Evaluate a series of biphenyl C-cyclopropylalkylamides to determine their potential as 
ERβ-selective ligands. 
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Aim 2.  Identify and quantify the NMPs present in tamoxifen responsive and resistant breast 
cancer cell lines and how the levels of these NMPs change in response to ER-selective ligands. 
Aim 3.  Identify and quantify the NMPs differentially expressed in ductal carcinoma in situ. 
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2.0  AN ER BETA SELECTIVE BIPHENYL C-CYCLOPROPYLALKYLAMIDE 
THAT INHIBITS THE GROWTH OF BREAST CANCER CELLS IN VITRO 
2.1 ABSTRACT 
The potential benefits of selectively targeting ERβ are well documented.  Previously, through the 
screening of a library of homoallylic amides, allylic amides and C-cyclopropylalkylamides, a 
new structural scaffold for antiestrogens was identified. A second-generation library was 
synthesized and screened for ERα and ERβ binding using a fluorescence polarization (FP) assay 
with a fluorescent derivative of E2. One compound demonstrated concentration-dependent 
displacement with close to 50% displacement at the highest concentration tested. Six analogues 
of this lead compound were synthesized in an attempt to more selectively target ERβ and 
improve cellular potency.  These six compounds were evaluated for their ability to bind to both 
ERs using the FP assay. Two of the compounds demonstrated modest affinity and selectivity for 
ERβ. The compounds were then evaluated for their ability to inhibit estradiol-induced 
proliferation of MCF-7 human breast cancer cells expressing both ERα and ERβ, ATCC MCF7 
breast cancer cells expressing only ERα, and ER negative MDA-MB231 human breast cancer 
cells. The two compounds demonstrated to be selective for ERβ had 50% growth inhibitory 
(GI50) values of 1 and 4 µM in the MCF-7 cells, while demonstrating much less inhibition of the 
growth of the ATCC MCF7 or MDA-MB231 cells. Finally, the compounds did not increase 
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expression of the growth promoter c-Myc but did increase expression of the cyclin-dependent 
kinase inhibitors p21 and p27.  This newly identified structural scaffold for ERβ-selective agents 
may be useful in understanding the differences between the two receptor isoforms, as well as 
provide insight into the design of other subtype selective ligands. 
2.2 INTRODUCTION 
The ERs are ligand-activated transcription factors.  ERα and ERβ show moderate (~55%) 
sequence homology in their LBD, but their ligand-binding pockets differ by only two amino 
acids: ERα Leu384 versus ERβ Met336, and ERα Met421 versus ERβ ILe373 (Sun, 2003). ERβ’s 
ligand binding pocket is also about 100 Å3 smaller than that of ERα (Pike, 1999).  Additionally, 
the tissue distributions of these receptors are distinct in certain tissues (Kuiper, 1997).  There is 
much data demonstrating the benefits of selectively targeting the ERβ.  ERβ expression inhibits 
E2-induced proliferation in T47D and MCF-7 breast cancer cells and leads to a reduction in 
xenograft volume (Ström, 2004; Paruthiyil, 2004; Hartman, 2006).  ERβ also has a growth 
inhibitory mechanism in medullary thyroid carcinoma, prostate cancer and ovarian cancer (Cho, 
2007; Ji, 2005; Pravettoni, 2007; Chan, 2008).  ERβ-selective agonists have also demonstrated 
potential as anti-inflammatory agents (Harris, 2003).  Several ERβ-selective agents have been 
identified (Figure 4). One of these is the compound, DPN (8), a 70-fold selective ERβ agonist 
(Meyers, 2001).  DPN has been used in a variety of studies involving various tissues because of 
its ER binding, and a thorough search of the literature shows no off targets for DPN.  Genistein 
(9) is a plant-derived ERβ-selective ligand (Kuiper, 1997).  In addition to activity with ERβ, 
genistein has a variety of other targets.  Genistein induces DNA strand breaks and cause 
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chromosomal aberrations (Kuiper, 1997; Boos, 2006). Genistein also specifically inhibits the 
activity of tyrosine-specific protein kinases such as EGFR (Akiyama, 1987).  Additionally, 
genistein acts on DNA topoisomerase II by inhibiting ATP hydrolysis  (Markovits, 1989; 
Robinson, 1993).  Biphenyl derivatives have also been investigated for ERβ-selectivity.  Simple 
4-OH-biphenyls demonstrate 20-70 fold selectivity for ERβ over ERα (Edsall, 2003).  In order to 
attempt to mimic the C-ring of genistein, an oxime moiety was incorporated into the 4-OH-
biphenyl core.  Altering the substitutions on the biphenyl core provided various levels of 
selectivity: biphenyl oximes 10 and 11 were 11-fold and 43-fold selective for ERβ, respectively 
(Figure 4) (Yang, 2004). No off targets were found for these biphenyl oximes after a thorough 
literature search. 
 
Figure 4:  The structure of several ERβ-selective ligands. 
DPN (8) is a 100-fold ERβ-selective compound.  Genistein (9) is a plant derived compound that also 
possesses ERβ-selectivity.  Biphenyl oximes 10 and 11 were recently synthesized in an attempt to mimic the C-ring 
of genistein and different substituents to the core were added to improve ERβ–selectivity. 
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Previously, through screening a library of homoallylic amides, allylic amides and C-
cyclopropylalkylamides, a new structural scaffold for antiestrogens was discovered (Janjic, 
2005A). Synthesis of a second generation library provided three additional agents that were 
found to bind strongly to ERα (Wipf, 2005). This second generation library was then screened 
for competing with a fluorescent E2 derivative for binding to ERβ using an FP assay. The 
efficiency of displacement demonstrated for ERβ by the initial screening library was 
significantly lower than that for ERα. One compound demonstrated a concentration-dependent 
displacement over the concentration range tested and almost 50% displacement at the highest 
concentration tested. This compound (12) was chosen as the lead structure for efforts to improve 
ERβ-selectivity (Figure 5). 12 did not quite reach 50% displacement on ERβ, so the selection 
criteria were modified to include structural features previously known to promote ERβ affinity 
(Yang, 2004).  Screening results on ERα were used as co-selection criteria, and 12 was not a hit 
for ERα (Wipf, 2005).   
 
Figure 5:  Lead compound for an ERβ-selective biphenyl C-cyclopropylalkylamide (12) and structure activity 
relationships. 
The only compound (12) of the second generation library that demonstrated concentration-dependent 
displacement of E2 from ERβ and close to 50% displacement at the highest concentration tested.  Regions A, B, and 
C were used for structure activity relationships. 
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Figure 5 demonstrates the three regions in 12 that were used for structure activity 
relationships (SAR).  The biphenyl core is known to aid in selective targeting of ERβ (Yang, 
2004).  Regions A and B were chosen for further elaboration and the structures were assembled 
with the biphenyl core, the cyclopropane ring and the amide linkage preserved.  The biphenyl 
group was substituted with a key 4’-OH group expected to promote hydrogen bonding with ERβ 
Glu305 and ERβ Arg346.  A fluorine substituent for the biphenyl core was chosen based upon 
published SAR for biphenyl-containing agents (Yang, 2004). The phenylamide was changed into 
a smaller acetylamide, or completely removed.  The alkyl chain in region C was not altered 
because an increase in size abolished all activity.  The six new compounds synthesized based on 
lead structure 12 can be seen in Figure 6.  The synthesis of these compounds is reported in Janjic 
2005B. 
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Figure 6:  Library of six new compounds (13-18). 
These compounds were synthesized based upon lead compound 12 in an attempt to improve selective 
targeting of ERβ. 
The ability of these compounds to compete with E2 for binding to both ERs and inhibit 
the growth of breast cancer cells was investigated.  Additionally, to gain some insight into the 
growth inhibition mechanism of these compounds, their effects on the protein levels of c-Myc, 
p21, and p27 were investigated.   
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2.3 RESULTS 
2.3.1 Binding to the Estrogen Receptors 
The six new compounds (13 - 18) and the control compound 3-fluoro-4’-hydroxy-1,1’-biphenyl-
4-carbaldehyde oxime (10) were first evaluated for their ability to compete with the fluorescent 
E2 derivative (ES2) for binding to both ERs using the FP assay.  The percent displacement of the 
E2 derivative by the test compound was evaluated from the difference in FP measured upon 
incubation with and without the test compound.  When competition is absent, the fluorescent 
compound is bound to the receptor and tumbles slowly, giving a high polarization value.  When 
the fluorescent ligand is competed out of the ER, it tumbles rapidly and gives a low polarization 
value.  Polarization values are reported in units of mP (Parker, 2000).  Figure 7 shows results for 
ERα and ERβ.  Two compounds, 14 and 18, significantly competed with ES2 and are presented 
in Figure 7.  The curves in Figure 7 were constructed from one-site competition best-fit curves of 
mP versus concentration using Graph Pad Prism 4 software.  The IC50 values determined from 
this fit are presented in Table 2. Biphenyl carbaldehyde oxime 10 and E2 were used as positive 
controls in this assay. ERβ/ERα selectivity ratios were calculated by dividing the IC50 
determined for ERα by that determined for ERβ.  14 was at least 48-fold selective for ERβ with 
an IC50 value of 2.0 µM for ERβ, while 18 had an IC50 of 15 µM for ERβ and did not compete 
with ES2 for binding to ERα (Table 2). 
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Figure 7:  Competition of test compounds with ES2 for binding to ERα and ERβ in the FP assay.   
The percent displacement of ES2 in ERα (A) and ERβ (B) by controls E2 and 10 and test compounds 14 
and 18 was determined by the difference in FP measured upon incubation with and without the test compound.  
Graph Pad Prism 4 was used to construct the curves using a one-site best-fit curve of mP versus concentration (Log 
M). 
Table 2:  IC50 values for competition for both ERs from the FP assay.   
Compound ERα IC50 (nM) ERβ IC50 (nM) ER β Selectivity 
E2 0.627 0.316 2.00 
10 795 32.3 24.6 
14 > 100,000 2048 > 48.8 
18 N/A 15030 N/A 
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2.3.2 Inhibition of the Growth of Breast Cancer Cells 
The compounds were evaluated for their ability to inhibit E2-induced proliferation of MCF-7 
human breast cancer cells.  This was done using two variants of the MCF-7 cell line:  the later 
passage ATCC variant that expresses only ERα, and an earlier passage that expresses both ERα 
and ERβ.  Additionally, to demonstrate selectivity, the compounds were also tested for their 
ability to inhibit the growth of the ER negative breast cancer cell line MDA-MB231 (Cailleau, 
1978).  The Western blot demonstrating receptor expression patterns is seen in Figure 8.  Both 
the ATCC MCF7 and MCF-7 lines express ERα, while only the MCF-7 line expresses ERβ.  The 
MDA-MB231 cell line was confirmed to be ER negative, as expression of neither ER isoform is 
seen in the Western blot. 
 
Figure 8:  Western blot of ER expression in ATCC MCF7, MCF-7, and MDA-MB231 cell lines. 
The expression of ERα and ERβ in the three breast cancer cell lines was determined.  Actin was used to 
verify equal loading of the gel. 
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Using these ATCC MCF7, MCF-7, and MDA-MB231 cell lines, which express different 
isoforms of the ERs, in a cell proliferation assay helped to determine the selectivity of 
compounds 14 and 18.  Figure 9 shows the growth inhibition curves for all three cell lines.  
These curves were generated for compounds determined to be selective for ERβ using the MTS 
assay.  Raloxifene (4), an antiestrogen known to inhibit the proliferation of MCF-7 cells, was 
included as a control (Thompson, 1988).  GraphPad Prism 4 was used to estimate GI50 values 
using a non-linear best curve fit.  The GI50 values can be seen in Table 3.  In the ERα and ERβ 
expressing MCF-7 cells GI50 values of 4.1 and 1.2 µM were estimated for compounds 14 and 18, 
respectively.  In the ERα expressing ATCC MCF7 cells, compound 14 did not demonstrate 
inhibition, while a GI50 value of 51.7 µM was estimated for compound 18. 14, 18, and raloxifene 
(4) did not demonstrate significant growth inhibitory activity against the MDA-MB231 cell line. 
Prior to adding the MTS reagent, cell morphology was examined by light microscopy.  ATCC 
MCF-7 and MDA-MB-231 cells exposed to 25 µM of raloxifene (4), 14, and 18 showed 
substantial morphological changes and appeared shrunken with many cells detached from the 
culture dish suggesting toxicity at this concentration.  
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Figure 9:  Growth inhibition curves of compounds 4, 14, and 18 for ATCC MCF7, MCF-7, and MDA-MB-
231 cells.  
The growth inhibition curves generated using control compound raloxifene (4) and test compounds 14 and 
18 for ATCC MCF7 (A), MCF-7 (B) and MDA-MB231 (C) cell lines with the MTS assay.  GraphPad Prism 4 was 
used for a non-linear best curve fit. 
 
Table 3:  GI50 values for compounds 14 and 18 in MCF-7 and ATCC MCF7 cell lines. 
 GI50 Value (µM)  
Compound MCF-7 ATCC MCF7 
14 4.1 N/A 
18 1.3 52 
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2.3.3 Effects on the Protein Levels of c-Myc, p21, and p27 
c-Myc plays a major role in cell proliferation and malignant transformation in breast cancer 
(Liao, 2000).  E2 treatment causes a rapid increase in the level of c-Myc expression in human 
breast cancer cells (Dubik, 1987).  Expression of ERβ in breast cancer cells inhibits c-Myc 
expression at both the mRNA and protein level, while increasing the levels of its regulators, the 
cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip1) (Paruthiyil, 2004).  The effects of 
14 and 18 on the protein levels of c-Myc, p21, and p27 were determined because of their link to 
breast cancer and E2.  Western blot analyses from whole cell lysates of MCF-7 cells treated with 
the indicated compounds can be seen in Figure 10. The densitometric analyses performed on 
these Western blots can be seen in Table 4.  ImageJ was used to determine band intensity and 
levels were standardized to actin.  The relative fold change was determined by comparison to the 
DMSO-treated band for each protein.  Both compounds 14 and 18 decreased the levels of cMyc 
to 0.77 and 0.59 of control, respectively.  Compound 14 increased the levels of p21 and p27 by 
3.64 and 3.90 fold compared to control, respectively.  Compound 18 did not have as great of an 
effect on p21 and p27 with relative fold changes of 1.10 and 1.51 compared to control, 
respectively.  PPT, a 410-fold ERα-selective agonist, and DPN, a 70-fold ERβ-selective agonist, 
were included as controls (Stauffer, 2000; Meyers, 2001).  These two compounds increased the 
levels of cMyc, p21 and p27.  
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Figure 10: Western blot analysis of the levels of c-Myc, p21, p27, and actin in MCF-7 cells in response to ER 
ligands. 
MCF-7 cells were treated with the indicated compound for 12h and whole cell lysates were prepared and 
then analyzed for the indicated proteins.  DMSO is the vehicle control, E2 is 17β-estradiol, PPT is a 410–fold ERα-
selective agonist, DPN is a 100–fold ERβ-selective agonist, and 14 and 18 are library members that demonstrated 
selectivity for ERβ and inhibited the growth of human breast cancer cells.  Densitometry was performed using 
ImageJ with standardizing the levels to actin.  The fold-change relative to DMSO is reported in Table 4. 
 
Table 4:   Densitometry analysis of Western blots in Figure 10. 
Protein 10 nM E2 1 µM PPT 1 µM DPN 1 µM 14 1 µM 18 
cMyc 3.84 2.17 2.67 0.77 0.59 
p21 1.15 4.05 3.47 3.64 1.10 
p27 1.76 2.47 3.32 3.90 1.51 
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2.4 DISCUSSION   
The ongoing goal of this project is to develop new chemical tools to assist in studying the 
complex biology and interplay of the ERs by synthesizing and studying biphenyl C-
cyclopropylalkylamides.  The C-cyclopropylalkylamide core was previously identified as a 
scaffold for antiestrogens (Janjic, 2005A; Wipf, 2005).  Modifications of this core were 
performed in an attempt to gain selectivity for ERβ.   Six new ligands were synthesized using the 
one ERβ hit from the second generation library and what has been demonstrated in the literature 
to contribute to ERβ selectivity (Janjic, 2005B).  These compounds were evaluated for their 
ability to selectively bind ERβ and their inhibition of the proliferation of breast cancer cell lines.   
Two of the six new C-cyclopropylalkylamides, 14 and 18, demonstrate selectivity for 
ERβ as determined by the FP assay measuring the ability of the test compound to compete with 
ES2 for binding to ERα and ERβ. Biphenyl carbaldehyde oxime 10, used as a control in this 
assay, gave an IC50 comparable to that previously determined in a radioligand binding assay 
(Yang, 2004).  These two compounds, 14 and 18, also inhibit the E2-induced proliferation of 
breast cancer cells.  They demonstrate greater inhibition of cells expressing both isoforms of the 
ER compared to those expressing only ERα. This supports the idea that the compounds are 
performing a specific effect through the ERβ.  In breast cancer cells expressing both ERβ and 
ERα a significantly more potent anti-proliferative effect is demonstrated compared to breast 
cancer cells expressing only ERα or no ERs.  It can also be concluded that the compounds are 
likely functioning as ERβ agonists based on what has been demonstrated for ERβ’s behavior in 
breast cancer.  ERβ inhibits the proliferation of breast cancer cells in response to E2 and 
represses c-Myc, cyclin D1, and cyclin A1 expression while increasing expression of the cyclin 
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dependent kinase inhibitors p21 and p27 (Omoto, 2003; Ström, 2004; Paruthiyil, 2004; Willams, 
2008).  
Compound 18 has a 4.1 µM GI50 against ER positive MCF-7 cells; however, its IC50 is 
15.0 µM for binding to ERβ.  Similarly, compound 14 potently inhibits MCF-7 cell growth  with 
a GI50 of 1.2 µM, but its IC50 for binding to ERβ is 2 µM.  If the growth inhibition of MCF-7 
cells seen in this assay is solely through the compound binding to ERβ, a higher affinity of 14 
and 18 for ERβ would be expected.  The discrepancy suggests that the antiproliferative effects of 
these compounds are likely much more complex than a simple binding event to ERβ.  One 
possible explanation for this discrepancy is that the activity of 18 may be derived from an active 
metabolite of the aliphatic primary amine that has a much higher affinity for ERβ than the parent 
compound.  Additionally, compounds 14 or 18 may interact with the ER in a way other than via 
the LBD and not detected by the FP assay.  It is possible that compounds 14 or 18 may interact 
with the coactivator domain of ERβ and alter the cofactors recruited to the receptor.  Studies 
using the ERβ-selective compound liquiritigenin, a herb extracted from the root of Glycyrrhizae 
uralensis, supports this idea. Liquiritigenin has only 20-fold selectivity for ERβ compared to 
ERα as determined using the FP assay.  Yet, this compound activates an ERE-luciferase reporter 
only in the presence of ERβ but not ERα.  This was explained by a CHIP assay demonstrating 
that liquiritigenin causes recruitment of SRC-2 to E2-regulated genes only in cells expressing 
ERβ and not ERα (Mersereau, 2008).  A similar mechanism could occur with compound 14 or 
18. 14 or 18 may cause recruitment of only certain cofactors when bound to ERβ but not ERα 
that exert an effect on the proliferation of the MCF-7 cells.   The agents presented here should be 
explored further for their ability to target the coregulator binding domain of ERβ.  Interestingly, 
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introducing the –OH group to the biphenyl core in 18 did not result in a significant improvement 
in the biological activity as well as the presence of an aliphatic alkyl chain on the compounds.  
Compounds 14 or 18 may also exert an effect on the cell through ERα.  While 18 did not 
compete with ES2 for binding to ERα, 14 did demonstrate some competition for binding ERα.  
The discrepancy between the binding data and the cellular data suggests the involvement of other 
pathways in addition to those involving the ERs. 
To further understand the cellular activities of the compounds, their effects on several cell 
cycle proteins was determined.  c-Myc has been implicated in cell proliferation, apoptosis and 
differentiation (Dang, 1999). It is a key player in cell cycle regulation, and can induce cell cycle 
progression in antiestrogen-arrested cells (Prall, 1997; Prall, 1998).  Additionally, E2 is known to 
cause rapid increase in the level of c-Myc expressed by human breast cancer cells (Dubik, 1987). 
Induction of the expression of ERβ inhibits c-Myc at both the mRNA and protein level, while 
increasing the levels of p21 and p27 (Paruthiyil, 2004). Compounds 14 and 18, which are 
selective for ERβ and inhibit the proliferation of ER positive breast cancer cells, slightly 
decrease c-Myc protein levels while increasing the levels of p21 and p27.  The known ERβ 
agonist DPN increases p21 and p27 levels also, but it also increases c-Myc levels about three-
fold.  While the EC50 for DPN for ERβ is 0.85 nM, it also has an EC50 for ERα of 66 nM as 
determined by a luciferase reporter transcription assay (Meyers 2001).  In another luciferase 
reporter transcription assay, DPN produces a 20-fold increase in transcription in the presence of 
ERα and a 75-fold increase in the presence of ERβ compared to vehicle control (Mersereau, 
2008).  14 and 18 are targeting cell cycle regulators that are influenced by ERβ.  Additionally, 
compounds 14 and 18 hold promise because of their ability to cause increased levels of cyclin-
dependent kinase inhibitors, likely inhibiting cell cycle progression.     
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In conclusion, compounds 14 and 18 demonstrate selectivity for ERβ as well as 
promising antiproliferative effects in breast cancer cells.   The compounds are likely acting as 
agonists for ERβ based on what has been shown about ERβ’s activity in breast cancer, and this 
encourages future investigation (Ström, 2004; Parythiyil, 2004; Hartman, 2006).  Luciferase 
reporter assays should be conducted with compounds 14 and 18 in order to verify their activity as 
ERβ agonists.  Compared to the lead compounds 10 and 11, 14 and 18 show no affinity for ERα 
and moderate affinity for ERβ.  This initial investigation into the biphenyl C-
cyclopropylalkylamide pharmacophore demonstrates the potential of this scaffold to deliver ER-
selective antiestrogens. Furthermore, the preliminary SAR provides clues for improving 
selectivity for ERβ.  A subtype-selective antiestrogen will help to understand the complex 
biology of the ERs and their interplay.  The arrival of new ER ligands with differential subtype 
selectivity ratios enables the tailoring of antiestrogenic or estrogenic therapy according to the 
condition and level of receptor isoforms present in patients. 
2.5 MATERIALS AND METHODS 
2.5.1 Fluorescence Polarization Assay 
The ERα and ERβ FP competitor assays were performed according to the manufacturer’s 
(Invitrogen, Carlsbad, CA) recommendations with some modifications.  Human recombinant ER 
was used at the recommended concentration of 15 nM and the Fluormone ES2 was used at a 
concentration of 1 nM in the final mixture.  Aliquots (20 µL) of the mixture of ER and 
Fluormone ES2 were distributed in 384-well, black flat-bottom plates and serial dilutions of 
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test compounds prepared in DMSO were then added.  Each compound was tested in duplicate, 
and 1 µM E2 was used as a positive control.  The DMSO concentration was kept at 1% (v/v) 
throughout the experiment.  After 2 h, FP was measured using an Analyst AD & HT Assay 
Detection Systems reader (Molecular Devices, Sunnyvale, CA) equipped with 485 nm excitation 
and 530 nm emission filters with the appropriate FL505 dichroic mirror.  The instrument was 
validated using serial dilutions of methylfluorescein in the screening buffer.  FP was determined 
after background subtraction from perpendicular and horizontal fluorescence measurements by 
the Analyst AD & HT Assay Detection Systems integrated software.  mP was determined by 
the equation: mP = 1000 x (S-(G*P))/(S+(G*P)), where S and P are the background-subtracted 
intensity measurements for the parallel and perpendicular components respectively and G is a 
constant of the instrument. Data was then analyzed using GraphPad Prism’s one site competition 
method.  The fit was constrained by the high polarization control, which was the ER/ES2 
complex with no competition, and the low polarization control, which was the ER/ES2 complex 
with 1 µM E2 for 100% competition.    
2.5.2 Cell Proliferation Assay 
MCF-7 and ATCC MCF7 breast cancer cells were seeded in 96-well plates at a density of 4 x 
103 cells per well in phenol red free RPMI-1640 medium containing 10% charcoal-dextran 
stripped fetal bovine serum (FBS) (to remove estrogens) and allowed to adhere overnight.  Test 
compounds were then added (concentrations ranging from 25 pM to 50 µM) along with 1 nM 
E2, and cells were incubated for 6 days.  Effect of the test compounds on growth was determined 
using the CellTiter Aqueous One assay system (Promega, Madison, WI), which utilizes the MTS 
dye reduction assay with phenazine methanesulfonate as the electron acceptor.  Absorbance was 
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measured at 490 nm using an M5 plate reader (Perkin Elmer, Boston, MA) and the background 
absorbance at 630 nm was subtracted after 2 h incubation with the reagents.  Data represents the 
average of at least two independent experiments done in quadruplicate.  A plate of control cells 
(16 wells) was measured at day 0 to establish 0% growth. E2-stimulated growth at day 6 was set 
to 100% growth.  GraphPad Prism 4 (GraphPad Software Inc, La Jolla, CA) software was used 
for constructing dose-response curves and calculating GI50 values. 
MDA-MB231 cells were plated in 96-well plates at 1 x 103 cells/well and allowed to 
adhere for 72 h in phenol red-free RPMI-1640 containing 10% FBS.  Test agents were added 
(concentrations ranging from 3.2 nM to 50 µM) and cells were incubated for 72 h.  Cell density 
was determined using the MTS assay as described above. 
2.5.3 Western Blots 
Cells were plated in 25-cm2 flasks in RPMI-1640 with 10% FBS and allowed to attach 
for 48 h.  Media was then changed to RPMI-1640 with charcoal-dextran stripped FBS.  After 48 
h, cells were incubated with test agent at the given concentration or with vehicle (DMSO) for 
12h.  Cells were washed in cold phosphate buffered saline (PBS) and lysed in RIPA buffer with 
phenylmethanesulphonyl fluoride (PMSF), sodium orthovanadate, and protease inhibitors 
according to the manufacturer’s protocol (Santa Cruz Biotechnology, Santa Cruz, CA).  Lysates 
were centrifuged at 10,000xg for 10 min at 4°C.  Concentration of protein in the supernatant was 
determined using the bicinchoninic acid (BCA) Protein Assay (Thermo Fisher Scientific, 
Rockford, IL).  Equal amounts of protein were loaded into wells of 4-12% Bis/Tris gels 
(Invitrogen, Carlsbad, CA) with 3-(N-morpholino)propanesulfonic acid (MOPS) buffer and 
separated by SDS-PAGE.  Proteins were transferred onto nitrocellulose membranes using a Bio-
  57 
Rad (Hercules, CA) Trans-Blot Semi Dry transfer system.  The Amersham ECL™ Western 
Blotting Detection Reagents (GE Healthcare, Piscataway, NJ) were used to detect protein bands.  
Band quantitation was performed using the ImageJ program (National Institutes of Health, 
Bethesda, MD). 
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3.0  SPECIFIC ALTERATIONS TO THE NUCLEAR MATRIX IN A TAMOXIFEN 
RESISTANT CELL LINE 
3.1 ABSTRACT 
Tamoxifen has long been the standard of treatment in women with ER+ breast cancer.  One of 
the major problems with tamoxifen is drug resistance.  Only about half of ER+ breast cancers 
respond to tamoxifen initially, and those that do respond eventually develop resistance over the 
course of treatment.  The mechanism behind this resistance is not completely understood.  
Several mechanisms have been proposed, such as alterations to cofactors, loss of ER expression, 
and compensation by growth factor signaling pathways.  In order to investigate the alterations to 
the proteins of the NM, the NMPs from MCF-7 breast cancer cells, and their antiestrogen 
resistance derivative, MCF-7/LY2, were isolated and examined.  These two cell lines were also 
exposed to several ER isoform-selective ligands in order to discern how the two receptor 
isoforms may alter NMP composition of tamoxifen responsive and resistant cell lines. The 8-plex 
iTRAQ method was used in order to identify and quantify the NMPs present in these cell lines.  
A total of 148 NMPs were identified, and several interesting changes between the resistant and 
responsive line and in response to the subtype selective ligands were found.  These proteins may 
shed some light on the mechanism behind antiestrogen resistance and eventually serve as 
biomarkers to help customize breast cancer treatment. 
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3.2 INTRODUCTION 
Tamoxifen was developed in the 1970’s as an antiestrogen (Jensen, 2003).  Tamoxifen has been 
a major component used for the treatment and prevention of breast cancer for the past thirty 
years through its role as a SERM and the blocking of the action of estrogen in the breast (Jordan, 
2007). Tamoxifen functions by competing with E2 for binding to the ER and repositioning helix 
12 in the receptor, so coactivators can no longer bind and corepressors are recruited 
(Brzozowkski, 1997; Shiau, 1998; Nettles, 2005). Adjuvant treatment for five years with 
tamoxifen has been shown to reduce the annual risk of recurrence and death from the disease by 
47% and 26% respectively (Early Breast Cancer Trialists’ Collaborative Group, 2005). 
One of the major problems in tamoxifen therapy is de novo or acquired drug resistance. 
Only about half of ER+ tumors respond to the drug initially and those that do respond eventually 
develop resistance over the course of treatment (Osborne, 1998).  An explanation for acquired 
resistance to tamoxifen is the loss of ER expression; however, only about 17-28% of tumors with 
acquired resistance lose ER expression (Johnston, 1995; Gutierrez, 2005).  20% of tamoxifen-
resistant tumors respond to another therapy that involves targeting the ER (Howell, 2005; 
Osborne, 2002).  This suggests that the cell has altered the way it handles the ER-tamoxifen 
complex when it has developed resistance (Clarke, 1996).  There are two similar isoforms of the 
ER, ERα and ERβ.  While structurally similar, there are some differences in their N- and C-
terminal domains, which contribute to their subtype specific actions (McInerney, 1998). ERβ has 
a negative influence on ERα-mediated transcription (Sugiura, 2007). Alteration of the expression 
level of ERβ has also been shown in tamoxifen resistant cell lines. There is controversial as both 
low and high levels of ERβ expression have been associated with tamoxifen resistance (Hopp, 
2004; Esslimani-Sahla, 2004; Speirs, 1999). Altered expression of coregulators that significantly 
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influence ER-mediated transcription may also play a part in tamoxifen resistance (McKenna, 
1999).  Overexpression of coactivators and down-regulation of corepressors can inhibit the 
effects of SERMs (Smith, 1997).  The ER lies in a complex system of interlocking signal 
transduction pathways that may also play a role in the development of resistance (Zilli, 2009). 
A particular area of the cell that may hold important clues to understand how the ERs 
influence the behavior of a breast cancer cell in its response to antiestrogens is the NM. The 
shape of the nucleus, commonly used as a pathological marker in cancer, is partially determined 
by the NM (Replogle-Schwab, 1996; Samuel, 1997).  The NM is the structural scaffolding of the 
nucleus and is a dynamic structure involved in DNA replication, transcription, repair, RNA 
processing, and a modulator of hormone action (Getzenberg, 1990).  Specific binding sites for 
E2 have been demonstrated in the NM and the structure plays a role in regulating hormone action 
(Barrack, 1980). The ER localizes to the NM in response to E2 (Alexander, 1987).  NMPs 
specific to several types of cancer have been identified and used as specific biomarkers for 
several types of malignancies (Leman, 2008).  Adding to their potential as biomarkers is the fact 
that NMPs can be identified in the serum of patients (Miller, 1992).  This detection may allow 
for the development of a non-invasive screening procedure that could be used in the clinic to 
detect the development of resistance to tamoxifen. 
This study was performed in order to examine how the protein content of the NM 
changes in a cell that progressed to antiestrogen resistance in the constant presence of an 
antiestrogen in culture.  These alterations to the NM may aid in the development of biomarkers 
for tamoxifen resistance that may be used to more effectively treat breast cancer.  This study was 
performed by using the MCF-7 ER+ breast cancer cell line and its ER+ antiestrogen resistant 
derivative, MCF-7/LY2 (Bronzert, 1985).  Additionally, by using ligands that are ER isoform-
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selective antagonists or agonists, the effect of specific targeting of the ER isoforms on the 
proteins in the NM was also determined.   
The 8-plex iTRAQ method was used to identify changes on NMP levels between the two 
different cell lines and four treatments investigated.  The iTRAQ method employs amine-specific 
isobaric tags that allow for the multiplexed relative quantitation of proteins by MS (Ross, 2004).  
In this study, two sets of iTRAQ labeling were performed in which the order of the labels was 
reversed to account for any label specific effects.  Two separate methods, strong cation exchange 
chromatography (SCX) and OFFGEL electrophoresis, were then used to fractionate the iTRAQ-
labeled peptides generated by trypsin digestion. Nanoscale-liquid chromatography-matrix 
assisted laser desorption ionization-time of flight/time of flight (Nano-LC-MALDI-TOF/TOF) or 
nanoscale-liquid chromatography-electrospray ionization-quadrupole-time-of-flight (nano-LC-
ESI-Q-TOF) MS were then performed for protein identification and quantification.  Figure 11 
shows the three different workflows used.  In addition to understanding the changes in the 
abundances of NMPs in the samples, comparisons can also be made between the different 
fractionation and MS techniques employed by each of three different workflows to aid in future 
iTRAQ experiments. 
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Figure 11:  The three proteomic workflows used in this study. 
MCF-7 and MCF-7/LY2 were treated with 5 µM PPT, 5 µM MPP, 5 µM DPN, or DMSO control for 48h 
and NMPs were isolated.  Overnight trypsin digestion was performed and iTRAQ labeling was done as seen.  One 
set of labeling follows solid arrows and the second set follows dashed arrows.  The first workflow fractionated using 
SCX spin columns and then LC-MS/MS analysis using the ABI 4700 Proteomics analyzer.  The second workflow 
used the same set of labeled samples as the first workflow and also separated by SCX spin columns; however, LC-
MS/MS analysis was done using the ABI QSTAR.  The third workflow changed the label each sample was tagged 
with and separated by OFFGEL fractionation.  These samples were then analyzed by the ABI 4800 Proteomics 
Analyzer. 
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3.3 RESULTS 
3.3.1 Estrogen Receptor Expression in MCF-7/LY2 Breast Cancer Cells 
The early passage MCF-7 line and the MCF-7/LY2 derivative of this line, which has developed 
antiestrogen resistance in culture, were used.  This MCF-7 cell line is different from the later 
passage ATCC MCF7 commonly used.  Expression of the ER isoforms in these lines was 
determined by Western blotting (Figure 12).  The ATCC MCF7 line expressed primarily ERα, 
while the early passage MCF-7 cells expressed similar levels of both ERα and ERβ. The MCF-
7/LY2 cell line maintained expression of ERα but has lost expression of ERβ. 
 
Figure 12:  ER expression in the ATCC MCF 7, MCF-7, and MCF-7/LY2 breast cancer cell lines. 
Whole cell lysates were prepared from ATCC MCF7, MCF-7, and MCF-7/LY2 cell lines, and these lysates 
were investigated for the expression of ERα and ERβ by Western blotting.  Actin was used as a loading control for 
the gel. 
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3.3.2 Nuclear Matrix Proteins Identified in MCF-7 Cells 
The first aspect of this study is the determination of what proteins are located in the NM of the 
MCF-7 breast cancer cell line.  In order to verify the integrity of NMP preparations from these 
cells, Western blotting was performed using the fractions generated during the preparation.  
Figure 13 shows a schematic of how the NM is isolated from cells in culture and the different 
protein fractions generated throughout the isolation. 
 
Figure 13:  The isolation procedure for NMPs from cells in culture. 
The NMP preparation involves a series of buffer changes and centrifugations.  Different cellular fractions 
are generated through the procedure, including soluble protein, cytoskeletal elements, chromatin, and finally, the 
nuclear matrix. 
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Figure 14 shows an example Western blot of the fractions isolated during the NM 
preparation. Actin is present in the soluble, cytoskeletal and chromatin fractions generated during 
the isolation procedure but absent in the final NMP isolation.  The NM marker, Lamin B1, is 
specific to the NM fraction (Fey, 1988). 
 
Figure 14:  Western blot verification of a NMP preparation. 
The proteins generated during each step of the NMP preparation were precipitated and a Western blot was 
performed to show the lack of actin in the final NM fractions, but presence of the specific NM marker Lamin B1. 
 
After isolation the NMPs underwent the iTRAQ labeling procedure.  The NM isolations 
were separated and two separate labeling schemes were followed.  These labeling schemes can 
be seen in Figure 11.  After labeling, three different workflows were followed for protein 
identification and quantitation.  These workflows can also be seen in Figure 11. Combining the 
confident protein identifications made from all of the workflows used a total of 148 NMPs with a 
ProtScore > 1.3 were identified using ProteinPilot analysis software.  A ProtScore of 1.3 
corresponds to an identification with 95% confidence.  Eighty-six of these proteins were 
identified from at least two distinct peptides with 95% confidence for each peptide identification.  
A complete list of these proteins is presented in Table 14 (Appendix A).  The table lists all of the 
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NMPs that were identified with 95% confidence from any of the three workflows used from the 
NMP preparation.   
An example of the protein coverage for one of the proteins identified can be seen in 
Figure 15.  This is the amino acid sequence of hNRNP R and the peptides that were identified 
following workflow 3, offgel fractionation and the ABI 4800 Proteomics Analyzer, in Figure 11.  
This protein was identified with a ProtScore of 4.28 and 46.7% coverage. 
 
MANQVNGNAVQLKEEEEPMDTSSVTHTEHYKTLIEAGLPQKVAERLDEIFQTGLV
AYVDLDERAIDALREFNEEGALSVLQQFKESDLSHVQNKSAFLCGVMKTYRQREKQGSK
VQESTKGPDEAKIKALLERTGYTLDVTTGQRKYGGPPPDSVYSGVQPGIGTEVFVGKIPR
DLYEDELVPLFEKAGPIWDLRLMMDPLSGQNRGYAFITFCGKEAAQEAVKLCDSYEIRPGK
HLGVCISVANNRLFVGSIPKNKTENILEEFSKVTGLTEGLVDVILYHQPDDKKKNRGFCFL
EYEDHKSAAQARRRLMSGKVKVWGNVVTVEWADPVEEPDPEVMAKVKVLFVRNLATT
VTEEILEKSFSEFGKLERVKKLKDYAFVHFEDRGAAVKAMDEMNGKEIEGEEIEIVLAKP
PDKKRKERQAARQASRSTAYEDYYYHPPPRMPPPIRGRGRGGGRGGYGYPPDYYGYEDY
YDDYYGYDYHDYPGGYEDPYYGYDDGYAVRGRGGGRGGRGAPPPPRGRGAPPPRGRAGY
SQRGAPLGPPRGSRGGRGGPAQQQRGRGSRGSRGNRGGNVGGKRKADGYNQPDSKRRQT
NNQQNWGSQPIAQQPLQQGGDYSGNYGYNNDNQEFYQDTYGQQWK 
 
Figure 15:  The amino acid coverage of hnRNP R as determined by workflow 3 using offgel fractionation and 
the ABI 4800 Proteomics Analyzer. 
This is the amino acid sequence of hnRNP R.  Peptides that were identified with > 95% confidence are 
bold.  Peptides that were identified with > 50% but < 95% confidence are underlined.  Peptides that were identified 
with  > 0% but < 50% confidence are italic.  These are the peptide identifications made using workflow 3, which 
involved fractionation using OFFGEL electrophoresis and nano-LC-MALDI-TOF/TOF with the ABI 4800 
Proteomics Analyzer. 
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An example spectrum of one of the peptides identified by workflow 3 from hnRNP is 
shown in Figure 16.  Table 5 shows the predicted y and b ions for this peptide and indicates 
which of these ions were found in this spectrum.  The matched ions are shown in bold.  This 
peptide was identified with 99% confidence. 
 
Figure 16:  The mass spectrum of an example peptide from hnRNP R. 
An example mass spectrum of one of the peptides of hnRNP R.  This spectrum was generated on the ABI 
4800 Proteomics Analyzer.  Assignment of the y and b ions can be seen in Table 5. 
Table 5:  The y and b ions identified for the peptide seen in Figure 16. 
Residue b y 
S 88.0393 1758.7758 
T 189.0870 1671.7438 
A 260.1241 1570.6590 
Y 423.1874 1499.6590 
E 552.2300 1336.5957 
D 667.2570 1207.5531 
Y 830.3203 1092.5261 
Y 993.3836 929.4628 
Y 1156.4469 766.3995 
H 1293.5059 603.3362 
P 1390.5586 466.2772 
P 1487.6114 369.2245 
P 1584.6642 272.1717 
R 1740.7653 175.1190 
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3.3.3 Nuclear Matrix Protein Abundance Levels Altered in MCF-7/LY2 Cells 
Of the 148 NMPs identified in the MCF-7 cells, abundance was determined for 131 using the 
iTRAQ labels.  This represents 88% of the total proteins identified.  70% of these 131 proteins 
were quantified based on at least two peptides.  The first comparison that can be made using the 
iTRAQ ratios from the three different sets of data is to compare levels of the different NMPs 
between the parental MCF-7 cell line and its antiestrogen resistant derivative MCF-7/LY2.  Of 
the 131 proteins quantified, 52 provided a MCF-7/LY2:MCF-7 ratio with a p-value less than 
0.05 indicating that the levels of expression were different between the cell lines.  In every case 
except one where quantification of a protein was determined by more than one of the workflows, 
the increase or decrease in abundance of the protein was consistent between the different 
workflows.    Table 15 in Appendix B presents these 52 proteins and the ratio of expression 
between the resistant (MCF-7/LY2) and responsive (MCF-7) line. Cut-off values for statistically 
significantly altered proteins were determined by taking the mean value of all protein ratios 
obtained and moving out two standard deviations from this mean.  These values were 0.451 and 
1.63.  Table 6 presents the seventeen proteins that fell outside of these limits when comparing 
abundance in MCF-7/LY2 to that in MCF-7 cells. A standard deviation for the ratio is provided 
in the table for those proteins where more than one workflow provided a ratio.  Ten proteins 
were more abundant and seven proteins were less abundant in the MCF-7/LY2 cells.  One 
protein, represented by a ratio of 9999, was found in the MCF-7/LY2 cells but not the MCF-7 
cells.  Three proteins, represented by a ratio of 0, were found in the MCF-7 cells but not in the 
MCF-7/LY2 cells. 
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Table 6: Statistically significantly alterations to NMP abundance in MCF-7/LY2 cells compared to MCF-7 
cells. 
 
 
Protein Name 
Accession 
Number (IPI) 
Gene 
Symbol 
MCF-7/ 
LY2: 
MCF-7 Std Dev 
NUMA1 variant protein 00872028.2 NUMA1 9999  
Histone H3.1 00902514.1 HIST1H2AD 3.439 2.114 
ATP synthase subunit alpha 00440493.2 ATP5A1 2.537  
Histone H2B 00646240.3 HIST2H2BA 2.301  
Small nuclear ribonucleoprotein Sm D3 00017964.1 SNRNPD3 2.191 0.5964 
P37 AUF1 00903278.1 HNRNPD 2.178  
60S acidic ribosomal protein P1 00008527.3 RPLP1 1.813  
Lamin-B2 00009771.6 LMNB2 1.766 0.5235 
Fus-like protein 00260715.5 FUS 1.728  
40S ribosomal protein S19 00215780.5 RPS19 1.693  
Keratin, type II Cytoskeletal 8 00554648.3 KRT8 0.4466 0.08853 
Splicing factor, proline- and glutamine-rich 00010740.1 SFPQ 0.3955  
Desmoplakin, isoform DPI 00013933.2 DSP 0.3705 0.2411 
Keratin, type II cytoskeletal 1 00220327.3 KRT1 0.2214  
Dynein heavy chain 5, axonemal 00152653.3 DNAH5 0  
hnRNP R, isoform 1 00644055.3 HNRNPR 0  
Serpin H1 00032140.4 SERPINH1 0  
 
An example of the reporter region of an MS/MS spectrum of a peptide from hnRNP R isoform 1 
obtained on the ABI 4800 Proteomics Analyzer can be seen in Figure 17.  The lack of a signal 
from the 119 reporter ion in this spectrum demonstrates this peptide is not present in the NMP 
isolation from MCF-7/LY2 cells.  This is represented by the ratio of 0 seen in Table 6 for MCF-
7/LY2:MCF-7. 
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Figure 17:  iTRAQ reporter region of an MS/MS spectrum from a peptide identified as hnRNP R.   
There is no peak present at 119, which corresponds to the isolation from MCF-7/LY2 cells.  This spectrum 
was obtained on the ABI 4800 Proteomics Analyzer. 
3.3.4 Nuclear Matrix Protein Abundance Levels Altered in MCF-7 and MCF-7/LY2 Cells 
in Response to PPT 
In addition to understanding how the protein composition of the NM changes with antiestrogen 
resistance, it was also of interest to determine how the two isoforms of the ER differently 
influence the protein composition of the NM.  In order to do this, the MCF-7 and MCF-7/LY2 
cells were treated with one of three ER-subtype selective ligands at a concentration of 5 μM for 
48 h or the DMSO vehicle control, followed by NM isolation.  The first ligand, PPT, is a 410-
fold selective agonist for ERα and does not stimulate transcription through ERβ (Stauffer, 2000).   
Table 16 in Appendix C presents 30 NMPs with altered levels of abundance in MCF-7 
cells in response to PPT.  Table 7 presents the proteins that were significantly altered when 
comparing abundance of NMPs in MCF-7 cells treated with PPT to those treated with the vehicle 
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control.  Three proteins demonstrate a significantly increased abundance in MCF-7 cells in 
response to PPT. 
Table 7: Statistically significant alterations to NMP abundance in MCF-7 cells in response to PPT. 
 
Protein Name 
Accession Number 
(IPI) 
 
Gene Symbol 
PPT : 
DMSO 
Histone H3.1 00902514.1 HIST1H2AD 2.196 
60S acidic ribosomal protein P1 00008527.3 RPLP1 2.100 
TUBA1B protein 00793930.1 TUBA1B 1.739 
 
Table 17 in Appendix C presents the eleven NMPs with altered levels of abundance in 
response to PPT in MCF-7/LY2 cells.  No proteins in the NM of MCF-7/LY2 cells were 
significantly altered in response to PPT. 
3.3.5 Nuclear Matrix Protein Abundance Levels Altered in MCF-7 and MCF-7/LY2 Cells 
in Response to MPP 
MPP is an ERα-selective antagonist that binds ERα with about 200-fold more affinity than ERβ 
and suppresses E2-stimulation through ERα but not through ERβ (Sun, 2002). Table 18 in 
Appendix D presents forty-six NMPs with altered levels of abundance in MCF-7 cells in 
response to MPP.  Table 8 presents the proteins that were significantly altered when comparing 
abundance of NMPs in MCF-7 cells treated with MPP to those treated with vehicle control. 
Fourteen proteins demonstrate an increased abundance and five proteins demonstrate a decreased 
abundance in the NM of MCF-7 cells in response to MPP.   One of these proteins is NuMA, 
which with a ratio of 9999 was present in the NM of MCF-7 cells in response to MPP but absent 
in the vehicle-treated cells. 
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Table 8: Statistically significant alterations to NMP abundance in MCF-7 cells in response to MPP. 
 
 
Protein Name 
Accession 
Number 
(IPI) 
 
Gene 
Symbol 
 
MPP : 
DMSO 
 
Std 
Dev 
NUMA1 variant protein 00872028.2 NUMA1 9999  
Keratin, type I cytoskeletal 15 00290077.1 KRT15 141.5  
Dynein heavy chain 5, axonemal 00152653.3 DNAH5 49.53  
48 kDa protein 00879060.1 GCAT 47.36  
Epiplakin 00010951.2 EPPK1 42.24  
hnRNP R, isoform 1 00644055.3 HNRNPR 32.83  
Interferon-induced guanylate-binding protein 2 00848358.1 GBP2 27.45  
Cingulin-like protein 1, isoform 1 00307829.7 CGNL1 25.9  
Highly similar to AF4/FRM2 family member 1, 
CDNA FLJ61397 
00396310.5 AFF1 
21.10  
Tau-tubulin kinase 00217437.6 TTBK2 15.68  
Keratin 7 00847342.1 KRT7 10.86  
60S acidic ribosomal protein P1 00008527.3 RPLP1 4.651  
ATP synthase subunit alpha 00440493.2 ATP5A1 2.032 0.7981 
40S ribosomal protein s20 00012493.1 RPS20 1.749  
Zinc finger protein 595 00478170.1 ZNF595 0.487  
hnRNPQ, isoform 2 00402182.2 SYNCRIP 0.4418  
hnRNP F 00003881.5 HNRNPF 0.4017  
Keratin, type I cytoskeletal 24 00004550.5 KRT24 0.2323  
Keratin, type I cytoskeletal 16 00217963.3 KRT16 0.1578  
 
Table 19 in Appendix D presents twenty-nine NMPs with altered levels of abundance in 
MCF-7/LY2 cells in response to MPP.  Table 9 presents the proteins that were significantly 
altered when comparing abundance of NMPs in MCF-7/LY2 cells treated with MPP to those 
treated with vehicle control. Ten proteins demonstrate an increased abundance and one protein 
demonstrate a decreased abundance in the NM of MCF-7/LY2 cells in response to MPP.  NuMA 
and dynein heavy chain 5 have ratios of 9999 meaning they were present in the NM of MCF-
7/LY2 cells in response to MPP but absent in the vehicle treated cells. 
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Table 9: Statistically significant alterations to NMP abundance in MCF-7/LY2 cells in response to MPP. 
 
 
Protein Name 
Accession 
Number 
(IPI) 
 
 
Gene Symbol 
 
MPP : 
DMSO 
Dynein heavy chain 5, axonemal 00152653.3 DNAH5 9999 
hnRNP R, isoform 1 00644055.3 HNRNPR 9999 
Zinc finger protein 595 00478170.1 ZNF595 2.988 
60S acidic ribosomal protein P2 00008529.1 RPLP2 2.855 
hnRNPA3, isoform 1 00419373.1 HNRNPA3 2.401 
hnRNP A1, isoform A1-A 00215965.4 HNRNPA1 2.15 
hnRNP A2/B1, Isoform B1 00396378.3 HNRNPA2B1 1.95 
60S ribosomal protein L12, isoform 1 00024933.3 RPL12 1.846 
hnRNPL, isoform a 00027834.3 HNRNPL 1.812 
hnRNPQ, isoform 2 00402182.2 SYNCRIP 1.671 
Interferon-induced guanylate-binding protein 2 00848358.1 GBP2 0.3863 
 
3.3.6 Nuclear Matrix Protein Abundance Levels Altered in MCF-7 and MCF-7/LY2 Cells 
in Response to DPN 
DPN is a selective ERβ agonist that binds to ERβ with 70-fold selectivity compared to ERα and 
it activates transcription through ERβ with 170-fold more potency than through ERα (Meyers, 
2001).  Table 20 in Appendix E presents forty NMPs with altered levels of abundance in the NM 
of MCF-7 cells in response to DPN.  Table 10 presents the proteins that were significantly 
altered when comparing abundance of NMPs in the NM of MCF-7 cells treated with DPN to 
those treated with vehicle control. Eleven proteins demonstrate an increased abundance and two 
proteins demonstrate a decreased abundance in the NM of MCF-7 cells in response to DPN.   
One of these proteins is NuMA; with a ratio of 9999 NuMA is present in the NM of MCF-7 cells 
in response to DPN but not in the vehicle treated cells.  Histone H2A type 1A with a ratio of 0 is 
no longer found in the NM of MCF-7 cells when treated with DPN. 
 
  74 
Table 10: Statistically significant alterations to NMP abundance in MCF-7 cells in response to DPN. 
 
 
Protein Name 
Accession 
Number 
(IPI) 
 
 
Gene Symbol 
 
DPN : 
DMSO 
NUMA1 variant protein 00872028.2 NUMA1 9999 
48 kDa protein 00879060.1 GCAT 5.748 
Cingulin-like protein 1, isoform 1 00307829.7 CGNL1 3.542 
60S ribosomal protein L12, isoform 1 00024933.3 RPL12 3.531 
Interferon-induced guanylate-binding 
protein 2 
00848358.1 GBP2 
2.909 
Keratin 7 00847342.1 KRT7 2.507 
Highly similar to AF4/FRM2 family 
member 1, CDNA FLJ61397 
00396310.5 AFF1 
2.002 
Histone H2B 00646240.3 HIST2H2BA 1.995 
Putative Histone H2B type 2-C 00454695.4 HIST2H2BC 1.765 
P37 AUF1 00903278.1 HNRNPD 1.748 
51 kDa protein 00479191.2 HNRNPH1 1.707 
hnRNP F 00003881.5 HNRNPF 0.4783 
Enhancer of rudimentary homolog 00029631.1 ERH 0.343 
Histone H2A type 1-A 00045109.3 HIST1H2AA 0 
 
Table 21 in Appendix E presents forty-one NMPs with altered levels of abundance in 
MCF-7/LY2 cells in response to DPN.  Table 11 presents the eight proteins that were 
significantly altered when comparing abundance of NMPs in the NM of MCF-7/LY2 cells 
treated with DPN to those treated with vehicle control. Six proteins demonstrate an increased 
abundance and two protein demonstrate a decreased abundance in the NM of MCF-7/LY2 cells 
in response to DPN.  hnRNP R and dynein heavy chain 5 have ratios of 9999 meaning they were 
found in the NM of MCF-7/LY2 cells in response to DPN, while histone H2A type 1-A has a 
ratio of 0 meaning it was no longer found in the NM of MCF-7/LY2 cells in response to DPN. 
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Table 11: Statistically significant alterations to NMPs in MCF-7/LY2 cells in response to DPN. 
 
 
Name 
Accession 
Number 
(IPI) 
 
Gene 
Symbol 
 
DPN : 
DMSO 
 
Std 
Dev 
Dynein heavy chain 5, axonemal 00152653.3 DNAH5 9999  
hnRNP R, isoform 1 00644055.3 HNRNPR 9999  
Keratin, type II cytoskeletal 1 00220327.3 KRT1 4.0085  
Interferon-induced guanylate-binding 
protein 2 
00848358.1 GBP2 
1.843  
Keratin, Type II Cytoskeletal 19 00479145.2 KRT19 1.842 1.937 
Putative elongation factor 1-alpha-like 3 00472724.1 EEF1A1 1.769  
Histone H2B 00646240.3 HIST2H2BA 0.4359  
Histone H2A type 1-A 00045109.3 HIST1H2AA 0  
 
3.3.7 Western Blot Validation 
In order to validate the data obtained using the iTRAQ methodology, a second NM isolation was 
performed on MCF-7 and MCF-7/LY2 cells creating a biological replicate.  Western blotting 
was then performed using antibodies for several of the proteins quantification was obtained for in 
Table 6. The Western blots for these proteins are shown in Figure 18.  Additionally the ratios 
provided by iTRAQ for these proteins is seen below in Table 12. 
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Figure 18:  Western blot validation of NMPs quantified by iTRAQ. 
Several of the proteins quantified in NMP preparations from MCF-7 and MCF-7/LY2 cells were verified 
using Western blot analysis.  A second NMP isolation was performed to generate a biological replicate and Western 
blot analysis with the appropriate antibody was performed.  Table 12 gives the iTRAQ ratios obtained for these 
proteins. 
 
Table 12:  iTRAQ ratios obtained for NMPs validated by Western blotting in Figure 18. 
Protein MCF-7/LY2 :MCF7 
NuMA 9999 
Serpin H1 0 
hnRNP M 0.7657 
Lamin A/C 1.203 
hnRNP L 0.7024 
hnRNP F 0.5719 
H2B 2.301 
H2A 1.595 
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3.3.8 Comparison of the Different Workflows  
Figure 11 shows the three different workflows used in this study.  Within these three workflows, 
there were two separate labelings performed, in which a different label was used on each sample 
to account for any label specific effects.  For the first set of labeling, the peptides were 
fractionated using SCX.  The first workflow involved analysis by nano-LC-MALDI-TOF/TOF 
with the ABI 4700 mass spectrometer.  The second workflow involved the same SCX 
fractionation, but then nano-LC ESI Q-TOF was performed with the ABI QSTAR Elite mass 
spectrometer.  The third workflow used the second set of labeled samples and fractionated using 
OFFGEL electrophoresis followed by nano-LC-MALDI-TOF/TOF with the ABI 4800 mass 
spectrometer. 
The first workflow using SCX spin column fractionation and the ABI 4700 gave a total 
of thirty proteins with a ProtScore > 1.3 (95% confidence).  Of these NMPs, thirteen were 
identified from at least two distinct peptides with 95% confidence.  A total of 16,130 MS/MS 
spectra were searched and quantified in this workflow. In the second workflow, using the SCX 
spin column fractionation and the QSTAR, sixty-nine NMPs with a ProtScore > 1.3 (95% 
confidence) were identified.  Of these NMPs, twenty-two were identified from at least two 
distinct peptides with 95% confidence. A total of 69,094 MS/MS spectra were searched and 
quantified in this workflow.  With the third workflow, using the OFFGEL electrophoresis and 
4800, 99 NMPs with a ProtScore > 1.3 (95% confidence) were identified.  Of these NMPs, forty-
eight were identified from at least two distinct peptides with 95% confidence. A total of 63,049 
MS/MS spectra were searched and quantified in this workflow.   
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Eleven NMPs were identified by all three workflows with a ProtScore > 1.3.  Thirty-nine 
NMPs were identified in at least two workflows with a ProtScore > 1.3, and 109 NMPs were 
identified by only one workflow.  A Venn diagram demonstrating the number of NMPs 
identified in each of the workflows can be seen in Figure 19.   
 
Figure 19:  Protein identifications corresponding to the three different workflows used. 
This Venn diagram demonstrates how the 148 NMPs were identified by each of the three different 
workflows.  Workflow 1 involved the SCX spin column fractionation and analysis with the ABI 4700 Proteomics 
Analyzer.  Workflow 2 involved the SCX spin column fractionation and analysis with the ABI QSTAR Elite.  
Workflow 3 involved the OFFGEL fractionation and analysis with the ABI 4800 Proteomics Analyzer. 
3.4 DISCUSSION 
The antiestrogen resistant cell line, MCF-7/LY2, maintains expression of ERα but does not 
express significant levels of ERβ compared to the parental MCF-7 cells (Figure 12). The loss of 
ERβ expression in MCF-7/LY2 corroborates studies suggesting that low levels of ERβ are 
predictive of antiestrogen resistance (Hopp, 2004; Esslimani-Sahla, 2004).  Since ERβ has a 
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negative influence on the transcription of ERα-regulated genes, the loss of ERβ expression in 
tamoxifen resistance allows ERα to overcome this repression (Sugiura, 2007). 
This study is the most comprehensive examination to date of the NM proteome in breast 
cancer.  Most studies of the NM in breast cancer describe differences between spots on two-
dimensional gels, but the identification of these spots is lacking.  In one study that examined the 
NM in breast cancer, a two-dimensional gel of NMPs isolated from MCF7 breast cancer cells 
revealed fifty-six protein spots.  Three of these spots were identified as Lamins A, B, and C, and 
many of the RNP complex proteins were present on the gel.  Despite attempts to remove the IFs 
from the preparation, cytokeratins 8, 18 and 19 were the top identifications.  Actin was also seen 
in the gel (Fey, 1988).  The iTRAQ analysis of the NM in MCF-7 cells agrees with this study, as 
cytokeratins 8, 18, and 19 were the top hits.  Actin was also observed.  Cytokeratins 8, 18 and 19 
were also previously demonstrated to be expressed at higher levels in an estrogen-independent 
breast cancer cell line compared to an estrogen-dependent line.  These three cytokeratins were 
shown to be estrogen regulated (Coutts, 1996).  Of these three cytokeratins, cytokeratin 8 is 
significantly less abundant in the NM of MCF-7/LY2 resistant cells compared to MCF-7 
responsive cells.  This cytokeratin may play a role in the ability of an antiestrogen to act on a 
breast cancer cell and warrants further investigation. 
  Many other proteins that have never before been detected in the NM of MCF-7 cells 
were identified. ProteinCenter software was used to classify the NMPs identified into the gene 
ontology (GO) categories of cellular component and molecular function.  Within cellular 
component, proteins from many different organelles were present in the NM.  Nucleus was the 
most abundant category, but cytoplasm, membrane, cytoskeleton, and organelle lumen were also 
strongly represented.  It is likely that in these MCF-7 breast cancer cells, proteins that are not 
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normally found in the NM are being retained by the structure.  If one of these proteins is specific 
to breast cancer it may be very useful as a biomarker.  Protein binding, nucleotide binding, DNA 
binding, and RNA binding were the top molecular functions assigned to the NMPs identified in 
MCF-7 cells.  This reinforces the idea that the proteins of the NM interact with DNA, RNA, and 
transcription factors to regulate gene expression. 
The proteins that have the potential to serve as biomarkers for tamoxifen resistance are 
those with significant alterations in antiestrogen resistant cells.  There are several of these 
proteins in MCF-7/LY2 cells and they should be investigated in other antiestrogen resistant cell 
lines and tissue samples.  NuMA (nuclear mitotic apparatus) is not found in the NM of MCF-7 
cells, but it is present in the NM of resistant MCF-7/LY2 cells.  NuMA was identified in 1980 
and determined to function as an NMP in interphase that plays a role in microtubule organization 
around centrosomes during mitosis (Lyderson, 1980).  NuMA moves from the nucleus of 
interphase poles to the spindle poles of mitotic cells (Saredi, 1997).  NuMA is bound to small 
nuclear ribonucleoprotein particles and may connect RNA metabolism to the NM (Zeng, 1994).  
NuMa’s localization patterns differ from diffuse nuclear staining to punctate staining, and this 
staining pattern has been attributed to different functions of the protein depending upon cell type 
(Zeng, 2000).  The NuMA region on chromosome 11q13 is a candidate for breast cancer 
susceptibility (Kammerer, 2005).  When confluent MCF-7 cells are cultured long-term, they no 
longer express NuMA in the nucleus (Taimen, 2000). NuMA associates with the NM in 
estrogen-responsive MCF-7 cells and disperses into the cytoplasm during the onset of mitosis 
(Gobert, 2001).   NuMA is an interesting protein because its ability to control the proliferation of 
cancer cells is influenced by environmental factors and depending on external stimuli NuMA 
may participate in cell division or apoptosis.  Relevant to breast cancer is the fact that NuMA 
  81 
expression is regulated by hormones (Yam, 1998).  The NM of antiestrogen resistant MCF-
7/LY2 cells contains NuMA while the NM of antiestrogen responsive MCF-7 cells lacks this 
protein.  This is worth further investigation as it provides insight into the mechanism of 
antiestrogen resistance, and the difference seen between responsive and resistant cells may mean 
NuMA is a biomarker for determining when to stop tamoxifen treatment.  NuMA abundance in 
the other protein fractions generated during NM preparation should be determined in order to 
confirm that NuMA is altered specifically in the NM or whether it is a global change in the cell. 
 Three proteins are present in the NM of MCF-7 cells, but absent in the NM of 
antiestrogen resistant MCF-7/LY2 cells.  These proteins are dynein heavy chain 5, serpin H1, 
and hnRNP R.  Dynein is a cytoskeletal motor protein consisting of several different 
components, and the movement of this protein is produced by the heavy chain component of the 
protein (Asai, 2001).  Dynein heavy chain 5 is an axonemal dynein, and is a component of the 
axoneme, or central cytoskeletal core of a cilium.  This particular isoform of dynein has only 
been studied in primary ciliary dyskinesia, which is a disease characterized by dysfunctioning 
motile cilia and flagella.  Recurrent respiratory infections and reduced fertility in males are often 
observed with the disease.  One of the major causes of this disease is mutations in the dynein 
heavy chain 5 (Hornef, 2006).  Therefore it is very novel to find this axonemal dynein in the NM 
of breast cancer cells.  Specific loss of dynein heavy chain 5 in tamoxifen resistant cells 
demonstrates its potential as a biomarker.  Other components of the dynein complex have been 
investigated in breast cancer.  Dynein light chain 1 is known to promote the growth of breast 
cancer cells and plays a role in estrogen receptor signaling (Rayala, 2005). 
Serpin H1 is also known as HSP47.  HSP47 is associated with the binding and processing 
of collagens in the endoplasmic reticulum (Sauk, 2005).  This protein is overexpressed in 
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pancreatic cancer, osetosarcomas and squamous cell carcinoma of the head and neck (Maitra, 
2002; Uozaki, 2000; Poschmann, 2009).  This is the first report of any alteration to the protein in 
breast cancer. Further investigation into HSP47’s role in breast cancer is necessary, as it may 
play an important role based on its specific expression loss in the NM of antiestrogen resistant 
cells. 
hnRNP proteins are RNA-binding proteins.  They were first described as a family of 
proteins that bind RNA polymerase II transcripts to form hnRNP particles.  Originally it was 
thought the complex consisted of only six proteins, but additional factors have since been 
identified (Choi, 1984; Carpenter, 2006).  Thirty spots are observed on a two dimensional gel 
when the immunopurified complex is run (Pinol-Roma, 1988).  A variety of functions have been 
attributed to the hnRNP proteins, including roles in both DNA and RNA regulation.  Because of 
their involvement in these fundamental cell processes, several of these proteins have been 
proposed to play roles in tumor development (Carpenter, 2006). hnRNP R is one of the least 
studied members of the family.  Recently, hnRNP R was demonstrated to enhance transcription 
of the proto-oncogene c-fos.  This supports the emerging view that transcription is tightly 
coupled to subsequent RNA metabolism (Fukuda, 2009).  There is still much to determine about 
hnRNP R’s role, but its absence in the NM of antiestrogen resistant breast cancer cells suggests it 
may play a role in ER signaling.   
PPT, the ERα-selective agonist, has very little effect on the composition of the NM of  
either of the cell lines.  In MCF-7 calls, PPT significantly increased the abundance of three 
proteins in the NM, but no NMPs were effected in MCF-7/LY2 cells.  PPT has a very strong 
affinity for ERα with a Ki of 0.54 nM (Stauffer, 2000).  It may be that when activated by PPT, 
ERα does not interact strongly with the NM.  Other ERα-selective agonists should be used in 
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order to determine if this is a compound or receptor specific phenomenon.  MPP demonstrates 
the largest effect of the subtype selective ligands on the NMPs in both MCF-7 and MCF-7/LY2 
cells.  MPP has a Ki of 2.7 nM for ERα.  MPP does not bind to ERα as strongly as PPT, but it 
functions as an antagonist and alters the confirmation of the receptor in a different way.  The 
compound also does have some affinity for ERβ with a Ki of 1800 nM (Sun, 2002).  It may be 
that MPP has a greater effect on the composition of the NM in MCF-7 cells compared to MCF-
7/LY2 cells, because this cell line retains expression of both ER isoforms.  In MCF-7 cells, 
NuMA is present in the NM upon treatment with MPP.  This supports the idea that NuMA’s 
interactions with the NM are hormone-regulated.  Further investigation should be done to 
understand how the different ER isoforms influence NuMA to determine its function in breast 
cancer and possible role as a biomarker.  Dynein heavy chain 5 and hnRNP R were not present in 
the NM of MCF-7/LY2 cells until the cells were treated with MPP.  Since these cells do not 
express ERβ, this response is likely a result of MPP’s interaction with ERα.  These proteins 
warrant further investigation as they may be specifically regulated in the NM by ERα.   
DPN, the ERβ-selective agonist, impacted the NM composition of both cell lines 
somewhat.  Since it is an ERβ-selective ligand, it is interesting to see it exerting an effect in 
MCF-7/LY2 cells, which lack this isoform of the receptor.  DPN does have considerable activity 
on ERα though, demonstrating an EC50 of 66 nM for ERα in a luciferase reporter assay (Meyers, 
2001).  As MPP did in MCF-7/LY2 cells, DPN also lead to the retention of dynein heavy chain 5 
and hnRNP R in the NM.  This further supports the localization of these proteins to the NM is 
effected by ER signaling.  NuMA was found in the NM of the MCF-7 cells when they were 
treated with DPN, similar to what is seen with MPP.  It is possible that MPP and DPN both 
interact with the NM in a similar way as they are sharing several effects in the cell lines 
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investigated. Further investigation into these mechanisms may help in tailoring antiestrogen 
therapies. 
3.5 MATERIALS AND METHODS 
3.5.1 Cell Culture 
MCF-7 and MCF-7/LY2 breast cancer cells were obtained from Dr. Marc E. Lippman. The 
generation of the MCF-7/LY2 cell line can be seen in Bronzert DA et al. (Bronzert, 1985).  The 
cells were maintained in phenol red-free RPMI-1640 with 10% charcoal-dextran stripped FBS.  
2,3-bis(4-hydroxyphenyl)propionitrile (DPN) and propylpyrazole (PPT) were obtained from 
Tocris Bioscience.  Methyl-piperidinopyrazole (MPP) was obtained from Sigma Aldrich.  Stock 
solutions (10 mM) of each compound were made in DMSO.  Cells were treated with the 
appropriate compound at a concentration of 5 µM for 48 hours. 
3.5.2 Nuclear Matrix Isolation 
The NM was isolated according to the method of Fey and Penman (Fey, 1988).  Briefly, 
10,000,000 to 50,000,000 cells were incubated in 0.5% Triton X-100 in a buffered solution with 
2 mM vanadyl ribonucleoside, an RNase inhibitor, for 10 min on ice to release lipids and soluble 
proteins.  Remaining sample was then pelleted at 1800 rpm at 4°C for 10 min and incubated in  
ammonium sulfate (0.25 M) with 2 mM vanadyl ribonucleoside for 10 min on ice.  This step was 
performed as a salt extraction to release soluble cytoskeletal elements.  The remaining sample 
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was then pelleted at 1800 rpm at 4°C for 10 min.  Dnase I treatment was then added to remove 
soluble chromatin for 30 min at room temperature and then the sample was pelleted at 2200 rpm 
at 4°C for 10 min. RNase A was then added to remove RNA with a 10 min incubation at room 
temperature and then the sample was pelleted at 2200 rpm at 4°C for 10 min.   The intermediate 
filaments and NMPs were then disassembled with 8 M urea and the insoluble carbohydrates and 
extracellular matrix components were pelleted with ultracentrifugation at 50,000 rpm for 1 h at 
15°C.  Dialysis was performed overnight in an assembly buffer containing KCl and imidazole-
HCl to remove the urea and reassemble the intermediate filaments.  Ultracentrifugation at 45,000 
rpm for 90 min at 20°C is then done to pellet out the intermediate filaments.  The NMPs were 
precipitated with ethanol then quantified using the Coomassie (Bradford) Protein Assay (Thermo 
Scientific, Waltham, MA).  All solutions contained 1 mM phenylmethylsulfonyl fluoride to 
inhibit serine proteases. 
3.5.3 iTRAQ Labeling 
The manufacturer’s protocol for iTRAQ was followed (Applied Biosystems, Foster City, CA).  
Briefly, 60 μg of precipitated NMPs from the 8 different samples were each resuspended in 20 
μL of Dissolution Buffer (0.5 M triethylammonium bicarbonate) with 1 μL of Denaturant (0.1% 
SDS).  2 μL of the Reducing Reagent, 5 mM tris(2-carboxyethyl) phosphine (TCEP), was then 
added to each sample and incubated at 60°C for 1 h.  They were then alkylated with 1 μL of the 
Cysteine Blocking Reagent, 10 mM methyl methanethiosulfonate (MMTS), at room temperature 
for 10 min.  Trypsin (10 μg) was then added to each sample and they were digested at 37°C 
overnight.  The eight iTRAQ reagents were then added to the appropriate sample and incubated 
at room temperature for 2 h.  After labeling, the eight samples were then pooled.  Using the same 
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NM preparations, two aliquots of the NMPs were taken through the iTRAQ procedure with the 
only difference being the label that was used for each sample.  The first set of labeling used was:  
113 – MCF-7, DMSO; 114 – MCF-7/LY2, DMSO; 115 – MCF-7, PPT; 116 - MCF-7/LY2, PPT; 
117 – MCF-7, MPP; 118 – MCF-7/LY2, MPP; 119 – MCF-7, DPN; 121 – MCF-7/LY2, DPN.  
The second set of labeling used was:  113 - MCF-7/LY2, DPN; 114 – MCF-7, DPN; 115 – 
MCF-7/LY2, MPP; 116 – MCF-7, MPP; 117 – MCF-7/LY2, PPT; 118 – MCF-7, PPT; 119 - 
MCF-7/LY2, DMSO; 121 – MCF-7, DMSO. 
3.5.4 SCX Fractionation 
The first set of the pooled iTRAQ samples was speed vacuumed dry, resuspended in 10 mM 
potassium phosphate, 20% ACN, pH 2.7, and fractionated using PolySULFOETHYL A macro 
spin columns (PolyLC, Columbia, MD).  The column was first pre-conditioned with 10 mM 
potassium phosphate, 20% ACN, pH 2.7.  The sample was then applied and washed.  Increasing 
concentrations of KCl (20, 40, 60, 80, 100, 120, 140, 160, 180, 200, 225, 250, 275, 300, 350, 
400, 450, and 500 mM) in 10 mM potassium phosphate with 20% ACN at pH 2.7 were then used 
to elute off the peptides. Each fraction was then desalted using a PepClean C-18 Spin Column 
(Pierce) according to the manufacturer’s protocol.  They were then resuspended in 0.1% TFA for 
nanoLC. 
3.5.5 OFFGEL Fractionation 
The second set of pooled iTRAQ samples was desalted using a SepPak and then speed vacuumed 
dry for OFFGEL fractionation. OFFGEL fractionation was performed according to the 
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manufacturer’s guidelines with minor modifications as described.  The 3100 OFFGEL 
Fractionater and the OFFGEL Kit pH 3-10 (Agilent Technologies, Santa Clara, CA) was used 
following a 24-well set up.  An Immobiline DryStrip pH 3-10, 24 cm (GE Healthcare Bio-
Sciences, Piscataway, NJ) was used instead of the strip provided in the kit.  Fifteen minutes 
before sample loading, the gel strip was rehydrated in the assembled device with 40 µL OFFGEL 
Rehydration solution per well.  The iTRAQ peptides were resuspended in the Peptide OFFGEL 
solution to a final volume of 3.6 mL.  150 µL of the diluted sample was distributed into the 24 
wells.  The default OFFGEL peptide 24 cm strip program on the instrument was used with a max 
current of 50 µA until 50 kVh was reached.  The fractions were then recovered from each well.  
150 µL of 50% MeOH, 0.1% TFA was then added back to each well and left on the benchtop for 
20 min.  This solution was then recovered and added back to the appropriate fraction and the 
entire sample was speed vacuumed dry and resuspended in 0.1% TFA for nanoLC. 
3.5.6 Nano-LC-MALDI-TOF-TOF-MS with the ABI 4700 Proteomics Analyzer 
The SCX-fractionated samples were loaded onto a RP LC-Packing Ultimate system (Dionex, 
Sunnyvale, CA).  Samples were loaded onto a trap column (300 μm i.d. x 5 mm, PepMap 100 
C18 material 5 μm, 100 Å) (Dionex, Sunnyvale, CA) and washed for 5 min with 2% ACN, 0.1% 
FA at a flow of 30 μL/min.  They were then loaded onto an analytical column (75 μm i.d. x 100 
mm,  ProtePep II C18 material 5 μm, 300 Å) (New Objective, Woburn, MA) and fractionated 
using a gradient of 5-30% B in 95 minutes, 30-60% B in 50 minutes, and 60-100% B in 10 
minutes at a flow rate of 300 nL/min.  Solution A was 2% ACN, 0.1% TFA, and solution B was 
80% ACN, 0.1% TFA with a flow rate of 300 nL/min. The Probot™Micro Fraction Collector 
was used to collect 50 sec spots on the 192 well ABI 4700 metal target off-line.  5 min after 
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sample injection, the Probot™ was signaled to begin spotting.   One target was used for each 
fraction from SCX.  Once the LC run was complete, 10 mg/mL α-cyano-4-hydroxy cinnamic 
acid (CHCA) with 5 fmol of a 3 peptide calibration mix was spotted on top of each sample spot.  
For 4700 (Applied Biosystems, Foster City, CA) analysis, MS spectra were acquired from 900 to 
4000 Da with a focus mass of 2500 Da.  MS Processing was done using 2 of the 3 internal 
standards spiked into the matrix with a 5 ppm max outlier error.  Up to 15 peaks with a S/N filter 
of 20 were selected for MS/MS.  Peptide CID (air) was performed at 1 kV.  The MS/MS default 
calibration was updated before each target was run by using a peptide in the calibration mix 
spots.  
3.5.7 Nano-LC-ESI-Qq-TOF-MS with the ABI QSTAR Elite 
The Ultimate 3000 RP-LC system (Dionex, Sunnyvale, CA) interfaced with the QSTAR Elite 
(Applied Biosystems, Foster City, CA) consisted of a trap column (300 μm i.d. x 5 mm, PepMap 
C18 100 material 5 μm, 100 Å) (Dionex, Sunnyvale, CA) and an analytical column (75 μm i.d. x 
100 mm,  ProteoPep II C18 material 5 μm, 300 Å) (New Objective, Woburn, MA).  Samples were 
loaded onto the trap column at 20 μL/min and washed for 10 min in 0.1% FA.  They were then 
loaded onto the analytical column and resolved using a gradient of 5-30% B in 95 min, 30-60% 
B in 50 min, and 60-100% B in 10 min with a flow rate of 200 nL/min.  Solution A was 2% 
ACN, 0.3% FA, and solution B was 80% ACN, 0.3% FA.  The mass spectrometer was set up for 
information-dependent acquisition (IDA) mode with the scan cycles set up to perform a 1 s MS 
scan in the mass range of 300 – 1500 Da, followed by three MS/MS scans in the mass range of 
100 – 1800 Da of the 3 most abundant ions with a +2 to +4 charge and above a 10 count 
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threshold for 2 s each.  Dynamic exclusion was performed for 30 s with a ±50 amu mass 
tolerance. 
3.5.8 Nano-LC-MALDI-TOF-TOF-MS with the ABI 4800 Proteomics Analyzer 
For the samples fractionated by OFFGEL fractionation, they were further fractionated on an RP-
LC Ultimate system (Dionex, Sunnyvale, CA).  They were first loaded onto a trap column (300 
μm i.d. x 5 mm, PepMap C18 100 material 5 μm, 100 Å) (Dionex, Sunnyvale, CA) and washed 
for 10 min with 2% ACN, 0.1% TFA at a flow of 30 μL/min.  They were then loaded onto an 
analytical column (75 μm i.d. x 150 mm, Pep Map C18 100 material 3 μm, 100 Å) (Dionex, 
Sunnyvale, CA) and fractionated using a gradient of 5-30% B in 110 minutes, 30-60% B in 60 
minutes, and 60-100% B in 10 minutes with a flow rate of 250 nL/min.  Solution A was 5% 
ACN, 0.1% TFA, and solution B was 85% ACN, 5% IPA, and 0.1% TFA.  5 minutes after the 
sample injection, the Probot was signaled to start spotting. The Probot™Micro Fraction 
Collector was used to collect 15 second spots on the ABI 4800 LC-MALDI (ABI, Foster City, 
CA) metal target in a 16 x 48 array.  5 min after the sample injection, the Probot™ was signaled 
to begin spotting. 768 spots were collected for each OFFGEL fraction, and 2 LC runs were done 
on each target.  This resulted in a total of 12 plates.  The μTee mixer was used to co-spot matrix 
(7 mg CHCA in 1 mL of 50% ACN, 0.1% TFA, with mM ammonium citrate and 10 fmol of 
angiotensin II), delivered at a flow rate of 1.577 μL/min. For 4800 (ABI, Foster City, CA) 
analysis, MS spectra were acquired from 900 to 4000 Da with a focus mass of 2000 Da.  MS 
processing was done using the Angiotensin II internal standard with a 250 ppm max outlier error.  
Up to 10 peaks were selected for MS/MS.   Peptide CID (air) was performed at 2 kV.  
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3.5.9 Protein Identification and Quantification 
The Paragon algorithm in ProteinPilot™ Software 2.0 (Applied Biosystems, Foster City, CA) 
was used for protein identification for all three of the workflows followed.  Proteins were 
identified by searching against the IPI database.  For the 4700 Proteomics Analyzer, v 3.49 was 
used.  For the QSTAR Elite, v 3.58 was used.  For the 4800 Proteomics Analyzer, v 3.46 was 
used.  Searched results were processed by the Pro Group algorithm.  Search parameters included 
iTRAQ labeling of the N-terminus and lysine residues, cysteine modification by MMTS, and 
digestion by trypsin.  Isoform specific identification and quantification was done by excluding all 
shared peptides and including only unique peptides.  Proteins identified with >95% confidence 
or ProtScore > 1.3 were used for further analysis.  The p-value calculated by the software was 
used to determine if the change in protein expression was real or not.  This p-value tests the null 
hypothesis, the actual protein ratio is 1 and the observed protein ratio is different than 1 only by 
chance.  Cut-off values for statistically significant alterations were determined by calculating the 
mean of all ratios obtained and moving two standard deviations away from this mean.  Proteins 
that met these two stipulations were analyzed using ProteinCenter (Proxeon, Cambridge, MA). 
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4.0  ALTERATIONS TO THE NUCLEAR MATRIX IN DUCTAL CARCINOMA IN 
SITU 
4.1 ABSTRACT 
DCIS is the earliest identifiable breast cancer lesion.  It is a pre-invasive malignancy that may or 
may not progress to invasive disease.  There is no true understanding as to why and what cases 
of DCIS will progress to invasive breast cancer.  DCIS is not easy to study, as there are no 
commercial cell lines available.  The Latimer lab at the University of Pittsburgh Cancer Institute 
has recently developed a novel tissue engineering system that allows for the culture of both 
normal breast cells and early stage breast tumor cells, including DCIS, in an environment that is 
more similar to the in vivo environment than most tissue culture systems.  The normal cells are 
able to form organotypic three-dimensional structures in the system.  Using two of the normal 
breast reduction lines and one set of the DCIS lines, consisting of the tumor, the margin adjacent 
to the tumor, and the non-diseased contralateral lines the NM was investigated.  NMPs are 
specifically altered in cancer and can be detected in the blood and urine of patients.  Therefore 
identifying a NMP specifically altered in DCIS may help to create an early detection assay.  Two 
NMPs, HSP90 and EEF1D, were altered in the DCIS series and warrant further investigation. 
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4.2 INTRODUCTION 
In order to better understand the origins of breast cancer and work towards prevention, one must 
study the earliest stages of the disease.  DCIS is the earliest identifiable breast cancer lesion. It is 
a pre-invasive malignancy that may or may not progress to an invasive disease.  Around 53,000 
women are expected to be diagnosed with DCIS in 2009.  This represents 20-25% of breast 
cancer cases currently being diagnosed  (American Cancer Society, 2009).  It is the fourth 
leading cause of cancer in women in the United States.  The detection of the disease has 
improved dramatically since the introduction of screening mammography. Treatment, which 
includes surgery and often radiation and/or tamoxifen therapy, is aimed at preventing the 
development of invasive disease.  There is, however, no true understanding of the mechanisms 
that will cause DCIS progression to invasive disease (Kuerer, 2009).  The University of 
Pittsburgh Medical Center reports a 20-25% ten year recurrence rate of breast CIS, both ductal 
and lobular.  Therefore, the majority of patients diagnosed with DCIS are probably overtreated.  
An understanding of the basis of the disease and ways to identify those with the more aggressive 
form that will progress to invasive disease would be of great benefit to tailor treatment and avoid 
overtreating women who do not need it. 
One of the major issues in studying DCIS is that there are currently no cell lines that 
represent this early form of breast cancer.  The majority of breast cancer cell lines used in 
research are late stage tumors that have metastasized to the pleural sack around the lung.  The 
most frequently studied breast cancer cell lines is MCF-7, originally developed by Dr. Herbert 
Soule at the Michigan Cancer Foundation in 1973 from a pleural effusion in a postmenopausal 
woman with metastatic breast cancer treated with hormones (steroids) and radiation (Soule, 
1973).  A problem using cell lines is that cell lines are prone to genotypic and phenotypic drift 
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during long-term culture, and this has been demonstrated to occur in the MCF-7 cell line. MCF-7 
lines demonstrate different degrees of amplification of the oncogene N-ras (Graham, 1985).  
Karyotyping and restriction fragment length polymorphism analyses show an early passage 
MCF-7 from the Michigan Cancer Foundation and a later passage MCF-7 from the American 
Type Culture Collection (ATCC) likely came from different individuals (Graham, 1986).  More 
MCF-7 lines were then analyzed, including several that were obtained from the Michigan Cancer 
Foundation at different time periods and one from the ATCC. The lines from the Michigan 
Cancer Foundation had similar chromosomal alterations and marker chromosomes; however, the 
ATCC line shares almost no chromosomal alterations with the other lines. In spite of the 
karyotypic differences these lines did appear morphologically similar.  The ATCC line grows 
much slower than the other lines and it is not responsive to estrogen or antiestrogen treatment.  
Even the lines obtained from the same place, Michigan Cancer Foundation, but cultured in 
different labs, demonstrate unique biological properties, such as ER level, cell proliferation rates, 
and cloning efficiency despite having similar karyotypes (Osborne, 1987).  More recent studies 
using comparative genomic hybridization (CGH) and fluorescent in situ hybridization have 
demonstrated that MCF-7 lines from different labs have undergone unique changes (Jones, 2000; 
Wenger, 2004; Bahia, 2002). These changes could have resulted from clonal evolution under 
different culture conditions, inherent genetic instability of cells in long-term culture, or 
contamination with another cell line (Osborne, 1987). Therefore it is hard to compare the results 
different labs obtain using different variants of the MCF-7 cells.  Additionally, this line came 
from a pleural effusion in a late stage case, therefore it is likely very different from the original 
cells in the early primary tumor.  Lines more representative of what occurs in the breast in vivo 
and representative of the earlier stages of the disease are needed. 
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The recently developed tissue engineering system for culture of human mammary 
epithelial cells (HMEC) generated by Dr. Jean Latimer’s laboratory allows for the culture of both 
normal breast cells and early breast tumor cells in an environment more representative of the 
human breast. A schematic of this method for non-diseased breast can be seen in Figure 20.  It 
involves the disaggregation of the tissue in a medium that is adapted from media used in stem 
cell culture (Latimer, 2002).  A diluted form (1:1) of Matrigel is used to create a substratum for 
the tissue.  Initially, the system contains cell types from the stroma, epithelial, myoepithelial cells 
and adipose compartments of the breast.  This maintains the paracrine and juxtacrine factors the 
cells see in vivo. The minced tissue adheres to the substratum within 24 to 48 hours.  Within 
three days, the living cells appear as monolayer outgrowths of multiple cell types, epithelial and 
fibroblastic.  After 10-11 days, there is a marked increase in the proliferation and migration of 
both cell populations.  The first recognizable three-dimensional structure the cells form is an 
episphere.  This is a cluster of 20-100 epithelial cells in which only the bottom of layer of cells is 
in contact with the Matrigel. These epispheres then differentiate into complex organotypic 
branching ducts and lobules.  These structures demonstrate Epithelial Specific Antigen (ESA) 
staining, cytokeratin (CK)-18 and -19 staining, lumen, polarized nuclei, desmosomes along 
lateral cell surfaces, microvilli on apical surfaces and β-casein secretion into the lumen.  The 
system allows normal cells to form organotypic structures (Johnson, 2006).  39 out of 39 primary 
HMEC cultures have been established by the Latimer lab including tissue from European derived 
white women, African American women, Middle Eastern women and one Native American 
woman. 
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Figure 20:  The Latimer tissue engineering system for the culture of Human Mammary Epithelial Cells. 
The cells begin by forming epispheres (a) and then proceed to form organotypic ducts (b) and lobules (c).  
The flasks used are coated with a thin layer of Matrigel.   
Cell lines have been established from this tissue engineering system.  Using conservative 
trypsinization, the primary cell cultures of breast reduction epithelium were passaged out to 
passage thirty and beyond without the use of any transformation agents.  Figure 21 shows the 
generation of a cell line using the Latimer system.  The primary explant culture is trypsinized off 
of the chamber slide into a flask where it is considered an extended explant culture up to thirteen 
passages, at which point it is now considered a cell line.  These cell lines are more heterogeneous 
than the commercial lines that are available.  Some of the non-diseased cell lines are able to 
reiterate the ductal structure seen in the breast (Johnson, 2006).   
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Figure 21:  Generation of cell lines using the Latimer tissue engineering system. 
Cell lines are generated by performing conservative trypsinization.  The primary explant is made on a 
chamber slide and is then trypsinized into a flask where it is considered an extended explant up to thirteen passages.  
After passage thirteen it is then considered a cell line. 
Cell lines are advantageous because they are renewable resources and provide fresh, 
intact samples for proteins and nucleic acids for research.  They can also be experimentally 
manipulated.  The Latimer lab offers these lines that provide access to samples from breast tissue 
that were never available before.  Additionally the cells behave more like they would in vivo in 
this system. 
All thirty-nine of the primary HMEC cultures have originated cell lines.  Many of these 
breast reduction cell lines maintain a normal karyotype.  The karyotype of JLBRL- (breast 
reduction line) 14, one of the normal lines used in this study, is shown in Figure 22.  
Karyotyping was performed by Suzanne Gollin and Sharon Wenger. 
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Figure 22:  The karyotype of JLBRL-14. 
This is one of the normal breast reduction lines generated using the Latimer tissue engineering system.  It 
displays a normal 46, XX karyotype. 
The Latimer tissue engineering system also allows for the development of tumor lines, 
including DCIS.  Currently, the Latimer lab has established 45 tumor lines ranging from stage 1 
to 4 and six DCIS-derived cell lines along with their matching isogenic normal counterparts.  
These tumor cell lines do not demonstrate the structures formed by the normal breast reduction 
lines but rather a distinct tumor phenotype.  These cultures do not contain the stromal elements 
but come from within the tumor where there is no possibility of stromal contamination.  The 
culture system can culture both normal and tumor cell lines, which makes it an ideal 
experimental model for the study of transformation (Johnson, 2006).  A table demonstrating 
what is known about several of the Latimer lines available for study compared to the commonly 
used commercial lines can be seen in Table 22 in Appendix F.  
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In this study, three different DCIS lines that came from one woman were investigated. 
The patient was a 39-year old woman with widespread ER+ DCIS and an 8 cm mass.  The tumor 
line is designated JLDCIS-1A.  A second line designated JLNTALDCIS-1 was derived from the 
margin adjacent to the tumor.  The non-diseased contralateral (unaffected) breast line is 
designated JLDCIS-1Contra.  The karyotypes of these three lines can be seen in Figures 23, 24, 
and 25, respectively.  JLDCIS-1Contra displays a normal karyotype. JLNTALDCIS-1 has an 
extra copy of chromosome 17. JLDCIS-1A has an extra copy of 5q on chromosome 14.   Two 
normal breast reduction lines were also used, JLBRL-14 and JLBRL-24.  These lines were 
derived from breast reduction mammoplasties performed on pre-menopausal women.  The 
normal karyotype of JLBRL-14 was discussed earlier and can be seen in Figure 22.  
 
 
Figure 23:  The karyotype of JLDCIS-1Contra. 
This is the cell line developed from the contralateral, unaffected breast in a woman who had widespread 
ER+ DCIS.  It displays a normal 46, XX karyotype. 
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Figure 24:  The karyotype of JLNTALDCIS-1. 
This is the karyotype derived from the non-tumor adjacent tissue in the woman with widespread DCIS.  
The karyotype is:  47,XX,i(17)(q10)[3]/46. 
 
 
Figure 25:  The karyotype of JLDCIS-1A. 
This is the karyotype generated from the actual DCIS tumor.  The karyotype is:  45, X, -X, 
der(14)t(5;14)(q11.2;p11.2)[3]/46,X,-X,der(14)t(5;14)(q11.2;p11.2)[3]/46, XX [10]. 
  100 
Expression microarray and supervised hierarchical clustering have been performed on 
many of the Latimer lab lines to compare them with the commonly used, commercial cell lines.  
Expression microarray was performed by the University of Pittsburgh Genomics core and 
analysis was performed by Dr. Stephen Grant and Tim Furphee.  Clustering based on a set of 521 
genes/probe sets based on replication can be seen in Figure 26.  This clustering generates three 
major groups.  The cluster on the far left contains eight distinct BRLs, some of which replicate 
runs were performed on, generated by the Latimer lab and includes the karyotypically normal 
contralateral line from the woman with DCIS, JLDCIS-1Contra, and the non-tumor adjacent line, 
JLNTALDCIS-1.  The next closet cell lines are derived from stage I tumors, JLBTL (breast 
tumor line) -4 and -8, which flank the JLDCIS-1A line.  Then finally is MCF-10A, an 
established, originally normal cell line (Soule, 1990).  This line now has an abnormal karyotype 
(45-48,XX,i(1)(q10),-3,del(3)(p13),+4,der(9),der(9),+19 (Latimer, personal communication).  
This is the most abnormal line of this first cluster.  The middle cluster contains three stage II 
derived cell lines, JLBTL-34, -7, and -10.  These lines flank JLDCIS-4, which is a DCIS line 
with an invasive component.  This patient had a palpable DCIS mass surrounding a 0.4 mm 
internal focus of microinvasion.  The third cluster shows the commercially available stage IV 
pleural effusion cell lines along with JLBTL-12, which is a stage III cell line derived from the 
primary tumor site. Clustering based on a set of 811 genes/probe sets based on invasiveness can 
be seen in Figure 27.  There are more clusters than there were in Figure 26, but the lines follow 
generally the same order as they did when clustered based upon replication.  It is interesting to 
see just how different the Latimer lab lines are from the commercially available later-stage lines.  
These lines offer the opportunity to access cells in culture from normal breast tissue and early 
stage breast cancers. 
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Figure 26:  Latimer lines and commercial lines investigated by replication-based genes.  
Supervised expression microarray with a probe set of 521 replication-based genes. The color bars are set so 
that the <5 percentile of expression are the brightest green and the >95 percentile of expression is the brightest red.  
The Affymeterix HGU133 Plus 2.0 Array is comprised of 51,000 probe sets. 
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Figure 27:  Latimer lines and commercial lines investigated by invasion-based genes. 
Supervised expression microarray with a probe set of 811 invasion-based genes. The color bars are set so 
that the <5 percentile of expression are the brightest green and the >95 percentile of expression is the brightest red.  
The Affymeterix HGU133 Plus 2.0 Array is comprised of 51,000 probe sets. 
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In this study, the NM proteome of some of the Latimer lines was studied. Alterations to 
the NM have been examined before in breast cancer cell lines, however most of these studies 
were performed on late stage tumor samples or breast cancer cell lines (Samuel, 1997; Khanuja, 
1993; Spencer, 2000; Spencer, 2001).  Therefore many of the changes that occur in the NM 
during the early stages of tumor formation may have been missed.  Investigating this early stage 
of the disease may allow for the identification of potential biomarkers and new tools for 
prevention of disease progression.   
Characterization of the novel lines compared to traditional commercial lines was first 
done using the Transwell invasion assay.  The JLDCIS-1 cell line series was used along with 
HT-1080, MCF-7, and MDA-MB231 cell lines.  HT-1080 cells are a commonly used as a control 
in the assay.  NMPs were then isolated from the JLDCIS-1 series along with JLBRL-14 and -24, 
MCF-7, and MDA-MB231 cells.  The 8-plex iTRAQ proteomics technology was then used to 
identify and quantify the NMPs in these cell lines.  Based upon how the JLDCIS-1 series 
behaved in the invasion assay and specific alterations seen in the NM of the cell lines compared 
to normal BRL lines, some understanding of the changes that occur in a cell to induce DCIS has 
been made.  These specifically altered NMPs may serve as biomarkers of the disease or potential 
new therapeutic targets to treat breast cancer in its earliest stages. 
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4.3 RESULTS 
4.3.1 Transwell Invasion Assay 
The BD BioCoat Matrigel Invasion Assay studies the cellular invasion of both malignant and 
normal cells (Albini, 2004).  The assay uses an 8-micron pore size PET membrane, which is 
covered in a thin layer of Matrigel basement membrane matrix to occlude the pores and block the 
non-invasive cells from migrating through the membrane.  Invasive cells enzymatically digest 
the Matrigel matrix and, in addition, migrate through the pores.   The assay has been used to 
develop an orthotypic model for human bladder cancer (Dinney, 1995).  It has also been used to 
investigate a series of breast cancer cell lines and demonstrated that MDA-MB231 cells were 
much more invasive than MCF-7 cells (Hughes, 2008).   
The behavior of the isogenic JLDCIS-1 cell lines in this assay was determined.  This 
includes the tumor line, JLDCIS-1A, the non-tumor adjacent line, JLNTALDCIS-1, and the 
contralateral, normal line, JLDCIS-1Contra.  As a control for this assay a highly invasive human 
fibrosarcoma line, HT-1080, was used.  The commonly used commercial breast cancer cell lines, 
MCF-7 and MDA-MB231, were also used.  Migration was measured by the cells ability to move 
through the uncoated membrane, and invasion was measured by the cells ability to move through 
the membrane coated with matrigel.  All cell counts were standardized to the average number of 
HT-1080 cells that migrated.  Figure 28A contains the graph demonstrating the migration and 
invasion ability of each cell line expressed as a ratio to HT-1080 migration.  The number of cells 
per 200x field were counted with three 200x fields taken for each filter.  A total of three filters 
were counted for each line.  Figure 28B shows the JLDCIS-1 series.  MCF-7 cells, previously 
reported to scarcely migrate or invade, did not move much in this assay.  MDA-MB231 cells did 
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migrate and were invasive, although slightly less than what has been reported in previous studies 
relative to HT-1080 (Hughes, 2008). MDA-MB231 migrates and invades similarly to JLDCIS-
1A but more than JLNTALDCIS-1 (p<0.01), derived from the breast tissue adjacent to the tumor 
(though not proven to be tumor free) and JLDCIS-1Contra (p<0.01) (which was karotypically 
normal). JLDCIS-1A demonstrates migration and invasion that are significantly greater than 
JLNTALDCIS-1 and JLDCIS-1Contra. The migration and invasion of JLDCIS1-Contra and 
JLNTALDCIS-1 are not statistically significantly different from each other. 
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Figure 28:  Migration and invasion data of DCIS1 series and HT-1080, MCF-7, MDA-MB-231 cell lines. 
Migration was measured using uncoated control filters, while invasion was measured using Matrigel-coated 
filters.  The average number of cells was determined using at least three filters with three fields of 200x counted per 
filter.  All values are normalized to the number of migratory HT-1080 cells as an experimental standard.  Error bars 
represent standard error of the mean.  * denotes statistically significant difference from JLContraDCIS-1 and 
JLNTALDCIS-1 values with p-value < 0.01 using a Student’s T-Test. 
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4.3.2 Protein Identification in the Nuclear Matrix of DCIS  
Using iTRAQ with NMPs isolated from MDA-MB231, MCF-7, two breast reduction lines 
(JLBRL-14 and JLBRL-24), and the JLDCIS-1 series (JLDCIS-1A, JLNTALDCIS-1, and 
JLDCIS-1Contra), the proteins present in the NM of these cell lines were determined.  The 
OFFGEL fractionation technique and 4800 MALDI-TOF/TOF analysis developed in Section 3 
was used for this analysis.  A total of 270 NMPs were identified with a ProtScore > 1.3 (95% 
confidence).  The entire list of these NMPs along with their unused ProtScore and percent 
coverage can be seen in Table 23 in Appendix G.  
4.3.3 Alterations to the Nuclear Matrix in DCIS 
iTRAQ allowed for quantification of the levels of each of these NMPs in the lines analyzed.  In 
the search for a biomarker to allow for the early detection of DCIS and a better understanding of 
the alterations to the NM that play a role in breast cancer development, NMPs that were present 
at similar levels in the two normal breast reduction lines and the DCIS contralateral line but 
altered in the DCIS tumor line were of interest.  Assessment of the trends shown by these 
markers against the most well known breast cancer tumor cell lines was also performed.   Table 
13 demonstrates the two proteins that fit this criteria.  The p-value determined by the ProteinPilot 
software for the ratio is given in parentheses below the fold increase.  Both eukaryotic translation 
elongation factor 1 delta (EEF1D) and HSP90 were identified by at least two peptides that were 
sequenced with 95% confidence.  Both of these proteins are present at similar levels in JLDCIS-
1Contra, JLBRL-14, and JLBRL-24.  EEF1D abundance is decreased almost six-fold in the non- 
tumor adjacent JLNTALDCIS-1 line and decreased eighteen-fold in the tumor JLDCIS-1A line 
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compared to the normal JLDCIS-1Contra line.  EEF1D abundance is also decreased about four 
and three fold in the MCF-7 and MDA-MB231 commercial lines, respectively, showing a 
consistent trend among tumor cell lines but not a specificity to early stage disease.  HSP90 is less 
abundant in the non-tumor adjacent JLNTALDCIS-1 line, 8.1 fold, than in the tumor JLDCIS-
1A line, 3.0 fold. HSP90 abundance is increased in MCF-7 and MDA-MB231 by 3.5 and 1.9 
fold, respectively. 
 
Table 13:  Fold alterations to NMP levels in several cell lines in comparison to JLDCIS-1Contra line.  
 
 
Protein Name 
(Normal) 
JLBRL-
14 
(Normal)
JLBRL-
24 
 
JLNTAL
DCIS-1 
 
JLDCIS-
1A 
 
 
MCF-7 
 
MDA-
MB231 
Eukaryotic translation 
elongation factor 1 delta, 
isoform 3 
1.4 
(0.34) 
1.3 
(0.51) 
5.7 
(0.090) 
18 
(0.016) 
4.1 
(0.026) 
2.9 
(0.056) 
Heat shock 90 kDa 
protein 1, alpha isoform 1 
1.4 
(0.29) 
1.1 
(0.48) 
8.1 
(0.12) 
3.0 
(0.01) 
3.5 
(0.02) 
1.9 
(0.04) 
 
4.4 DISCUSSION 
Through the use of the novel DCIS cell lines described in this study new knowledge about the 
earliest stages of breast cancer has been obtained.  Tissue classified as normal because it is 
located adjacent to the tumor, such as JLNTALDCIS-1, is not necessarily normal.  The 
karyotype, seen in Figure 24, demonstrates an abnormality with chromosome 17.  In the invasion 
and migration assay, the non-tumor adjacent line behaves very similar to the contralateral, 
normal line, while the tumor line is significantly more invasive and migratory than both lines.  
Thus, these non-tumor adjacent cells, while harboring changes in karyotype, did not behave as 
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aggressively as the tumor line.  Therefore the tumor line is likely further transformed or mutated 
differently, which allows it to be more invasive. The non-tumor adjacent line does harbor 
alterations to its karyotpe, and is not normal tissue, therefore it should also be removed with the 
tumor during surgery. This is true particularly in a case of widespread disease, which is 
manifested outside the rather significant DCIS mass, as was the case in this patient.  The 
presence of widespread disease is often the case in DCIS patients.  Non-tumor adjacent tissue 
harbors changes even though pathologically it may be morphologically considered to be 
“normal” and if left behind may lead to recurrence. 
This invasion and migration assay should be used on DCIS lines in the future in order to 
characterize their behavior.  Knowledge can be gained by comparing recurrence in these women 
with DCIS and how invasive and migratory the cell line generated from their DCIS is when 
using this assay.  Recurrence rates are rather low since DCIS is treated by removal of a large 
portion of the breast plus radiation and tamoxifen treatment.  The fact that treatment works 
underscores the need for cell lines derived from DCIS to be utilized in functional assays such as 
invasion.  Additionally, the migration and invasion assay allows for isolation of the cells that are 
more invasive than the others.  Iteratively investigating these cells for unique alterations 
compared to the others in the DCIS may help to identify a biomarker that could be of great use in 
determining how aggressively to treat a woman who presents with DCIS.  Currently, women 
who are diagnosed with DCIS undergo surgery, radiation and often tamoxifen treatment.  For 
women who have DCIS that will never become invasive (i.e. indolent), removing the DCIS 
lesion would be proper treatment compared to those women who have DCIS that may become 
invasive who should have the more aggressive treatment (radiation and hormone treatment). 
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In the search for biomarkers to diagnose DCIS and understand the origins of the disease, 
the NM was investigated.  Two proteins with altered abundance in DCIS compared to 
contralateral normal breast and two normal breast reduction lines from other women 
demonstrated promise.  The first of these proteins is EEF1D.  EEF1D is a subunit of elongation 
factor-1 complex that is responsible for delivering aminoacyl tRNAs to the ribosome and plays a 
role in the elongation step of protein synthesis (Proud, 1994).  Until now, EEF1D overexpression 
has been studied exclusively in the context of advanced tumor stage in various organs.  EEF1D 
overexpression is associated with advanced tumor stage in gastrointestinal carcinomas (Joseph, 
2004).  Additionally, mRNA expression of EEF1D is higher in esophageal carcinomas compared 
to normal tissue, and the higher the expression, the more advanced the disease is (Ogawa, 2004).  
Additionally, in medulloblastoma, the most common malignant brain tumor of childhood, 
EEF1D gain of expression is associated with adverse outcome (De Bortoli, 2006).  In a 
proteomics investigation of adriamycin-resistant squamous cell lung cancer, EEF1D is correlated 
with invasion (Keenan, 2009).  Other groups have demonstrated this protein to have 
transcriptional repressor activities (Sekido, 1997).  In breast cancer, EEF1D has been mainly 
studied for its role in invasive and metastatic breast cancer.  One study examined the EpFosER 
mouse mammary epithelial cells as an inducible tumor model system.  These cells constitutively 
express a fusion protein of c-Fos and the LBD of the ER. Upon stimulation with E2, the cells 
undergo epithelial-mesenchymal transition (Eger, 2000).  When the cells are treated with E2 and 
undergo this transition, an increase in the expression of EEF1D is seen.  This increased 
expression of EEF1D coincides with transcriptional repression of E-cadherin, and EEF1D was 
directly represses transcription of E-cadherin (Eger, 2005). E-cadherin is a major component of 
the epithelial to mesenchymal transition, and down-regulation of this protein plays a role in the 
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progression of breast cancer (Berx, 2001).  Therefore, EEF1D is a key player in late stage 
carcinogenesis (Eger, 2005). EEF1D mRNA levels were also investigated in several 
commercially available breast cancer cell lines, and higher levels of EEF1D mRNA are seen in 
MDA-MB231 cells compared to MCF-7 cells.  The levels of EEF1D mRNA in MDA-MB231 
are slightly increased compared to normal HMEC-184B5 cells established from normal 
mammary gland (Eger, 2005).   Most consistent with the present findings, bone morphogenetic 
protein-6 (BMP-6) down-regulates EEF1D, which leads to an up-regulation of E-cadherin in 
MDA-MB-231 cells transfected with E-cadherin and EEF1D (Yang, 2007).  EEF1D acts as a 
transcriptional activator of the ovalbumin gene when estrogen is added to chick oviduct tubular 
gland cells (Dillner, 2002; Dillner, 2004). 
EEF1D is downregulated six-fold in the non-tumor adjacent DCIS and eighteen-fold in 
the DCIS tumor compared to the contralateral DCIS line.  Since both of these cell lines are 
abnormal karyotypically and the DCIS in this woman was widespread and heterogeneous, this 
result is not surprising.  EEF1D is also down-regulated in MCF-7 and MDA-MB231 compared 
to the contralateral DCIS line, though not as much as it was in DCIS.  This is contrary to the 
study that showed higher levels of EEF1D mRNA in MDA-MB231 cells compared to normal 
breast cells (Eger, 2005).  A possible explanation is that this study examined global mRNA 
expression, while the current study is examining protein abundance in the NM.  More EEF1D 
was found in the NM of MDA-MB231 cells than MCF-7 cells, which corroborates what was 
found at the global mRNA level (Eger, 2005).  Support for the specific modulation of EEF1D in 
DCIS is also demonstrated by expression microarray analysis that has been done by the Latimer 
lab.  BMP-6 is modulated in JLDCIS-1A where it is turned on and expression increases 2-fold 
compared to normal control lines.  BMP-6 is known to repress EEF1D (Yang, 2007), so it is 
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interesting to see levels of BMP-6 increased in the microarray.  BMP-6 may likely be playing a 
role in DCIS and modulating the expression of EEF1D.  The expression of BMP-6 and related 
pathways should be investigated in the DCIS cell lines in future studies. 
EEF1D has previously not been shown to associate with the NM.  This study shows 
EEF1D is associated with the NM and this interaction is altered when DCIS develops.  A more 
dramatic alteration in EEF1D expression is seen in the early DCIS lines compared to the late 
stage commercial lines.  Perhaps this down-regulation of EEF1D is something that occurs very 
early in the development of breast cancer, making it both a promising target to prevent the 
progression of breast cancer and a potential biomarker of early stage disease. 
The second protein demonstrated to be present at different levels in DCIS is HSP90.  
HSP90 is an important molecular chaperone in cells (Welch, 1982).  It functions as part of a 
multi-chaperone complex and associates with cochaperones and client proteins.  In breast cancer, 
HSP90 chaperones several proteins known to play a role in the disease, such as hormone 
receptors, protein kinases, and proteins regulating the cell cycle and apoptosis.  HSP90 levels are 
increased in late stage breast cancer cell lines and patient samples and high expression is 
associated with decreased survival when examining patient specimens (Yano, 1999; Pick, 2007).  
HSP90 is also known to be a part of the chaperone complex that binds the unstimulated ER in a 
cell, and when MCF-7 cells were treated with HSP-90 drugs, the ERs are destabilized and their 
levels decreased (Bagatell, 2001).  Like with most biomarker discovery work, all of these studies 
have focused on HSP90 in the traditionally used late stage commercial breast cancer lines or late 
stage patient samples. 
In this work, HSP-90 is increased almost four-fold in MCF-7 cells and almost two-fold in 
MDA-MB231 cells.  These findings are consistent with what has been shown about HSP-90 
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expression in late stage breast cancer.  HSP-90 levels are, however, eight-fold less in the DCIS 
non-tumor adjacent line and decreased by about three-fold in the DCIS tumor line compared to 
the contralateral DCIS cell line.  Again, this is not unexpected, as both of these cell lines are 
abnormal karyotypically and the DCIS was widespread.  This may indicate that decreased 
expression of HSP90 is associated more with early stage DCIS.  More work is required to 
ascertain whether this early stage specificity is real.  It is likely HSP90 has a different role in the 
development of breast cancer than it does in later stages of the disease. HSP90 levels in lobular 
hyperplasia and lobular carcinoma in situ are decreased (Zagouri, 2008).  This is similar to the 
results reported in this study. 
This is the first report of the association of HSP90 with the NM.  Other HSPs are known 
to associate with the NM.  A recent study on the NM in rat liver carcinogenesis identified HSP70 
and HSP60 in the NM (Barboro, 2009).  The specificity of HSP90 to associate with the NM in 
breast cancer demonstrates that this protein may be a useful biomarker or drug target.  It is 
possible that HSP90 may play a role in the progression of in situ diseases to invasive disease, as 
a dramatic change in the levels of this protein in the NM of DCIS samples compared to late stage 
breast cancer cell lines occurs.  Further investigation into HSP90 levels in the NM of other cases 
of DCIS should be performed. 
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4.5 MATERIALS AND METHODS 
4.5.1 Cell Culture 
JLBRL-14, JLBRL-24, JLDCIS-1Contra, JLDCIS-1A, and JLNTALDCIS-1 were established by 
and obtained from the laboratory of Dr. Jean Latimer.  These lines were maintained on Matrigel-
coated flasks in MWRIα media (Latimer, 2002).  MCF-7, MDA-MB231, and HT-1080 were 
maintained on plastic flasks with DMEM with 10% FBS. 
4.5.2 Transwell Invasion Assay 
The BD BioCoat Matrigel Invasion Assay  (24-well format) was used according to the 
manufacturer’s protocol. JLDCIS-1Contra, JLDCIS-1A, and JLNTALDCIS-1 were cultured in 
MWRIα on Matrigel-coated flasks. To set up the assay, cells were pelleted and plated with 
25,000 cells per chamber in MWRI in 2.5% FBS and 2.5% CFBS (colostrum free bovine serum).  
The chambers were placed into wells that contained MWRI with 20% FBS. The Matrigel coated 
invasion filters were used to measure invasion, along with the control, uncoated membranes to 
measure migration.  Cells were plated and incubated for 22 h.  A cotton tipped swab was used to 
remove non-invading cells from the upper surface of the membrane.  The filters were then 
stained using the Fisher Hema 3 manual staining system according to the protocol.  The filters 
were mounted on slides and three images captured at 200x magnification for counting. 
  115 
4.5.3 Nuclear Matrix Isolation 
The NM was isolated according to the method of Fey and Penman (Fey, 1988).  Briefly, 
10,000,000 to 50,000,000 cells were incubated in 0.5% Triton X-100 in a buffered solution with 
2 mM vanadyl ribonucleoside, an RNase inhibitor, for 10 min on ice to release lipids and soluble 
proteins.  The remaining sample was then pelleted at 1800 rpm at 4°C for 10 min and incubated 
in  ammonium sulfate (0.25 M) with 2 mM vanadyl ribonucleoside for 10 min on ice.  This step 
was performed as a salt extraction to release soluble cytoskeletal elements.  The remaining 
sample was then pelleted at 1800 rpm at 4°C for 10 min.  Dnase I treatment was added to remove 
soluble chromatin for 30 min at room temperature and then the sample was pelleted at 2200 rpm 
at 4°C for 10 min. RNase A was then added to remove RNA with a 10 min incubation at room 
temperature and then the sample was pelleted at 2200 rpm at 4°C for 10 min.   The intermediate 
filaments and NMPs were then disassembled with 8 M urea and the insoluble carbohydrates and 
extracellular matrix components were pelleted with ultracentrifugation at 50,000 rpm for 1 h at 
15°C.  Dialysis was performed overnight in an assembly buffer containing KCl and Imidazole-
HCl to remove the urea and reassemble the intermediate filaments.  Ultracentrifugation at 45,000 
rpm for 90 min at 20°C was then done to pellet out the intermediate filaments.  The NMPs were 
precipitated with ethanol then quantified using the Coomassie (Bradford) Protein Assay (Thermo 
Scientific, Waltham, MA).  All solutions contained 1 mM phenylmethylsulfonyl fluoride to 
inhibit serine proteases. 
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4.5.4 iTRAQ Labeling 
The manufacturer’s protocol for iTRAQ was followed.  Briefly, 50 μg of precipitated NMPs 
from the 8 different cell lines were each resuspended in 20 μL of Dissolution Buffer (0.5 M 
triethylammonium bicarbonate) with 1 μL of Denaturant (0.1% SDS).  2 μL of the Reducing 
Reagent, 5 mM TCEP, was then added to each sample and incubated at 60°C for 1 h.  They were 
then alkylated with 1 μL of the Cysteine Blocking Reagent, 10 mM MMTS, at room temperature 
for 10 min.  10 μg trypsin was then added to each sample and they were digested at 37°C 
overnight.  The eight iTRAQ reagents were then added to the appropriate sample and incubated 
at room temperature for 2 h.  After labeling, the 5 samples were then pooled. The samples were 
labeled as follows: 113 - MCF-7; 114 – MDA-MB231; 116 – JLBRL-14; 117 – JLBRL-24; 118 
– JLDCIS-1Contra; 119 – JLDCIS-1A; 121 – JLNTALDCIS-1. 
4.5.5 OFFGEL Fractionation 
The pooled iTRAQ sample was desalted using a SepPak and then speed vacuumed dry for 
OFFGEL fractionation.  OFFGEL fractionation was performed according to the manufacturer’s 
guidelines with minor modifications as described.  The 3100 OFFGEL Fractionater and the 
OFFGEL Kit pH 3-10 (Agilent Technologies, Santa Clara, CA) was used following a 24-well set 
up.  An Immobiline DryStrip pH 3-10, 24 cm (GE Healthcare Bio-Sciences, Piscataway, NJ) was 
used instead of the strip provided in the kit.  Fifteen minutes before sample loading, the gel strip 
was rehydrated in the assembled device with 40 µL OFFGEL Rehydration solution per well.  
The iTRAQ peptides were resuspended in the Peptide OFFGEL solution to a final volume of 3.6 
mL.  150 µL of the diluted sample was distributed into the 24 wells.  The default OFFGEL 
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peptide 24 cm strip program on the instrument was used with a max current of 50 µA until 50 
kVh was reached.  The fractions were then recovered from each well.  150 µL of 50% MeOH, 
0.1% TFA was then added back to each well and left on the benchtop for 20 min.  This solution 
was then recovered and added back to the appropriate fraction and the entire sample was speed 
vacuumed dry and resuspended in 0.1% TFA for nanoLC. 
4.5.6 Nano-LC-MALDI-TOF/TOF with the ABI 4800 Proteomics Analyzer 
The OFFGEL- fractionated samples were further fractionated on an RP-LC Ultimate system 
(Dionex, Sunnyvale, CA).  They were first loaded onto a trap column (300 μm i.d. x 5 mm, 
PepMap C18 100 material 5 μm, 100 Å) and washed for 10 min with 2% ACN, 0.1% TFA at a 
flow of 30 μL/min.  They were then loaded onto an analytical column (75 μm i.d. x 150 mm, Pep 
Map C18 100 material 3 μm, 100 Å) and fractionated using a gradient of 5-30% B in 110 
minutes, 30-60% B in 60 minutes, and 60-100% B in 10 minutes with a flow rate of 250 nL/min.  
Solution A was 5% ACN, 0.1% TFA, and solution B was 85% ACN, 5% IPA, and 0.1% TFA.  5 
minutes after the sample injection, the Probot was signaled to start spotting. The Probot™Micro 
Fraction Collector was used to collect 15 second spots on the ABI 4800 LC-MALDI metal target 
in a  16 x 48 array.  5 minutes after the sample injection, the Probot™ was signaled to begin 
spotting. 768 spots were collected for each OFFGEL fraction, and 2 LC runs were done on each 
target.  This resulted in a total of 12 plates.  The μTee mixer was used to co-spot matrix (7 mg 
CHCA in 1 mL of 50% ACN, 0.1% TFA, with mM ammonium citrate and 10 fmol Angiotensin 
II), delivered at a flow rate of 1.577 μL/min. For 4800 analysis, MS spectra were acquired from 
900 to 4000 Da with a focus mass of 2000 Da.  MS processing was done using the Angiotensin II 
  118 
internal standard with a 250 ppm max outlier error.  Up to 10 peaks were selected for MS/MS.   
Peptide CID (air) was performed at 2 kV.  
4.5.7 Protein Identification and Quantification 
The Paragon algorithm in ProteinPilot™ Software 2.0 was used for protein identification.  
Proteins were identified by searching against the IPI database v 3.46.  Searched results were 
processed by the Pro Group algorithm.  Search parameters included iTRAQ labeling of the N-
terminus and lysine residues, cysteine modification by MMTS, and digestion by trypsin.  Isoform 
specific identification and quantification was done by excluding all shared peptides and 
including only unique peptides. The p-value calculated by the software was used to determine if 
the change in protein expression was real or not.  This p-value tests the null hypothesis that the 
actual protein ratio is 1 and the observed protein ratio is different than 1 only by chance.  
Proteins identified with >95% confidence or ProtScore > 1.3 were used for further analysis. 
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5.0  OVERALL DISCUSSION 
5.1 SUMMARY OF FINDINGS AND SIGNIFICANCE 
This study was undertaken in order to obtain a better understanding of how the NM is altered in 
breast cancer.  The NM was studied at several different stages of the disease.  Using the MCF-7 
commercial, late stage breast cancer cell line and an antiestrogen resistant version of this cell line  
(MCF-7/LY2), an exploration into how the NM is specifically altered in antiestrogen resistance 
was made.  Additionally, using the novel tissue engineering system created by the Latimer lab, it 
was possible to investigate the earliest, pre-invasive stage of breast cancer, DCIS. 
The first aim in this study was to search for an ERβ-selective ligand.  Previous work had 
focused on the development of new ER ligands and identified the C-cyclopropylalkylamide 
structure as a pharmacophore for the ER.  Efforts were then undertaken to optimize this 
pharmacophore for subtype selectivity.  There is much interest to create a ligand selective for 
ERβ, based upon its protective role in breast cancer and role in other diseases such as prostate 
cancer, medullary thyroid carcinoma, ovarian cancer, and inflammatory diseases (Ström, 2004; 
Paruthyiyil, 2004; Hartman, 2006; Cho, 2007; Ji, 2005; Pravettoni, 2007; Chan, 2008; Harris, 
2003).  This ERβ-selective ligand could also be used in the investigation of ER subtype specific 
interactions with the NM.  Two compounds that demonstrated selectivity for ERβ and promising 
anti-proliferative effects in breast cancer cell lines were identified.  Compared to other ERβ 
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selective compounds in the literature, these compounds demonstrated no affinity for ERα and 
modest affinity for ERβ.   While the compounds were not more selective than the commercially 
available ERβ-selective ligand, DPN, they do provide some insight into further modifying the 
biphenyl C-cyclopropylalkylamide core to improve selectivity.  Therefore DPN was used in the 
next aim to selectively target ERβ.  The biphenyl C-cyclopropylalkylamide scaffold does have 
the capability to deliver ER-selective antiestrogens.  Development of subtype-selective ER 
ligands will help to further understand the complex biology of the two isoforms and their 
different roles.  Additionally, in the clinical setting, ER-subtype selective ligands may allow for 
the customization of antiestrogen treatments and eliminate some of the current negative side 
effects associated with the therapy. 
The NM in breast cancer was next examined.  The first objective was to investigate 
alterations to the NM in an antiestrogen-resistant derivative of the commonly studied MCF-7 
breast cancer cell line, MCF-7/LY2.  In addition, subtype selective ER ligands were used to 
examine how selective agonism or antagonism of the different isoforms alters the composition of 
the NM.  The NM in breast cancer has been studied before, but the majority of studies were done 
using two-dimensional electrophoresis and noted protein spots that were changed from one 
sample to the next, but did not identify these proteins (Khanuja, 1993; Samuel, 1997). One 
hundred forty eight NMPs were identified in this analysis, giving the most complete 
understanding of the proteins found in the NM in breast cancer.  Quantification was obtained on 
many of these NMPs, and some very interesting changes were demonstrated to occur.  The most 
promising proteins are those that showed dramatic alterations.  There were four such proteins.  
Dynein heavy chain 5, hnRNP R, and Serpin H1 were not present at detectable levels in the 
resistant cell line, while NuMA 1 was present in the resistant line but not detected in the 
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responsive line.  All of these proteins should be investigated in patient samples in order to 
determine their potential as biomarkers to be used during tamoxifen treatment.  If these proteins 
play a role in the development of resistance to tamoxifen, monitoring them when a woman is 
receiving tamoxifen will help to customize the treatment and knowing when to change.  As 
tamoxifen is currently the most used therapy for breast cancer, an assay such as this may have a 
significant impact in the management of breast cancer.  Additionally, seeing how NMPs have 
been developed for the use in other cancer-related assays and that they can be detected in the 
blood and urine, these altered NMPs in antiestrogen resistant may be developed as biomarkers 
for antiestrogen resistance (Miller, 1992; Replogle-Schwab, 1998).  Specific alterations were 
also seen to the levels of NMPs present when the cells were treated with ER-selective ligands.  
Therefore the two isoforms seem to influence the composition of the NM in different ways.  
These alterations will help to understand the complex biology of the ERs, and perhaps help guide 
therapy.   
In this second aim a workflow was optimized for the identification and quantification of 
proteins in up to eight samples simultaneously.  This workflow involved using the iTRAQ 
methodology to label samples, fractionation using the OFFGEL technique, and mass 
spectrometry using the ABI 4800 Proteomics Analyzer for nano-LC-MALDI-TOF-TOF-MS and 
–MS/MS analyses.  This optimized workflow will be useful for future proteomic studies aimed at 
identifying and quantifying proteins from complex biological samples.  This workflow was used 
in the subsequent third aim. 
The third aim shifted to the investigation of the earliest, pre-invasive stage of breast 
cancer, DCIS, using the novel Latimer tissue engineering system.  Here, the workflow developed 
in aim 2 was used to identify 270 NMPs present in DCIS and breast reduction cell lines.  Two 
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proteins, HSP90 and EEF1D, were present at similar levels in the two normal breast reduction 
lines and the contralateral, normal line examined.  EEF1D was, however, strongly down-
regulated in the DCIS samples and somewhat downregulated in the late stage commercial breast 
cancer cell lines that were included for comparison.  HSP90 is strongly decreased in the DCIS 
lines, including the non-tumor adjacent tissue, but it is increased in the late stage commercial 
lines.  Both of these proteins may serve as the basis for future assays to improve the diagnosis of 
DCIS and diagnose breast cancer in its earliest stage.  Additionally, these proteins demonstrate 
some of the earliest changes that occur in the development of breast cancer and may allow for 
the design of new targeted therapies that improve treatment. 
5.2 FUTURE DIRECTIONS 
The compounds developed in aim 1 demonstrate the potential of the biphenyl C-
cyclopropylalkylamide pharmacophore for the development of ERβ-selective ligands.  While a 
compound was developed that was somewhat selective for ERβ and demonstrated promising 
effects in the inhibition of the proliferation of breast cancer cell lines, there is still room for 
improvement.  The compounds were only investigated for their ability to compete with E2 for 
binding to the LBD of the ERs.  They may also interact with the co-regulator binding domain of 
the ERs and should be examined for such activity.  Understanding exactly how the compounds 
interact with the ERs will allow for optimization of their structure.  As far as the development of 
a new compound for the treatment of breast cancer, the ideal ligand would act as an agonist when 
bound to ERβ and an antagonist when bound to ERα.  Future efforts should work to make a 
compound that possesses both of these properties. 
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 In aim 2, the NMPs that were demonstrated to be specifically altered in the antiestrogen 
resistant cell line should be investigated further.  To confirm their role within the MCF-7 and 
MCF-7/LY2 cell lines, the levels of the proteins should be controlled.  Overexpression of dynein 
heavy chain 5, hnRNP R, and Serpin H1 in the antiestrogen resistant cell line should, if the 
protein is playing a role in the development of resistance, restore their response to tamoxifen 
somewhat.  Knockdown of these three proteins in the responsive MCF-7 line should in turn 
abolish the response of these cell lines to tamoxifen.  Knockdown of NuMA in the MCF-7/LY2 
cell line should sensitize these cells to tamoxifen, while overexpression of NuMA in the MCF-7 
cell line should inhibit their response to tamoxifen.  The alterations demonstrated in these cell 
lines should be confirmed using the iTRAQ methodology with other breast cancer cell lines that 
have progressed to antiestrogen resistance.   Additionally, the levels of the proteins should be 
investigated in human tumor samples to confirm what was observed in the cell line models also 
occurs in vivo.  The ability to detect the NMPs in the blood should also be determined in order to 
decide whether or not they could be applicable in the development of a clinical assay. 
Knowledge of the alterations that occur to the NM in DCIS, the earliest identifiable 
lesion in breast cancer, was also gained through these studies.  Most of the work was done using 
only one DCIS case, however.  More DCIS lines need to be investigated using the iTRAQ 
method in order to validate the changes seen in the JL-DCIS-1 series.  If these changes are 
validated in many DCIS cell lines, then focus should be turned to the detection of these proteins 
in vivo and their potential as biomarkers.  Additionally, one of the major issues in DCIS is that 
there is no true understanding of whether or not the disease will become invasive (Kuerer, 2009).  
Therefore treatment of many women may be over-aggressive, as most women diagnosed with 
DCIS undergo surgery and often treatment with chemotherapy and tamoxifen.  The transwell 
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invasion assay was optimized for use with the Latimer lines; therefore the invasive potential of 
other DCIS lines can be determined.  In addition to determining their invasive potential, specific 
alterations to the NM and how these correspond to the line’s invasive potential may allow for the 
development of a biomarker that could be used to customize treatment for a woman who is 
diagnosed with DCIS and thereby given the opportunity to avoid unnecessary treatment. 
Finally, while the MCF-7 cell line has provided much information on breast cancer, 
including its use in investigating antiestrogen resistance as done in aim 2, the cell line does have 
its caveats.  It is prone to genotypic and phenotypic variation, and the MCF-7 line used by one 
lab is not the same as the MCF-7 line used by most other labs, making it very hard to compare 
results using this line (Burdall, 2002).  Additionally, the line came from a woman with very late 
stage disease and was made from her pleural effusion, not her actual breast tumor (Soule, 1973).  
Because of these reasons, the need for a system like that generated in the Latimer lab in breast 
cancer research is evident.  The system allows for both the culture of normal breast reduction 
lines and the earlier stages of the disease in an environment that more resembles what is seen in 
vivo.  These cell lines are more likely to represent what is truly occurring in the patient; 
therefore, their use in drug discovery and biomarker development should translate into patients 
more readily than what is generated using the later-stage cell lines.  The future direction of breast 
cancer research is to understand the disease in its earliest stage and eventually work towards 
prevention. 
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APPENDIX A 
NMPS IDENTIFIED IN MCF-7 BREAST CANCER CELLS 
Table 14:  NMPs identified in MCF-7 breast cancer cells. 
 
 
Protein Name 
Accession 
Number 
(IPI) 
 
 
Gene Symbol 
Beta actin variant (fragment) 00894498.1 ACTB 
Actin, cytoplasmic 2 00021440.1 ACTG1 
Highly similar to AF4/FRM2 family member 1, CDNA 
FLJ61397 
00396310.5 AFF1 
Putative uncharacterized protein ALB 00022434.4 ALB 
ATP synthase subunit alpha 00440493.2 ATP5A1 
ATP synthase subunit D, isoform 2 00456049.3 ATP5H 
Uncharacterized protein DKFXP564G0422 00553153.1 ATPIF1 
Uncharacterized protein C6ORF174 00647205.1 C6ORF174 
Chromobox protein homolog 3 00297579.4 CBX3 
24 kDa protein 00641672.1 CD320 
Cofilin-1 00012011.6 CFL1 
Cingulin-like protein 1, isoform 1 00307829.7 CGNL1 
Charged multivesicular body protein 4b 00025974.3 CHMP4B 
CDNA FLJ37462, Clone BRAWH2011343, highly similar 
to Cold-inducible RNA-binding protein 
00641579.1 CIRBP 
Clathrin light chain A, isoform 3 00790571.2 CLTA 
Dynein heavy chain 5, axonemal 00152653.3 DNAH5 
Desmoplakin, isoform DPI 00013933.2 DSP 
Elongation factor 1-alpha 1 00396485.3 EEF1A1 
Putative elongation factor 1-alpha-like 3 00472724.1 EEF1A1 
Epiplakin 00010951.2 EPPK1 
Enhancer of rudimentary homolog 00029631.1 ERH 
Electron transfer flavoprotein subunit beta, isoform 2 00556451.2 ETFB 
Ewing sarcoma breakpoint region 1 00879259.1 EWSR1 
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Protocadherin Fat 3, Isoform 1 00847978.2 FAT3 
CDNA FLJ46111 fis, clone TEST2034913, moderately 
similar to Keratin, type II cytoskeletal 8 
00396004.3 FLJ4611 
53 kDa protein 00645208.3 FUS 
Fus-like protein 00260715.5 FUS 
CDNA FLJ58049, highly similar to RNA-binding protein 
FUS 
00873762.1 FUS 
Interferon-induced guanylate-binding protein 2 00848358.1 GBP2 
48 kDa protein 00879060.1 GCAT 
Histone H2AV 00018278.3 H2AFV 
Probable E3 ubiquitin-protein ligase HECTD3, isoform 1 00456642.3 HECTD3 
Histidine triad nucleotide-binding protein 1 00239077.5 HINT1 
Histone H1.5 00217468.3 HIST1H1B 
Histone H1.3 00217466.3 HIST1H1D 
Histone H2A type 1-A 00045109.3 HIST1H2AA 
Histone H3.1 00902514.1 HIST1H2AD 
Histone H2A, type 1-J 00552873.2 HIST1H2AG 
Histone H2B, type 1-N 00794461.1 HIST1H2BN 
Histone H2B 00646240.3 HIST2H2BA 
Putative Histone H2B type 2-C 00454695.4 HIST2H2BC 
Similar to high mobility group 1 protein 00886784.1 HMG_HMG1/H
MG2 
19 kDa protein 00872915.1 HMG_HMGB1 
High-mobility group protein B1 00645948.4 HMGB1 
hnRNP A1, isoform A1-A 00215965.4 HNRNPA1 
hnRNP A1, isoform A1-A 00465365.4 HNRNPA1 
hnRNP A2/B1, Isoform B1 00396378.3 HNRNPA2B1 
hnRNPA3, isoform 1 00419373.1 HNRNPA3 
hnRNPA3, isoform 2 00216492.1 HNRNPA3 
Putative uncharacterized protein HNRNPAB 00742926.1 HNRNPAB 
CDNA FLJ53542, highly similar to hnRNP C 00909232.1 HNRNPC 
P37 AUF1 00903278.1 HNRNPD 
hnRNP D0, isoform 3 00220684.1 HNRNPD 
hnRNP F 00003881.5 HNRNPF 
51 kDa protein 00479191.2 HNRNPH1 
hnRNP H2 00026230.1 HNRNPH2 
hnRNP H3, isoform 1 00013877.2 HNRNPH3 
hnRNP H3, isoform 2 00216482.1 HNRNPH3 
CDNA FLJ54552, highly similar to hnRNP K 00910458.1 HNRNPK 
hnRNPL, isoform a 00027834.3 HNRNPL 
hnRNP M, isoform 1 00171903.2 HNRNPM 
hnRNP M, isoform 2 00383296.5 HNRNPM 
hnRNP R, isoform 1 00644055.3 HNRNPR 
hnRNP U, long isoform 00883857.1 HNRNPU 
CDNA FLJ54392, highly similar to heat shock 70 kDa 
protein 
00845339.1 HSPA1B 
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Heat shock cognate 71 kDa protein, isoform 1 00003865.1 HSPA8 
Stress-70 protein 00007765.5 HSPA9 
Heat Shock Protein, Beta-1 00025512.2 HSPB1 
Heat Shock Protein, 60 kDa 00784154.1 HSPD1 
Interleukin enhancer-binding factor 3, isoform 4 00418313.3 ILF3 
Keratin, type II cytoskeletal 1 00220327.3 KRT1 
Keratin, type I cytoskeletal 15 00290077.1 KRT15 
Keratin, type I cytoskeletal 16 00217963.3 KRT16 
Keratin, Type II Cytoskeletal 18 00554788.5 KRT18 
Keratin, Type II Cytoskeletal 19 00479145.2 KRT19 
21 kDa protein 00794644.1 KRT19 
Keratin, type I cytoskeletal 24 00004550.5 KRT24 
Keratin, type II cytoskeletal 5 00009867.3 KRT5 
Keratin 7 00847342.1 KRT7 
Keratin 77 00376379.3 KRT77 
Keratin, Type II Cytoskeletal 8 00554648.3 KRT8 
Lamin-A/C, Isoform C 00216952.1 LMNA 
Lamin-A/C, Isoform ADelta10 00216953.1 LMNA 
Progerin 00644087.1 LMNA 
Lamin-B1 00217975.4 LMNB1 
Lamin-B2 00009771.6 LMNB2 
Putative uncharacterized protein MATR3 00789551.1 MATR3 
Myosin regulatory light chain MRCL3 variant 00604523.1 MRCL3 
39S ribosomal protein L40 00099871.1 MRPL40 
Myosin-10, isoform 3 00790503.3 MYH10 
Myosin regulatory light chain 00719669.4 MYL12B 
Non-muscle isoform of myosin light polypeptide 6 00335168.9 MYL6 
CDNA FLJ56329, highly similar to myosin light 
polypeptide 6 
00796366.2 MYL6B 
Nucleosome assembly protein 1-like 1 00902909.1 NAP1L1 
Nucleolin, isoform 1 00604620.3 NCL 
32 kDa protein 00827674.1 NCL 
Nucleoside diphosphate kinase B, isoform 3 00795292.1 NME2 
Non-POU domain-containing octamer-binding protein 00304596.3 NONO 
Nucleophosmin, isoform 1 00549248.4 NPM1 
Nuclear ubiquitous casein and cyclin-dependent kinase 
substrate, isoform 1 
00872944.1 NUCKS1 
NUMA1 variant protein 00872028.2 NUMA1 
Polyadenylate-binding protein1, isoform 1 00008524.1 PABPC1 
Protein disulfide-isomerase A6, isoform 2 00299571.5 PDIA6 
Protein pigeon homolog, isoform 1 00893006.1 PION 
Peptidyl-prolyl cis-trans isomerase A 00419585.9 PPIA 
Peroxiredoxin 3, isoform b 00374151.1 PRDX3 
26S protease regulatory subunit 7 00021435.3 PSMC2 
Paraspeckle component 1, isoform 1 00103525.1 PSPC1 
RNA-binding protein 14, isoform 1 00013174.2 RBM14 
  128 
RNA-binding protein 3, putative 00024320.1 RBM3 
RNA-binding protein 8A, isoform 2 00216659.1 RBM8A 
hnRNP G 00304692.1 RBMX 
60S ribosomal protein L12, isoform 1 00024933.3 RPL12 
60S ribosomal protein L12, isoform 2 00816063.1 RPL12 
60S acidic ribosomal protein P1 00008527.3 RPLP1 
60S acidic ribosomal protein P2 00008529.1 RPLP2 
40S ribosomal protein S12 00847579.3 RPS12 
40S ribosomal protein S14 00026271.5 RPS14 
40S ribosomal protein S19 00215780.5 RPS19 
40S ribosomal protein s20 00012493.1 RPS20 
40S ribosomal protein S23 00218606.7 RPS23 
40S ribosomal protein S25 00012750.3 RPS25 
Putative uncharacterized protein RPS7 00893703.1 RPS7 
Sin3A-associated protein 00011698.4 SAP18 
Serpin H1 00032140.4 SERPINH1 
Splicing factor, proline- and glutamine- rich 00010740.1 SFPQ 
Splicing factor, arginine/serine-rich 3 00010204.1 SFRS3 
SWI/SNF complex subunit SMARCC2, isoform 1 00216047.3 SMARCC2 
Small nuclear ribonucleoprotein Sm D3 00017964.1 SNRNPD3 
Spectrin alpha chain, isoform 1 00844215.1 SPTAN1 
hnRNPQ, isoform 2 00402182.2 SYNCRIP 
hnRNP Q, isoform 1 00018140.3 SYNCRIP 
Transcription factor A 00020928.1 TFAM 
THO complex subunit 4 00328840.9 THOC4 
Transcription intermediary factor 1-b, isoform 1 00438229.2 TRIM28 
Tau-tubulin kinase 00217437.6 TTBK2 
TUBA1B protein 00793930.1 TUBA1B 
Tubulin, Beta Chain           00011654.2 TUBB 
Tubulin beta-2C chain 00007752.1 TUBB2C 
HCG2042771 00152453.1 TUBB3 
Tubulin alpha-1C chain 00218343.4 TUBA1C 
Tu translation elongation factor 00027107.5 TUFM 
Cytochrome B-C1 complex subunit 6 00296022.1 UQCRH 
Vimentin 00418471.6 VIM 
WD repeat-containing protein 21B 00295511.8 WDR21B 
YBX1 Protein 00643351.1 YBX1 
Zinc finger protein 595 00478170.1 ZNF595 
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APPENDIX B 
NMPS ALTERED IN MCF-7/LY2 CELLS  
Table 15: The ratio for NMP abundance in MCF-7/LY2 cells compared to MCF-7 cells. 
 
 
Protein Name 
Accession 
Number 
(IPI) Gene Symbol 
MCF-7/ 
LY2: 
MCF-7 Std Dev 
Beta actin variant (fragment) 00894498.1 ACTB 0.7804  
Actin, cytoplasmic 2 00021440.1 ACTG1 0.8005  
Putative uncharacterized protein ALB 00022434.4 ALB 0.6308  
ATP synthase subunit alpha 00440493.2 ATP5A1 2.537  
ATP synthase subunit D, isoform 2 00456049.3 ATP5H 0.7142  
Dynein heavy chain 5, axonemal 00152653.3 DNAH5 0  
Desmoplakin, isoform DPI 00013933.2 DSP 0.3705 0.2411 
Putative elongation factor 1-alpha-like 3 00472724.1 EEF1A1 0.7306  
Enhancer of rudimentary homolog 00029631.1 ERH 0.5597  
Fus-like protein 00260715.5 FUS 1.728  
Interferon-induced guanylate-binding 
protein 2 00848358.1 GBP2 0.6226  
Histone H2AV 00018278.3 H2AFV 1.588  
Histone H3.1 00902514.1 HIST1H2AD 3.439 2.114 
Histone H2A, type 1-J 00552873.2 HIST1H2AG 1.595  
Histone H2B, type 1-N 00794461.1 HIST1H2BN 1.541 0.1151 
Histone H2B 00646240.3 HIST2H2BA 2.301  
Similar to high mobility group 1 protein 
00886784.1 
HMG_HMG1/
HMG2 1.441  
High-mobility group protein B1 00645948.4 HMGB1 1.270  
hnRNP A2/B1, Isoform B1 00396378.3 HNRNPA2B1 0.7712  
P37 AUF1 00903278.1 HNRNPD 2.178  
hnRNP D0, isoform 3 00220684.1 HNRNPD 1.513  
hnRNP F 00003881.5 HNRNPF 0.5719  
51 kDa protein 00479191.2 HNRNPH1 1.106  
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hnRNPL, isoform a 00027834.3 HNRNPL 0.7024 0.0059 
hnRNP M, isoform 1 00171903.2 HNRNPM 0.7657  
hnRNP M, isoform 2 00383296.5 HNRNPM 0.8107  
hnRNP R, isoform 1 00644055.3 HNRNPR 0  
Heat Shock Protein, 60 kDa 00784154.1 HSPD1 1.391  
Interleukin enhancer-binding factor 3, 
isoform 4 00418313.3 ILF3 1.400  
Keratin, type II cytoskeletal 1 00220327.3 KRT1 0.2214  
Keratin, Type II Cytoskeletal 18 00554788.5 KRT18 0.5885 0.2307 
Keratin, Type II Cytoskeletal 19 00479145.2 KRT19 0.5041 0.2666 
Keratin, type I cytoskeletal 24 00004550.5 KRT24 1.377  
Keratin, Type II Cytoskeletal 8 00554648.3 KRT8 0.4466 0.08853 
Lamin-A/C, Isoform C 00216952.1 LMNA 1.203  
Lamin-A/C, Isoform ADelta10 00216953.1 LMNA 1.136  
Progerin 00644087.1 LMNA 1.234  
Lamin-B1 00217975.4 LMNB1 1.438 0.2368 
Lamin-B2 00009771.6 LMNB2 1.766 0.5235 
Myosin regulatory light chain 00719669.4 MYL12B 0.7596  
32 kDa protein 00827674.1 NCL 0.7411  
Non-POU domain-containing octamer-
binding protein 00304596.3 NONO 0.7291  
Nucleophosmin, isoform 1 00549248.4 NPM1 0.9076  
NUMA1 variant protein 00872028.2 NUMA1 9999  
60S acidic ribosomal protein P1 00008527.3 RPLP1 1.813  
40S ribosomal protein S19 00215780.5 RPS19 1.693  
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APPENDIX C 
NMP ALTERATIONS IN RESPONSE TO PPT 
Table 16:  Alterations to NMP abundance in MCF-7 cells in response to PPT.  
 
 
Protein Name 
Accession 
Number 
(IPI) 
 
 
Gene Symbol 
 
PPT : 
DMSO 
 
 
Std Dev 
Fus-like protein 00260715.5 FUS 1.453  
Interferon-induced guanylate-binding 
protein 2 
 
00848358.1 
 
GBP2 0.782  
Histone H3.1 00902514.1 HIST1H2AD 2.196  
Histone H2B, type 1-N 00794461.1 HIST1H2BN 1.063  
Histone H2B 00646240.3 HIST2H2BA 1.138  
19 kDa protein 00872915.1 HMG_HMGB1 1.413  
hnRNP A1, isoform A1-A 00465365.4 HNRNPA1 0.734  
hnRNP F 00003881.5 HNRNPF 0.657  
51 kDa protein 00479191.2 HNRNPH1 1.082  
Heat Shock Protein, Beta-1 00025512.2 HSPB1 1.287  
Keratin, Type II Cytoskeletal 18 00554788.5 KRT18 0.6695 0.3470 
Keratin, Type II Cytoskeletal 19 00479145.2 KRT19 0.8676 0.1015 
Keratin, Type II Cytoskeletal 8 00554648.3 KRT8 0.8263 0.0554 
Lamin-A/C, Isoform C 00216952.1 LMNA 1.239  
Lamin-A/C, Isoform ADelta10 00216953.1 LMNA 1.100  
Lamin-B1 00217975.4 LMNB1 1.231 0.1292 
Lamin-B2 00009771.6 LMNB2 1.206  
Non-muscle isoform of myosin light 
polypeptide 6 
 
00335168.9 
 
MYL6 1.484  
Non-POU domain-containing octamer-
binding protein 
 
00304596.3 
 
NONO 0.8664  
Nucleophosmin, isoform 1 00549248.4 NPM1 0.9097  
Peroxiredoxin 3, isoform b 00374151.1 PRDX3 1.123  
hnRNP G 00304692.1 RBMX 1.507  
60S acidic ribosomal protein P1 00008527.3 RPLP1 2.100  
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60S acidic ribosomal protein P2 00008529.1 RPLP2 1.308  
40S ribosomal protein s20 00012493.1 RPS20 0.8136  
40S ribosomal protein S25 00012750.3 RPS25 1.287  
Small nuclear ribonucleoprotein Sm 
D3 
 
00017964.1 
 
SNRNPD3 1.593  
TUBA1B protein 00793930.1 TUBA1B 1.739  
Tubulin, Beta Chain 00011654.2 TUBB 1.475  
YBX1 Protein 00643351.1 YBX1 1.352  
 
 
Table 17:  Alterations to NMP abundance in MCF-7/LY2 cells in response to PPT. 
 
 
Protein Name 
Accession 
Number 
(IPI) 
 
 
Gene Symbol 
 
PPT : 
DMSO 
 
Std 
Dev 
Histone H12AD 00902514.1 HIST1H2AD 0.8089  
Histone H2B, type 1-N 00794461.1 HIST1H2BN 1.233  
Histone 1 H2BJ 00515061.3 HIST1H2BJ 0.8619  
hnRNP A3 00419373.1 HNRNPA3 1.0977  
Heat Shock Protein, Beta-1 00025512.2 HSPB1 1.1718  
Keratin, Type II Cytoskeletal 18 00554788.5 KRT18 0.9538  
Keratin, Type II Cytoskeletal 19 00479145.2 KRT19 0.7879 0.02807 
Keratin, Type II Cytoskeletal 8 00554648.3 KRT8 0.9254  
Small nuclear ribonucleoprotein Sm D3 00017964.1 SNRNPD3 0.6201  
Putative elongation factor 1-alpha-like 3 00472724.1 EEF1A1 0.8337  
Protein disulfide isomerase A6 00299571.5 PDIA6 1.1565  
Tu translation elongation factor 00027107.5 TUFM 1.1563  
 
 
 
 
 
 
 
 
 
  133 
APPENDIX D 
NMP ALTERATIONS IN RESPONSE TO MPP 
Table 18: Alterations to NMP abundance in MCF-7 cells in response to MPP. 
 
 
Protein Name 
Accession 
Number 
(IPI) 
 
Gene Symbol 
 
MPP : 
DMSO 
 
Std 
Dev 
Highly similar to AF4/FRM2 family 
member 1, CDNA FLJ61397 
 
00396310.5 
 
AFF1 21.10  
ATP synthase subunit alpha 00440493.2 ATP5A1 2.032 0.7981 
ATP synthase subunit D, isoform 2 00456049.3 ATP5H 1.223  
Uncharacterized protein 
DKFXP564G0422 
 
00553153.1 
 
ATPIF1 1.167  
Cingulin-like protein 1, isoform 1 00307829.7 CGNL1 25.9  
Dynein heavy chain 5, axonemal 00152653.3 DNAH5 49.53  
Putative elongation factor 1-alpha-like 3 00472724.1 EEF1A1 0.6748  
Epiplakin 00010951.2 EPPK1 42.24  
Enhancer of rudimentary homolog 00029631.1 ERH 0.6234  
Interferon-induced guanylate-binding 
protein 2 
 
00848358.1 
 
GBP2 27.45  
48 kDa protein 00879060.1 GCAT 47.36  
Histone H2AV 00018278.3 H2AFV 1.198  
Histone H3.1 00902514.1 HIST1H2AD 1.401  
Histone H2A, type 1-J 00552873.2 HIST1H2AG 0.8286  
Histone H2B, type 1-N 00794461.1 HIST1H2BN 0.8655  
Histone H2B 00646240.3 HIST2H2BA 0.5326  
19 kDa protein 00872915.1 HMG_HMGB1 0.5358  
hnRNP A1, isoform A1-A 00465365.4 HNRNPA1 0.8873  
hnRNP A2/B1, Isoform B1 00396378.3 HNRNPA2B1 0.7661 0.1757 
hnRNPA3, isoform 1 00419373.1 HNRNPA3 0.8028  
hnRNP F 00003881.5 HNRNPF 0.4017  
51 kDa protein 00479191.2 HNRNPH1 0.9079  
hnRNP R, isoform 1 00644055.3 HNRNPR 32.83  
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Heat Shock Protein, Beta-1 00025512.2 HSPB1 0.7162  
Heat Shock Protein, 60 kDa 00784154.1 HSPD1 1.236  
Keratin, type I cytoskeletal 15 00290077.1 KRT15 141.5  
Keratin, type I cytoskeleral 16 00217963.3 KRT16 0.1578  
Keratin, Type II Cytoskeletal 18 00554788.5 KRT18 0.8870 0.4328 
Keratin, Type II Cytoskeletal 19 00479145.2 KRT19 0.9695 0.5037 
Keratin, type I cytoskeletal 24 00004550.5 KRT24 0.2323  
Keratin 7 00847342.1 KRT7 10.86  
Keratin, Type II Cytoskeletal 8 00554648.3 KRT8 0.9259 0.4946 
Lamin-A/C, Isoform C 00216952.1 LMNA 0.6018  
Lamin-B1 00217975.4 LMNB1 0.8022  
Lamin-B2 00009771.6 LMNB2 1.286  
Myosin-10, isoform 3 00790503.3 MYH10 0.6519  
Non-POU domain-containing octamer-
binding protein 
 
00304596.3 
 
NONO 0.6435  
Nucleophosmin, isoform 1 00549248.4 NPM1 0.7218 0.09143 
NUMA1 variant protein 00872028.2 NUMA1 9999  
Peroxiredoxin 3, isoform b 00374151.1 PRDX3 1.171  
60S acidic ribosomal protein P1 00008527.3 RPLP1 4.651  
40S ribosomal protein s20 00012493.1 RPS20 1.749  
Splicing factor, proline- and glutamine- 
rich 
 
00010740.1 
 
SFPQ 0.829  
hnRNPQ, isoform 2 00402182.2 SYNCRIP 0.4418  
Tau-tubulin kinase 00217437.6 TTBK2 15.68  
Zinc finger protein 595 00478170.1 ZNF595 0.487  
 
Table 19: Alterations to NMP abundance in MCF-7/LY2 cells in response to MPP. 
 
 
Protein Name 
Accession 
Number 
(IPI) 
 
 
Gene Symbol 
 
MPP : 
DMSO 
 
Std 
Dev 
Dynein heavy chain 5, axonemal 00152653.3 DNAH5 9999  
Elongation factor 1-alpha 1 00396485.3 EEF1A1 0.6337  
Interferon-induced guanylate-binding 
protein 2 
 
00848358.1 
 
GBP2 0.3863  
Histone H3.1 00902514.1 HIST1H2AD 0.592 0.3067 
Histone H2A, type 1-J 00552873.2 HIST1H2AG 0.8619  
Histone H2B, type 1-N 00794461.1 HIST1H2BN 1.233  
Histone H2B 00646240.3 HIST2H2BA 0.8263  
hnRNP A1, isoform A1-A 00215965.4 HNRNPA1 2.15  
hnRNP A2/B1, Isoform B1 00396378.3 HNRNPA2B1 1.95  
hnRNPA3, isoform 1 00419373.1 HNRNPA3 2.401  
hnRNPA3, isoform 2 00216492.1 HNRNPA3 1.11  
51 kDa protein 00479191.2 HNRNPH1 1.481  
hnRNPL, isoform a 0027834.3 HNRNPL 1.812  
hnRNP R, isoform 1 00644055.3 HNRNPR 9999  
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Heat Shock Protein, Beta-1 0025512.2 HSPB1 0.932 0.3391 
Keratin, Type II Cytoskeletal 18 00554788.5 KRT18 0.7855 0.2381 
Keratin, Type II Cytoskeletal 19 00479145.2 KRT19 0.6963 0.1582 
Keratin, Type II Cytoskeletal 8 00554648.3 KRT8 0.7454 0.2553 
Lamin-A/C, Isoform C 00216952.1 LMNA 1.174  
Lamin-B1 00217975.4 LMNB1 1.444  
Peptidyl-prolyl cis-trans isomerase A 00419585.9 PPIA 1.157  
60S ribosomal protein L12, isoform 1 00024933.3 RPL12 1.846  
60S acidic ribosomal protein P2 00008529.1 RPLP2 2.855  
40S ribosomal protein S19 00215780.5 RPS19 1.495  
40S ribosomal protein s20 00012493.1 RPS20 1.224  
hnRNPQ, isoform 2 00402182.2 SYNCRIP 1.671  
Tu translation elongation factor 00027107.5 TUFM 1.156  
YBX1 Protein 00643351.1 YBX1 1.474  
Zinc finger protein 595 00478170.1 ZNF595 2.988  
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APPENDIX E 
NMP ALTERATIONS IN RESPONSE TO DPN 
Table 20: Alterations to NMP abundance in MCF-7 cells in response to DPN. 
 
 
Protein Name 
Accession 
Number 
(IPI) 
 
 
Gene Symbol 
 
DPN : 
DMSO 
 
Std 
Dev 
Actin, cytoplasmic 2 00021440.1 ACTG1 0.689  
Highly similar to AF4/FRM2 family 
member 1, CDNA FLJ61397 
 
00396310.5 
 
AFF1 2.002  
Cofilin-1 00012011.6 CFL1 0.6621  
Cingulin-like protein 1, isoform 1 00307829.7 CGNL1 3.542  
Elongation factor 1-alpha 1 00396485.3 EEF1A1 1.225  
Enhancer of rudimentary homolog 00029631.1 ERH 0.343  
Interferon-induced guanylate-binding 
protein 2 
 
00848358.1 
 
GBP2 2.909  
48 kDa protein 00879060.1 GCAT 5.748  
Histone H2A type 1-A 00045109.3 HIST1H2AA 0  
Histone H2A, type 1-J 00552873.2 HIST1H2AG 0.8652  
Histone H2B 00646240.3 HIST2H2BA 1.995  
Putative Histone H2B type 2-C 00454695.4 HIST2H2BC 1.765  
19 kDa protein 00872915.1 HMG_HMGB1 0.5914  
High-mobility group protein B1 00645948.4 HMGB1 1.237  
hnRNP A1, isoform A1-A 00465365.4 HNRNPA1 0.5777  
hnRNP A2/B1, Isoform B1 00396378.3 HNRNPA2B1 0.7687 0.1644 
hnRNPA3, isoform 1 00419373.1 HNRNPA3 0.8445  
Putative uncharacterized protein 
HNRNPAB 
 
00742926.1 
 
HNRNPAB 0.5888  
P37 AUF1 00903278.1 HNRNPD 1.748  
hnRNP F 00003881.5 HNRNPF 0.4783  
51 kDa protein 00479191.2 HNRNPH1 1.707  
hnRNPL, isoform a 00027834.3 HNRNPL 0.6865  
hnRNP M, isoform 1 00171903.2 HNRNPM 0.6445  
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Heat Shock Protein, Beta-1 00025512.2 HSPB1 0.8039  
Keratin, Type II Cytoskeletal 18 00554788.5 KRT18 0.6249 0.6449 
Keratin, Type II Cytoskeletal 19 00479145.2 KRT19 0.7857 0.4963 
Keratin, type I cytoskeletal 24 00004550.5 KRT24 0.6479  
Keratin 7 00847342.1 KRT7 2.507  
Keratin, Type II Cytoskeletal 8 00554648.3 KRT8 0.6094 0.5604 
Lamin-B1 00217975.4 LMNB1 1.07  
Lamin-B2 00009771.6 LMNB2 1.192  
Non-POU domain-containing octamer-
binding protein 
 
00304596.3 
 
NONO 0.7414  
Nucleophosmin, isoform 1 00549248.4 NPM1 0.7831 0.05438 
NUMA1 variant protein 00872028.2 NUMA1 9999  
Peroxiredoxin 3, isoform b 00374151.1 PRDX3 1.148  
60S ribosomal protein L12, isoform 1 00024933.3 RPL12 3.531  
60S acidic ribosomal protein P2 00008529.1 RPLP2 0.6056  
40S ribosomal protein s20 00012493.1 RPS20 1.575 1.069 
40S ribosomal protein S23 00218606.7 RPS23 1.357  
Splicing factor, proline- and glutamine- 
rich 
 
00010740.1 
 
SFPQ 0.7821  
 
Table 21: Alterations to NMP abundance in MCF-7/LY2 cells in response to DPN. 
 
 
Name 
Accession 
Number 
(IPI) 
 
Gene 
Symbol 
 
DPN : 
DMSO 
 
Std 
Dev 
Actin, cytoplasmic 2 00021440.1 ACTG1 1.486  
Putative uncharacterized protein ALB 00022434.4 ALB 0.8555  
ATP synthase subunit alpha 00440493.2 ATP5A1 0.6799 0.04094 
Dynein heavy chain 5, axonemal 00152653.3 DNAH5 9999  
Elongation factor 1-alpha 1 00396485.3 EEF1A1 0.6362  
Putative elongation factor 1-alpha-like 3 00472724.1 EEF1A1 1.769  
Fus-like protein 00260715.5 FUS 0.5103  
Interferon-induced guanylate-binding 
protein 2 
 
00848358.1 
 
GBP2 1.843  
Histone H2A type 1-A 00045109.3 HIST1H2AA 0  
Histone H3.1 00902514.1 HIST1H2AD 0.5117 0.4192 
Histone H2B, type 1-N 00794461.1 HIST1H2BN 0.8394  
Histone H2B 00646240.3 HIST2H2BA 0.4359  
High-mobility group protein B1 00645948.4 HMGB1 0.6824  
hnRNP A1, isoform A1-A 00465365.4 HNRNPA1 1.45  
hnRNPA3, isoform 2 00216492.1 HNRNPA3 1.177  
P37 AUF1 00903278.1 HNRNPD 0.479  
hnRNP F 00003881.5 HNRNPF 1.627  
51 kDa protein 00479191.2 HNRNPH1 0.8714  
hnRNP H3, isoform 2 00216492.1 HNRNPH3 0.8147  
hnRNP R, isoform 1 00644055.3 HNRNPR 9999  
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hnRNP U, long isoform 00883857.1 HNRNPU 0.8837  
Heat shock cognate 71 kDa protein, 
isoform 1 
 
00003865.1 
 
HSPA8 1.139  
Stress-70 protein 00007765.5 HSPA9 0.8767  
Heat Shock Protein, Beta-1 00025512.2 HSPB1 1.274 0.5374 
Heat Shock Protein, 60 kDa 00784154.1 HSPD1 0.7283 0.0239 
Keratin, type II cytoskeletal 1 00220327.3 KRT1 4.0085  
Keratin, Type II Cytoskeletal 18 00554788.5 KRT18 1.255 0.9309 
Keratin, Type II Cytoskeletal 19 00479145.2 KRT19 1.842 1.937 
Keratin, type I cytoskeletal 24 00004550.5 KRT24 0.7362  
Keratin, Type II Cytoskeletal 8 00554648.3 KRT8 1.432 1.222 
Lamin-A/C, Isoform C 00216952.1 LMNA 0.8899  
Lamin-B1 00217975.4 LMNB1 0.8121  
Nucleophosmin, isoform 1 00549248.4 NPM1 1.177  
Peptidyl-prolyl cis-trans isomerase A 00419585.9 PPIA 1.415  
Peroxiredoxin 3, isoform b 00374151.1 PRDX3 1.272  
60S acidic ribosomal protein P2 00008529.1 RPLP2 1.624 0.0932 
40S ribosomal protein S25 00012750.3 RPS25 1.514  
Serpin H1 00032140.4 SERPINH1 0.6679  
Splicing factor, proline- and glutamine- 
rich 
 
00010740.1 
 
SFPQ 1.624  
THO complex subunit 4 00328840.9 THOC4 1.226  
YBX1 protein 00643351.1 YBX1 1.332  
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APPENDIX F 
CHARACTERIZATION OF BREAST CANCER CELL LINES USED 
Table 22:  Characteristics of Latimer cell lines and commercially available cell lines. 
 
Cell Line 
 
Description 
 
Karyotype 
Molecular 
Characteristics 
MDA-
MB231 
Stage IV 
Pleural Effusion 
Breast Cancer 
56-61,X,X, 
+1,+2,+3,del(3)(q12q25)x2,+4,+5,del(6)(
q21),add(7)(p21),+9,del(9)(p21)x2,+11x
2,add(11)(p11.2),+12,+14,der(15)t(7;15)(
q11.2;p11.2),dup(15)(q11.1q21),+17x2,i(
17)(q10),i(18)(q10),+20,+0-7mar[21] 
Basal 
ER- 
PR- 
Her2- 
MCF-7 Stage IV 
Pleural Effusion 
Breast Cancer 
82-83, 
X,add(X)(q26),+2,+2,+3,+4,+5,+5,+6,del
(6)(q21),+8,+9,+9, 
add(9)(p13)x2,+10,+11,del(11)(p13),+12
,del(12)(p11.2),+13,+14,+15,+15, 
+16,+17,del(17)(13)x2,+18,+19,der(19)t(
12;19)(q13;q13.3),+21,del(22)(q13),+5-
10mar[cp8] 
Luminal 
ER+ 
PR+ 
Her2- 
MCF-10A Derived from normal 
breast epithelium; 
Transformed over 
time in culture; 
DCIS.com in some 
systems 
45-48,XX,i(1)(q10),-3, 
del(3)(p13),+4,der(9), der(9),+19 
Currently ER- 
Originally ER+ 
JLBTL-7 Stage II  
Breast tumor 
33 chromosomes.  Loss of 2 copies of 
chromosome 1 and loss of one copy of 
chromosomes 4,5,7,8,9,10,11,18,19, and 
21. 
ER- 
PR- 
JLBTL-10 Stage II 
Breast tumor 
46, XX, but contains double minutes 
indicative of gene amplification 
ER- 
PR- 
JLBTL-12 Stage III 49-75,X,-X ER+ 
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Breast tumor [17],del(X)(q23)[12],+1[12],+1[3],del(1)
(q31)[16],del(1)(q31)x2[4],der(1)t(1;3;7)
(1qter1p10::3q103q24::7q11.27q
ter)[18],der(1;3)(p10;q10)[15-
1[15],del(2)(q12q22)[20],del(2)(q12q22)
x2[15],+3[7],del(3)(q10)[20],der(3)del(3)
(p10)t(3;?)(q26.1;?)[16],-
4[7].del(4)(p13p15)[10],-
5[7],+5[7],del(5)(q13.2q31.2)[19],de;(5)(
q13.2q31.2)x2[5],-
6[5],+6[9],add(6)(q24)[11],add(6)(p22.3)
[8],+7[11],+7[5],-
7[4],der(7)t(5;7)(q14;q31.3)[16],-
8[5],del(8)(p22)[-9[17],del(9)(q33)[15],-
10[9].del(10)(p12.3)[13],+11[9],add(11)(
q23)[4],der(11;15)(q10;p10)[17],-
12[10],del(12)(p10)[17],-13[19].-
13[11],add(13)(p10)[5]del(13)(q13;q21.3
)[5],-14[10],+14[5],-
15[12],i(15)(q10)[14],i(15)(q10)x2[2],+1
6[8],add(16)(p12)[12],add(16)(p12)[12],
add(16)(p12)x2[4],-
17[11],add(17)(p10)[11],add(17)(p10)x2[
4],-18[15],-18[6],-19[7],+19[5],-
20[9],+20[4],del(20)(q13.2)[9],-21[8],-
22[14],add(22)(q11.2)[18],+mar1[14],+
mar2[6],+mar3[2][cp20]  
PR+ 
Her2- 
JL-DCIS4 DCIS with an 
invasive component 
46,XX,16qh-[20] diploid or hypodiploid 
chromosome complement.  All of the 
cells had absence of heterochromatin in 
the proximal long arm of chromosome 16 
ER- 
PR- 
Her2+ 
JLDCIS-1A DCIS, no evidence 
of invasion or 
recurrence 
45,X,-
X,der(14)t(5;14)(q11.2;p11.2)[3]/46,X,-
X,der(14)t(5;14) 
(q11.2;p11.2)[3]/46,XX[10] 
ER+ 
PR+ 
JLNTALDC
IS-1 
Adjacent to JLDCIS-
1 
47,XX,i(17)(q10)[3]/46,XX[17] ER+  
PR+ 
JLDCIS-
1Contra 
Contralateral breast 
to DCIS 1 series 
46, XX ER+ 
PR+ 
JLBRL-14 Breast reduction 
mammoplasty  
46, XX  
JLBRL-23 Breast reduction 
mammoplasty 
46, XX  
JLBRL-24 Breast reduction 
mammoplasty 
46, XX  
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APPENDIX G 
NMPS IDENTIFIED IN DCIS CELL LINES 
Table 23:  NMPs identified in DCIS cell lines. 
Protein Name 
Accession 
Number 
(IPI) Gene Symbol Score 
% 
Coverage 
Vimentin 00418471.6 VIM 147 79.2 
Isoform A of Lamin-A/C 00021405.3 LMNA 62.9 63.4 
Neuroblast differentiation-associated 
protein AHNAK 00021812.2 AHNAK 61.0 48.5 
Nucleolin 00604620.3 NCL 44.1 59.3 
HSPA5 protein 00003362.2 HSPA5 42.7 52.7 
Keratin, type II cytoskeletal 8 00554648.3 KRT8 39.3 68.7 
Isoform B1 of hnRNP A2/B1 00396378.3 HNRNPA2B1 38.9 77.3 
Lamin-B1 00217975.4 LMNB1 33.7 56.7 
Annexin A2 isoform 1 00418169.3 ANXA2 33.4 69.5 
p180/ribosome receptor 00856098.1 RRBP1 30.1 52.0 
Histone H2B type 1-N 00794461.1 HIST1H2BN 29.8 73.5 
Isoform 1 of Nucleophosmin 00549248.4 NPM1 27.5 61.6 
Lamin-B2 00009771.6 LMNB2 26.9 45.3 
Keratin, type I cytoskeletal 19 00479145.2 KRT19 25.6 55.8 
Histone H1.2 00217465.5 HIST1H1C 25.4 87.8 
Putative elongation factor 1-alpha-like  00472724.1 EEF1A1 24.8 36.1 
60 kDa heat shock protein 00784154.1 HSPD1 24.0 59.7 
High mobility group protein B1 00419258.4 HMGB1 22.4 64.6 
Nuclease-sensitive element-binding 
protein 1 00031812.3 YBX1 22.0 44.4 
Keratin, type I cytoskeletal 18 00554788.5 KRT18 21.9 48.6 
cDNA FLJ56329, highly similar to 
myosin light polypeptide 6 00796366.2 MYL6B 21.9 64.3 
Filamin A, alpha 00644576.1 FLNA 20.4 21.5 
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Isoform 3 of plectin-1 00398002.6 PLEC1 20.0 29.5 
Isoform long of splicing factor, proline- 
and glutamine-rich 00010740.1 SFPQ 19.9 45.3 
Isoform 1 of Heat shock cognate 71 
kDa protein 00003865.1 HSPA8 19.5 40.9 
60S ribosomal protein L8 00012772.8 RPL8 19.1 47.5 
51 kDa protein 00479191.2 HNRNPH1 17.7 34.5 
Beta actin variant (Fragment) 00894498.1 ACTB 17.6 36.5 
Putative uncharacterized protein 
hnRNP AB 00742926.1 HNRNPAB 17.2 41.6 
ATP synthase subunit alpha, 
mitochondrial 00440493.2 ATP5A1 16.4 29.8 
Elongation factor 1-beta 00178440.3 EEF1B2 16.4 34.7 
similar to peptidylprolyl isomerase A 00887678.1 LOC654188 14.9 65.9 
Keratin 7 00847342.1 KRT7 14.5 45.6 
Protein disulfide-isomerase A3 00025252.1 PDIA3 13.9 37.6 
Isoform 1 of hnRNP Q 00018140.3 SYNCRIP Q 13.6 43.3 
Histone H2A type 1 00291764.5 HIST1H2AG 13.6 57.7 
Filamin B 00900293.1 FLNB 13.6 19.6 
Putative uncharacterized protein 
SPTAN1 00879810.1 SPTAN1 13.3 18.3 
TUBA1C protein 00166768.3 TUBA1C 13.3 37.7 
Highly similar to hnRNP C 00909232.1 FLJ53542 13.2 53.8 
Isoform HMG-I of high mobility group 
protein HMG-I/HMG-Y 00179700.3 HMGA1 12.8 73.8 
Isoform ASF-1 of splicing factor, 
arginine/serine-rich 1 00215884.4 SFRS1 12.7 78.2 
Peroxiredoxin-1 00000874.1 PRDX1 12.6 52.3 
Tubulin beta chain 00011654.2 TUBB 12.5 30.6 
Isoform 2 of hnRNP M 00383296.5 HNRNPM 12.1 36.9 
Isoform 2 of polyadenylate-binding 
protein 1 00410017.1 PABPC1 12.1 35.8 
Histone H1.4 00217467.3 HIST1H1E 11.6 91.8 
Laminin subunit gamma-1 00298281.4 LAMC1 11.6 14.9 
Isoform 3 of clathrin light chain A 00790571.2 CLTA 11.1 29.7 
Transitional endoplasmic reticulum 
ATPase 00022774.3 VCP 11.0 34.5 
Hepatoma-derived growth factor 00020956.1 HDGF 11.0 31.7 
Isoform 3 of plasminogen activator 
inhibitor 1 RNA-binding protein 00470498.1 SERBP1 10.9 29.0 
Glyceraldehyde-3-phosphate 
dehydrogenase 00219018.7 GAPDH 10.7 36.7 
Heat shock protein beta-1 00025512.2 HSPB1 10.5 47.8 
Isoform 1 of Myosin-9 00019502.3 MYH9 10.4 22.8 
Myosin regulatory light chain MRLC2 00033494.3 MYL12B 10.3 45.4 
Eukaryotic translation elongation 00789435.2 EEF1D 10.0 31.3 
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factor 1 delta isoform 3 
Putative uncharacterized protein ALB 00022434.4 ALB 9.75 20.4 
28 kDa heat- and acid-stable 
phosphoprotein 00013297.1 PDAP1 9.63 58.6 
Similar to 40S ribosomal protein S28 00887241.1 RPS28P9 9.52 53.9 
34 kDa protein 00927677.1 HNRNPA3 9.50 61.6 
Non-POU domain-containing octamer-
binding protein 00304596.3 NONO 9.33 40.3 
Histone H2A.Z 00218448.4 H2AFZ 9.10 64.1 
40S ribosomal protein S23 00218606.7 RPS23 9.08 53.9 
cDNA FLJ35087 fis, clone 
PLACE6005546, highly similar to 
polymerase I and transcript release 
factor 00924434.1 PTRF 8.98 38.8 
Histone H1.5 00217468.3 HIST1H1B 8.04 80.1 
Isoform 1 of triosephosphate isomerase 00465028.7 TPI1 8.01 36.4 
Putative uncharacterized protein 
hnRNP D 00915340.1 HNRNPD 8.00 35.6 
Annexin A1 00218918.5 ANXA1 8.00 31.2 
Fus-like protein (Fragment) 00260715.5 FUS 7.74 40.9 
Isoform A1-A of hnRNP A1 00465365.4 HNRNPA1 7.57 60.0 
Histone H3.1 00465070.7 HIST1H3C 7.56 44.1 
Endoplasmic reticulum protein ERp29 00024911.1 ERP29 7.11 22.2 
hnRNP F 00003881.5 HNRNPF 6.96 35.9 
Putative uncharacterized protein 
DKFZp564G0422 00553153.1 ATPIF1 6.75 54.2 
Stress-70 protein, mitochondrial 00007765.5 HSPA9 6.70 30.9 
Isoform 1 of hnRNP H3 00013877.2 HNRNPH3 6.61 43.1 
Putative uncharacterized protein MSN 
(Fragment) 00872814.1 MSN 6.54 31.9 
Upstream of NRAS isoform 3 00844264.7 CSDE1 6.52 24.9 
40S ribosomal protein S19 00215780.5 RPS19 6.47 66.9 
Tu translation elongation factor 00027107.5 TUFM 6.46 29.7 
HSPA1A cDNA FLJ54392, highly 
similar to heat shock 70 kDa protein 1 00845339.1 HSPA1B 6.25 24.8 
Endoplasmin 00027230.3 HSP90B1 6.24 15.2 
Keratin, type II cytoskeletal 1 00220327.3 KRT1 6.19 20.6 
Splicing factor, arginine/serine-rich 3, 
isoform CRA_a 00843996.1 SFRS3 6.17 71.0 
45 kDa protein 00796333.1 ALDOA 6.15 23.0 
Putative uncharacterized protein 
MECP2 (Fragment) 00872623.1 MECP2 6.05 26.2 
Isoform 2 of DNA-binding protein A 00219147.4 CSDA 6.03 36.0 
Sperm protein associated with the 
nucleus on the X chromosome B/F 00148062.1 SPANXF1 6.03 64.1 
Protein disulfide isomerase family A, 00878546.1 PDIA2 6.02 23.4 
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member 2 
30 kDa protein 00472119.2 30 kDa protein 6.01 24.2 
34 kDa protein 00872944.1 NUCKS1 6.00 29.6 
Stathmin 1 isoform b 00921996.1 STMN1 6.00 31.6 
cDNA FLJ52570, highly similar to 
splicing factor, arginine/serine-rich 2 00796848.1 SFRS2 6.00 40.2 
cDNA, FLJ96792, highly similar to 
Homo sapiens calmodulin 2 
(phosphorylase kinase, delta) 
(CALM2), mRNA 00916768.1 CALM2 6.00 40.3 
Similar to ribosomal protein L23 00795408.1 RPL23 5.74 40.7 
THO complex subunit 4 00328840.9 THOC4 5.62 40.1 
Transcription factor A, mitochondrial 00020928.1 TFAM 5.57 33.3 
heat shock 90kDa protein 1, alpha 
isoform 1 00382470.3 HSP90AA1 5.50 32.8 
Isoform UBF2 of nucleolar 
transcription factor 1 00220833.1 UBTF 5.33 17.9 
Enhancer of rudimentary homolog 00029631.1 ERH 5.32 44.2 
Isoform 1 of eukaryotic translation 
initiation factor 5A-1 00411704.9 EIF5A  5.31 44.8 
CFL1 Cofilin-1 00012011.6 CFL1  5.30 66.3 
40S ribosomal protein S4, X isoform 00217030.1 RPS4X 5.10 29.7 
Charged multivesicular body protein 
4b 00025974.3 CHMP4B 5.05 18.8 
Isoform 1 of RNA-binding protein raly 00216044.1 RALY 5.02 40.0 
Activated RNA polymerase II 
transcriptional coactivator p15 00221222.7 SUB1 4.90 43.3 
Isoform 2 of 60S ribosomal protein 
L11 00746438.2 RPL11 4.89 45.2 
Isoform 8 of titin 00759542.1 TTN 4.88 8.10 
Protein disulfide-isomerase 00010796.1 P4HB P 4.88 19.5 
Isoform 1 of protein disulfide-
isomerase A6 00644989.2 PDIA6 4.83 29.1 
60S ribosomal protein L7a 00299573.1 RPL7A 4.77 28.2 
PKM2 cDNA FLJ56065, highly similar 
to pyruvate kinase isozyme M1 00479186.6 PKM2 4.75 13.7 
27 kDa protein 00926903.1 CHCHD3 4.69 25.4 
Isoform 1 of caldesmon 00014516.1 CALD1 4.68 29.5 
High mobility group protein B2 00219097.4 HMGB2 4.55 49.3 
Laminin subunit beta-1 00013976.3 LAMB1 4.46 8.20 
Histone H2B type 1-J 00515061.3 HIST1H2BJ 4.44 92.1 
Histone H4 00453473.6 HIST1H4D 4.41 66.0 
Peptidyl-prolyl cis-trans isomerase B 00646304.4 PPIB 4.39 33.8 
18 kDa protein 00176755.4 Ribosomal 23 4.22 41.7 
  145 
Isoform 1 of 60S ribosomal protein 
L12 00024933.3 RPL12 4.21 49.1 
DnaJ homolog subfamily B member 11 00008454.1 DNAJB11 4.19 26.5 
40S ribosomal protein S3 00011253.3 RPS3 4.17 30.0 
Similar to RPL13 protein 00397611.2 RPL13P12 4.16 29.4 
High mobility group protein B3 00217477.5 HMGB3 4.15 56.5 
40S ribosomal protein S7 00013415.1 RPS7 4.07 32.0 
Putative uncharacterized protein 
DKFZp686J1372 00642042.3 TPM3 4.04 29.3 
Peroxiredoxin-2 00027350.3 PRDX2 4.02 36.9 
Isoform 1 of cytoskeleton-associated 
protein 4 00141318.2 CKAP4 I 4.01 27.2 
Serpin H1 00032140.4 SERPINH1 4.01 21.1 
Profilin-1 00216691.5 PFN1 4.01 47.9 
Histone H2A.x 00219037.5 H2AFX 4.00 58.7 
Tubulin beta-2C chain 00007752.1 TUBB2C 4.00 27.2 
26S protease regulatory subunit 7 00021435.3 PSMC2 4.00 24.7 
46 kDa protein 00791301.1 TMPO 4.00 16.4 
40S ribosomal protein S12 00013917.3 RPS12 4.00 31.1 
60S ribosomal protein L14 00925323.1 RPL14 6 4.00 22.1 
Ribosomal protein S21 00387084.1 RPS21 4.00 58.9 
cDNA FLJ31776 fis, clone 
NT2RI2008141, highly similar to 
Calumenin 00789155.1 CALU 4.00 11.2 
Chromobox protein homolog 3 00297579.4 CBX3 4.00 20.2 
Small acidic protein 00003419.1 C11orf58 4.00 18.6 
26S protease regulatory subunit 6A 00018398.4 PSMC3 3.98 12.5 
40S ribosomal protein S30 00397098.1 FAU 3.70 49.1 
Na(+)/H(+) exchange regulatory 
cofactor NHE-RF1 00003527.5 SLC9A3R1 3.70 16.2 
40S ribosomal protein S14 00026271.5 RPS14 3.70 33.1 
Sin3A-associated protein, 18kDa 00011698.4 SAP18 3.62 23.8 
Cytochrome c oxidase subunit 5B 00021785.2 COX5B 3.52 48.1 
interleukin enhancer binding factor 3 
isoform d 00418313.3 ILF3 3.42 15.5 
Isoform long of hnRNP U 00883857.1 HNRNPU 3.02 15.4 
10 kDa heat shock protein 00220362.5 HSPE1 3.01 71.6 
18 kDa protein 00796600.1 UBC 2.94 36.9 
Putative uncharacterized protein 
RPL31 00917298.1 RPL31 2.93 34.6 
cDNA FLJ59206, highly similar to 
Eukaryotic translation initiation factor 
4B 00908588.1 FLJ59206 2.90 18.1 
60S ribosomal protein L3 00550021.4 RPL3 2.90 14.9 
Isoform 2 of polyadenylate-binding 
protein 2 00414963.2 PABPN1 2.85 16.6 
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Isoform 2 of Na(+)/H(+) exchange 
regulatory cofactor NHE-RF2 00398293.1 SLC9A3R2 2.82 26.4 
NADH-ubiquinone oxidoreductase 
flavoprotein 3 isoform a precursor 00291016.8 NDUFV3 2.72 17.3 
Alpha-2-macroglobulin receptor-
associated protein 00026848.3 LRPAP1 2.66 24.1 
Poly(rC)-binding protein 1 00016610.2 PCBP1 2.65 24.2 
Ribosomal protein L28 isoform 3 00914529.1 RPL28 2.62 13.6 
Isoform brain of clathrin light chain B 00014589.1 CLTB 2.49 20.1 
ATP synthase subunit beta 00303476.1 ATP5B 2.38 17.6 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex, 
mitochondrial 00420108.5 DLST 2.35 13.2 
Isoform 3 of hnRNP K 00807545.1 HNRNPK 2.34 34.8 
Splicing factor, arginine/serine-rich 9 00012340.1 SFRS9 2.33 29.9 
LOC653884 hypothetical protein 00887543.1 LOC653884 2.33 51.4 
Nascent polypeptide-associated 
complex subunit alpha-2 00007471.2 NACA2 2.33 18.1 
Isoform 2 of filamin-C 00413958.4 FLNC 2.30 10.0 
highly similar to 40S ribosomal protein 
S20 00794659.1 RPS20 2.25 18.3 
Hypoxia up-regulated protein 1 00000877.1 HYOU1 2.24 12.6 
RPS2 40S ribosomal protein S2 00013485.3 RPS2 2.21 35.5 
Isoform 2 of nucleoside diphosphate 
kinase A 00375531.2 NME1 2.19 24.9 
LIM domain and actin binding 1 
isoform a 00883896.1 LIMA1 2.18 13.3 
highly similar to Histone H2B type 2-F 00419833.8 HIST1H2BK 2.14 86.6 
SRA stem-loop-interacting RNA-
binding protein 00009922.3 C14orf156 2.11 34.9 
hnRNP H2 00026230.1 HNRNPH2 2.10 32.1 
Heat shock protein HSP 90-beta 00414676.6 HSP90AB1 2.10 21.0 
60S ribosomal protein L22 00219153.4 RPL22 2.09 44.5 
Alpha-enolase 00465248.5 ENO1 2.09 23.0 
Similar to hCG1812668 00887758.1 RPL26P14 2.09 57.9 
Ubiquinol-cytochrome c reductase 
hinge protein, isoform CRA_c 00872952.1 UQCRH 2.07 42.4 
60S ribosomal protein L21 00247583.5 RPL21 2.05 46.3 
Cystatin-B 00021828.1 CSTB 2.05 18.4 
Highly similar to neutral alpha-
glucosidase AB 00383581.4 GANAB 2.04 11.7 
Nucleoprotein TPR 00742682.2 TPR 2.03 10.7 
FK506-binding protein 3 00024157.1 FKBP3 2.03 13.8 
20 kDa protein 00852745.1 MRPL40 2.03 22.2 
Isoform 1 of hnRNP D-like 00011274.3 HNRPDL 2.02 21.9 
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glutamyl-prolyl tRNA synthetase 00923606.1 EPRS 2.02 9.90 
Isoform 1 of histone deacetylase 
complex subunit SAP130 00748953.2 SAP130 I 2.02 3.70 
Elongation factor 2 00186290.6 EEF2 2.02 16.7 
hnRNP G 00304692.1 RBMX 2.01 28.9 
Similar to 60S ribosomal protein L17 00844321.1 Ribosomal L22  2.01 24.5 
Phosphoglycerate kinase 1 00169383.3 PGK1 2.01 18.7 
11 kDa protein 00793102.1 RPL35A 2.01 24.5 
Actin, cytoplasmic 2 00021440.1 ACTG1 2.00 36.5 
Isoform 2 of hnRNP A3 00455134.1 HNRNPA3 2.00 50.0 
Isoform HMG-Y of High mobility 
group protein HMG-I/HMG-Y 00177716.7 HMGA1 2.00 70.8 
PRDX4 Protein 00639945.1 PRDX4 2.00 26.7 
69 kDa protein 00872684.1 EZR 2.00 24.1 
High mobility group protein B3-like-1 00006437.2 HMGB3L1 2.00 49.2 
Histone H1x 00021924.1 H1FX 2.00 25.8 
cDNA FLJ38664 fis, clone 
HLUNG2002334, highly similar to 
Homo sapiens KH domain containing, 
RNA binding, signal transduction 
associated 2 (KHDRBS2) 00903310.1 
FLJ38664 
KHDRBS2  2.00 16.7 
Isoform 2 of ATP synthase subunit d, 
mitochondrial 00456049.3 ATP5H 2.00 25.5 
LisH domain-containing protein 
C16orf63 00043563.3 C16orf63 2.00 14.4 
hnRNP A0 00011913.1 HNRNPA0 2.00 27.9 
Serine hydroxymethyltransferase 00002520.1 SHMT2 2.00 26.8 
Electron transfer flavoprotein, alpha 
polypeptide isoform b 00895865.1 ETFA 2.00 14.8 
Staufen isoform c 00643664.1 STAU1 2.00 27.9 
NUMA1 variant protein 00872028.1 NUMA1 2.00 15.6 
Isoform 7 of transcription factor 
TFIIIB component B homolog 00893272.1 BDP1 2.00 7.90 
EBNA1 binding protein 2 00745955.3 EBNA1BP2 2.00 38.8 
Kinesin-1 heavy chain 00012837.1 KIF5B 2.00 14.7 
cDNA FLJ57496, moderately similar 
to tubulin-specific chaperone A 00909626.1 FLJ57496 2.00 17.8 
cDNA FLJ60539, highly similar to 
Nucleosome assembly protein 1-like 1 00797545.2 NAP1L1 2.00 5.70 
Isoform 1 of calcyclin-binding protein 00395627.3 CACYBP 2.00 8.80 
Prohibitin variant (fragment) 00791634.1 PHB 2.00 29.8 
Putative uncharacterized protein 
DKFZp686E2459 00375731.1 RBM10 2.00 6.30 
Highly similar to major vault protein 00910019.1 FLJ53437 2.00 8.40 
19 kDa protein 00883946.1 LASP1 2.00 40.4 
Septin 9 isoform c 00784936.1 SEPT9 2.00 9.00 
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Ribosomal protein S8 00645201.1 RPS8 2.00 30.3 
UPF0027 protein C22orf28 00550689.3 C22orf28 2.00 6.90 
Prohibitin-2 00027252.6 PHB2 2.00 22.1 
Isoform 3 of protein LSM14 homolog 
B 00471933.5 LSM14B 2.00 30.1 
11 kDa protein 00794121.1 RPL30 2.00 26.0 
GP2 cDNA FLJ56017, highly similar to 
pancreatic secretory granule 
membrane major glycoprotein GP2 00299429.8 FLJ56017 2.00 10.7 
Proteasome subunit alpha type-6 00029623.1 PSMA6 2.00 13.4 
Small nuclear ribonucleoprotein D2 00017963.1 SNRPD2 2.00 26.3 
Isoform 2 endothelial differentiation-
related factor 1 00006362.1 EDF1 2.00 28.8 
Putative uncharacterized protein 
WIBG (Fragment) 00914992.1 WIBG 2.00 19.2 
- cDNA FLJ57742 00910288.1 FLJ57742 2.00 16.3 
Putative uncharacterized protein 
HBE1 00853641.1 HBE1 2.00 27.6 
Cysteine and glycine-rich protein 1 00442073.5 CSRP1 2.00 9.80 
Prefoldin subunit 4 00015891.1 PFDN4 2.00 29.1 
21 kDa protein 00644034.1 CD99 2.00 11.4 
PHD finger-like domain-containing 
protein 5A 00005511.1 PHF5A 2.00 12.7 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 5 00554681.2 NDUFA5 2.00 8.60 
Eukaryotic translation initiation factor 
3 subunit I 00012795.3 EIF3I 2.00 3.40 
cDNA FLJ60076, highly similar to 
ELAV-like protein 1 00301936.4 ELAVL1 1.93 24.9 
Major histocompatibility complex, 
class I, A 00785070.4 HLA-A 1.77 19.1 
Topoisomerase (DNA) I 00902597.2 TOP1 1.76 29.0 
Isoform 1 of apoptotic chromatin 
condensation inducer in the nucleus 00007334.1 ACIN1 1.75 23.0 
Keratin, type I cytoskeletal 10 00009865.2 KRT10 1.74 11.3 
Protein CTF18 homolog 00178203.1 CHTF18 1.73 10.0 
Histone H2B type 1-M 00554798.2 HIST1H2BM 1.70 93.7 
Histone H1.3 00217466.3 HIST1H1D 1.70 66.5 
hnRNP R isoform 1 00644055.3 HNRNPR 1.70 31.8 
DnaJ homolog subfamily A member 1 00012535.1 DNAJA1 1.70 33.0 
Isoform 1 of SLIT and NTRK-like 
protein 2 00176104.1 SLITRK2 1.70 3.80 
Isoform 1 of protein SET 00072377.1 SET 1.70 20.0 
41 kDa protein 00794875.1 PA2G4 1.70 18.5 
Vitronectin 00298971.1 VTN 1.70 11.3 
Isoform 1 of synemin 00299301.1 SYNM 1.59 14.5 
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Isoform 4 of nesprin-1 00247295.3 SYNE1 1.57 10.1 
Reticulocalbin-1 00015842.1 RCN1 1.55 11.2 
Stomatin-like protein 2 00334190.4 STOML2 1.52 17.7 
LOC728470 similar to hCG1736317 00887971.1 LOC728470 1.52 6.80 
Isoform 1 of centrosomal protein of 
290 kDa 00784201.1 CEP290 1.42 14.0 
Proteasome 26S ATPase subunit 6 00926977.1 PSMC6 1.41 19.6 
Tankyrase-2 00019270.1 TNKS2 1.40 6.90 
Peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha 00033138.1 PPARGC1A 1.40 15.0 
- 19 kDa protein 00445053.1 - 19 kDa protein 1.40 7.10 
N-acetyltransferase 5 isoform c 00375483.2 NAT5 1.40 6.30 
Teneurin-2 00182194.7 ODZ2 1.34 6.70 
BAI1-associated protein 3 00828007.1 BAIAP3 1.34 5.80 
Isoform 1 of ATP-binding cassette sub-
family A member 8 00479296.2 ABCA8 1.31 5.80 
Isoform 1 of protein phosphatase 1 
regulatory subunit 14A 00059135.1 PPP1R14A 1.30 46.9 
Highly similar to probable ATP-
dependent RNA helicase DDX5 00798375.2 DDX5 1.30 13.8 
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APPENDIX H 
QUANTIFICATION OF NMPS IN DCIS CELL LINES 
Table 24:  Ratios obtained for NMPs in several cell line in comparison to the JLDCIS-1Contra line. 
Protein Name 
JLBRL
-14 
JLBRL
-24 
JL 
NTAL 
DCIS-1 
JL 
DCIS 
-1A MCF-7 
 MDA-
MB 
231 
- 19 kDa protein 0.0111      
18 kDa protein    0.112   
26S protease regulatory subunit 6A  0.0112    0.0126 
26S protease regulatory subunit 7 0.0631      
40S ribosomal protein S19 0.142   0.119   
40S ribosomal protein S3 0.3162  0.661 0.661   
40S ribosomal protein S30   0.0111    
40S ribosomal protein S7 0.0291      
51 kDa protein  0.0421     
60 kDa heat shock protein   0.106  6.03  
60S ribosomal protein L7a    7.24   
60S ribosomal protein L8 5.50 8.09 8.55 9.20   
69 kDa protein 0.0111      
Activated RNA polymerase II 
transcriptional coactivator p15 0.0759  0.0225    
Annexin A1     0.565  
Annexin A2 isoform 1   0.0679 0.187 1.906  
ATP synthase subunit alpha, 
mitochondrial  6.98   8.32  
cDNA FLJ31776 fis, clone 
NT2RI2008141, highly similar to 
Calumenin     0.0661  
cDNA FLJ52570, highly similar to 
splicing factor, arginine/serine-rich 2 8.71 6.19  7.66 28.3 13.9 
cDNA FLJ60076, highly similar to 0.129  0.0111   0.136 
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ELAV-like protein 1 
Chromobox protein homolog 3 0.0277      
Elongation factor 1-beta 0.233  0.0387 0.0319 0.172 0.236 
Eukaryotic translation elongation 
factor 1 delta isoform 3    0.0545 
 
0.247  
Filamin B     0.145 0.184 
Fus-like protein (Fragment)    0.0350   
glutamyl-prolyl tRNA synthetase 0.0126      
Glyceraldehyde-3-phosphate 
dehydrogenase 0.597      
heat shock 90kDa protein 1, alpha 
isoform 1    0.331 3.53 1.87 
Heat shock protein beta-1   4.45    
Heat shock protein HSP 90-beta 0.384 0.258     
High mobility group protein B1 0.161 0.111 0.0711  1.91  
High mobility group protein B2 0.092 0.020 0.047    
Histone H1.2   0.409 0.0322 0.366 0.506 
Histone H1.4 0.515   0.040 0.146 0.413 
Histone H4 0.229 0.0474   0.340 0.511 
hnRNP F 0.738 1.24 0.143 0.147   
hnRNP H2      0.0187 
HSPA1A cDNA FLJ54392, highly 
similar to heat shock 70 kDa protein 1 0.110      
HSPA5 protein     3.10 3.37 
Hypoxia up-regulated protein 1 0.0511      
Isoform 1 of eukaryotic translation 
initiation factor 5A-1 0.0111      
Isoform 1 of Heat shock cognate 71 
kDa protein  0.0955 0.161    
Isoform 1 of hnRNP Q 0.0912  0.0296  13.1 0.105 
Isoform 1 of Nucleophosmin 0.179 0.151 0.0322 0.0316 0.0592 0.138 
Isoform 1 of protein disulfide-
isomerase A6   87.9  86.3  
Isoform 1 of RNA-binding protein 
raly 6.08 3.44 4.49 0.724 4.06 8.79 
Isoform 1 of synemin 0.0114      
Isoform 1 of triosephosphate 
isomerase 0.637 6.98  5.70 4.74 4.61 
Isoform 2 of hnRNP M  0.294     
Isoform 2 of polyadenylate-binding 
protein 1   0.0196 0.0766 
 
1.854  
Isoform 3 of hnRNP K   0.0417 0.101  0.146 
Isoform 3 of plectin-1  0.090     
Isoform A of Lamin-A/C 0.203  0.0766  0.160  
Isoform ASF-1 of splicing factor, 
arginine/serine-rich 1   0.470  7.80  
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Isoform B1 of hnRNP A2/B1  0.141 0.0231 0.0211 0.545 1.98 
Isoform brain of clathrin light chain B 0.100 0.256  0.138   
Isoform HMG-I of high mobility 
group protein HMG-I/HMG-Y  0.0380     
Isoform long of hnRNP U 0.194  0.0113   0.0113 
Isoform long of splicing factor, 
proline- and glutamine-rich   
 
0.119    
Isoform UBF2 of nucleolar 
transcription factor 1     22.3  
Keratin 7    0.0608   
Keratin, type I cytoskeletal 18     6.14  
Keratin, type II cytoskeletal 8 0.115 2.81  0.242  0.115 
Lamin-B1      5.20 
Lamin-B2      7.94 
Laminin subunit gamma-1  36.3 5.01 4.21   
LOC653884 hypothetical protein 0.0655      
LOC728470 similar to hCG1736317 0.0191  0.0191    
NADH-ubiquinone oxidoreductase 
flavoprotein 3 isoform a precursor 0.0581      
Neuroblast differentiation-associated 
protein AHNAK 0.0887 0.0328 0.0377 0.0809 0.0409 0.196 
Nuclease-sensitive element-binding 
protein 1  0.0449 0.363 0.360 
 
0.215  
Nucleolin 0.0920 0.0643 0.0256 0.0545 0.344 0.154 
p180/ribosome receptor     0.187  
Peroxiredoxin-1      0.0497 
Peroxiredoxin-2 0.0946      
PKM2 cDNA FLJ56065, highly 
similar to pyruvate kinase isozyme 
M1 1.05 20.0 15.7 29.1 30.8 22.7 
Prohibitin-2      0.0156 
Proteasome subunit alpha type-6   0.0118    
Putative elongation factor 1-alpha-like 0.413  0.121  0.0802 0.366 
Putative uncharacterized protein 
ALB 1.66 10.0 2.63  1.85 1.41 
Putative uncharacterized protein 
DKFZp564G0422     3.56  
Putative uncharacterized protein 
DKFZp686J1372 0.0111      
Putative uncharacterized protein 
hnRNP AB   0.056 0.353 
 
2.83 
 
0.413 
Putative uncharacterized protein 
hnRNP D   0.028    
Putative uncharacterized protein 
SPTAN1 0.126      
Ribosomal protein S21   0.0111    
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Serine hydroxymethyltransferase 0.0158      
Similar to 40S ribosomal protein S28     0.357  
Similar to ribosomal protein L23 0.809      
Sperm protein associated with the 
nucleus on the X chromosome B/F   1.01 13.8   
Splicing factor, arginine/serine-rich 3, 
isoform CRA_a 0.809    2.94  
SRA stem-loop-interacting RNA-
binding protein      0.0724 
THO complex subunit 4  0.297 0.118  0.137  
Transcription factor A, mitochondrial     12.7  
Tu translation elongation factor     5.55  
Tubulin beta chain  0.766     
Ubiquinol-cytochrome c reductase 
hinge protein, isoform CRA_c 0.0149      
Vimentin 0.133 0.461 0.0619 0.109 0.129 0.305 
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